https://lymphoma-stg.clarovantdigital.com/library/transformation-and-survival-in-patients-with-waldenstrom-macroglobulinemia-a-population-based-study/2025-11-28T19:01:26+00:00https://lymphoma-stg.clarovantdigital.com/library/the-ratio-of-brain-to-liver-glucose-activity-and-prognosis-with-car-t-in-non-hodgkin-lymphoma/2025-11-28T19:01:26+00:00https://lymphoma-stg.clarovantdigital.com/library/tumor-metabolic-heterogeneity-based-on-18f-fdg-pet-ct-is-a-predictor-of-outcome-in-diffuse-large-b-cell-lymphoma/2025-11-28T19:01:26+00:00https://lymphoma-stg.clarovantdigital.com/library/evaluating-complete-response-remission-rate-as-a-surrogate-endpoint-in-relapsed-refractory-chronic-lymphocytic-leukemia/2025-11-28T19:01:26+00:00https://lymphoma-stg.clarovantdigital.com/library/prolonged-time-from-symptoms-to-diagnosis-is-associated-with-an-inferior-progression-free-survival-in-diffuse-large-b-cell-lymphoma/2025-11-28T19:01:26+00:00https://lymphoma-stg.clarovantdigital.com/library/btk-inhibitors-versus-venetoclax-as-first-or-second-line-therapy-in-chronic-lymphocytic-leukemia-small-lymphocytic-lymphoma-a-real-world-evidence-study/2026-01-22T22:07:57+00:00https://lymphoma-stg.clarovantdigital.com/library/an-insight-into-clinicopathological-parameters-and-prognostic-significance-of-double-expressor-diffuse-large-b-cell-lymphoma-in-a-tertiary-care-center/2025-11-28T19:01:27+00:00https://lymphoma-stg.clarovantdigital.com/library/hodgkin-lymphoma-associated-with-common-variable-immunodeficiency-the-role-of-early-diagnosis-and-multidisciplinary-management/2025-11-28T19:01:27+00:00https://lymphoma-stg.clarovantdigital.com/library/fluid-overload-associated-large-b-cell-lymphoma-two-case-report-and-review-of-literature/2025-11-28T19:01:27+00:00https://lymphoma-stg.clarovantdigital.com/library/early-stage-hodgkin-lymphoma-in-cape-town-south-africa-prognostic-risk-factors-at-diagnosis-and-treatment-outcomes/2025-11-28T19:01:27+00:00https://lymphoma-stg.clarovantdigital.com/library/engaging-stakeholders-along-health-technology-assessment-pathways-a-scoping-review-of-international-practice/2025-11-28T19:01:27+00:00https://lymphoma-stg.clarovantdigital.com/library/the-use-of-real-world-evidence-among-healthcare-payers-a-scoping-review-2/2025-11-28T19:01:27+00:00https://lymphoma-stg.clarovantdigital.com/library/a-noninvasive-machine-learning-model-using-a-complete-blood-count-for-screening-of-primary-vitreoretinal-lymphoma/2025-11-28T19:01:27+00:00https://lymphoma-stg.clarovantdigital.com/library/the-prognostic-and-clinical-utility-of-circulating-tumor-dna-in-diffuse-large-b-cell-lymphoma-a-systematic-review-and-meta-analysis/2025-11-28T19:01:27+00:00https://lymphoma-stg.clarovantdigital.com/library/fixed-duration-epcoritamab-plus-r2-drives-favorable-outcomes-in-relapsed-or-refractory-follicular-lymphoma-2/2026-01-14T18:34:34+00:00https://lymphoma-stg.clarovantdigital.com/library/infections-in-chronic-lymphocytic-leukemia-evolving-risks-and-prevention-strategies/2025-11-28T19:01:27+00:00https://lymphoma-stg.clarovantdigital.com/library/pirtobrutinib-a-highly-selective-noncovalent-reversible-btki-in-r-r-follicular-lymphoma-phase-1-2-bruin-study/2025-11-28T19:01:27+00:00https://lymphoma-stg.clarovantdigital.com/library/impact-of-age-on-outcomes-after-cd19-car-t-cell-therapy-for-large-b-cell-lymphomas/2025-12-05T14:50:52+00:00https://lymphoma-stg.clarovantdigital.com/library/late-failure-of-aggressive-b-cell-lymphoma-following-car-t-cell-therapy-a-lysa-study-from-the-descar-t-registry/2026-01-19T18:02:07+00:00https://lymphoma-stg.clarovantdigital.com/library/brentuximab-vedotin-combination-for-relapsed-diffuse-large-b-cell-lymphoma-2/2025-12-05T15:16:03+00:00https://lymphoma-stg.clarovantdigital.com/library/length-of-hospital-stay-and-outcome-in-primary-central-nervous-system-lymphoma-a-french-retrospective-multicentric-study/2025-12-05T18:22:58+00:00https://lymphoma-stg.clarovantdigital.com/library/i-missed-my-other-oncologist-established-relationships-as-barriers-and-facilitators-to-accessing-car-t-and-autologous-transplantation/2025-12-05T18:22:58+00:00https://lymphoma-stg.clarovantdigital.com/library/tp53-mutations-in-mantle-cell-lymphoma-from-backup-to-game-changer/2025-12-05T18:22:58+00:00https://lymphoma-stg.clarovantdigital.com/library/laboratory-prognostic-index-lab-pi-in-diffuse-large-b-cell-lymphoma-a-single-blood-analysis-predicts-outcomes-as-good-as-ipi-nccn-ipi-and-geltamo-ipi/2025-12-05T18:22:58+00:00https://lymphoma-stg.clarovantdigital.com/library/a-phase-2-study-of-ibrutinib-with-venetoclax-in-japanese-patients-with-untreated-cll-and-sll/2025-12-05T18:22:59+00:00https://lymphoma-stg.clarovantdigital.com/library/overall-good-quality-of-life-reported-by-survivors-of-childhood-hodgkin-lymphoma-in-sweden-and-finland/2025-12-05T18:22:59+00:00https://lymphoma-stg.clarovantdigital.com/library/clinicopathological-study-of-hodgkin-lymphoma-in-relation-to-programmed-death-ligand-1-pd-l1-expression-and-epstein-barr-virus-ebv-status/2025-12-05T18:22:59+00:00https://lymphoma-stg.clarovantdigital.com/library/nivolumab-in-combination-with-r-chop-for-treatment-naive-diffuse-large-b-cell-lymphoma-an-evaluation-of-safety-and-efficacy/2025-12-05T18:22:59+00:00https://lymphoma-stg.clarovantdigital.com/library/molecular-diagnostics-of-aggressive-b-cell-non-hodgkin-lymphomas/2025-12-05T18:22:59+00:00https://lymphoma-stg.clarovantdigital.com/library/safety-assessment-of-obinutuzumab-real-world-adverse-event-analysis-based-on-the-faers-and-jader-databases-from-2013-to-2025/2025-12-05T18:22:59+00:00https://lymphoma-stg.clarovantdigital.com/library/preliminary-analysis-of-a-multicenter-study-of-pola-r-chp-in-untreated-japanese-patients-with-dlbcl-polastar/2025-12-05T18:22:59+00:00https://lymphoma-stg.clarovantdigital.com/library/transformation-and-causes-of-death-in-follicular-lymphoma-a-finnish-nationwide-population-based-study/2025-12-05T18:23:00+00:00https://lymphoma-stg.clarovantdigital.com/library/time-to-progression-is-a-simple-and-robust-prognostic-factor-for-survival-in-relapsed-or-refractory-diffuse-large-b-cell-lymphoma/2025-12-05T18:23:00+00:00https://lymphoma-stg.clarovantdigital.com/library/venetoclax-and-ibrutinib-induces-durable-clinical-responses-in-marginal-zone-lymphoma/2026-03-25T20:22:39+00:00https://lymphoma-stg.clarovantdigital.com/library/inclusion-characteristics-and-reporting-of-older-patients-in-recent-registration-trials-for-dlbcl-a-systematic-review/2025-12-12T15:35:11+00:00https://lymphoma-stg.clarovantdigital.com/library/benefit-of-rituximab-maintenance-after-first-line-bendamustine-rituximab-in-patients-with-mantle-cell-lymphoma/2026-02-25T13:50:08+00:00https://lymphoma-stg.clarovantdigital.com/library/nemtabrutinib-in-participants-with-relapsed-or-refractory-follicular-lymphoma-updated-efficacy-and-safety-from-cohort-g-of-the-phase-2-bellwave-003-study/2025-12-12T19:32:40+00:00https://lymphoma-stg.clarovantdigital.com/library/high-complete-response-rates-and-minimal-residual-disease-mrd-negativity-with-durable-responses-in-high-risk-mantle-cell-lymphoma-mcl-with-glpg5101-a-fresh-early-memory-enriched-car-t-cell-the/2025-12-12T19:32:40+00:00https://lymphoma-stg.clarovantdigital.com/library/pirtobrutinib-versus-ibrutinib-in-treatment-naive-and-relapsed-refractory-chronic-lymphocytic-leukemia-small-lymphocytic-lymphoma/2025-12-12T19:32:40+00:00https://lymphoma-stg.clarovantdigital.com/library/prognostic-impact-of-diagnosis-to-treatment-interval-in-follicular-lymphoma-patients-treated-with-immunochemotherapy-evidence-from-an-international-cohort-with-independent-validation/2025-12-12T19:32:40+00:00https://lymphoma-stg.clarovantdigital.com/library/polatuzumab-vedotin-in-large-diffuse-b-cell-lymphoma-a-multicenter-observational-study-from-latin-america-2020-2024/2025-12-12T19:32:41+00:00https://lymphoma-stg.clarovantdigital.com/library/fixed-treatment-duration-mosunetuzumab-continues-to-demonstrate-clinically-meaningful-outcomes-in-patients-with-relapsed-refractory-r-r-follicular-lymphoma-fl-after-2-prior-therapies-5-year-foll/2025-12-15T19:34:37+00:00https://lymphoma-stg.clarovantdigital.com/library/ibrutinib-plus-r-chop-followed-by-maintenance-in-untreated-abc-dlbcl-patients-with-ipi-2-a-first-analysis-of-phase-ii-study-fil_ri-chop/2025-12-12T19:32:41+00:00https://lymphoma-stg.clarovantdigital.com/library/prognostic-impact-of-mantle-cell-lymphoma-frontline-induction-response-assessments-in-the-ecog-acrin-e1411-study-of-bendamustine-rituximab-bortezomib-and-maintenance-with-rituximab-lenalidomid/2025-12-12T19:32:41+00:00https://lymphoma-stg.clarovantdigital.com/library/epcoritamab-lenalidomide-and-rituximab-versus-lenalidomide-and-rituximab-for-relapsed-or-refractory-follicular-lymphoma-epcore-fl-1-a-global-open-label-randomised-phase-3-trial/2026-01-14T18:33:20+00:00https://lymphoma-stg.clarovantdigital.com/library/final-analysis-of-the-randomized-phase-2-rosewood-study-of-zanubrutinib-obinutuzumab-vs-obinutuzumab-monotherapy-in-patients-with-relapsed-refractory-follicular-lymphoma/2025-12-12T19:32:41+00:00https://lymphoma-stg.clarovantdigital.com/library/phase-ii-trial-of-an-orelabrutinib-based-combination-therapy-in-newly-diagnosed-primary-central-nervous-system-lymphoma/2025-12-12T19:32:42+00:00https://lymphoma-stg.clarovantdigital.com/library/the-phase-ii-study-of-zanubrutinib-combined-with-r-chop-in-previously-untreated-diffuse-large-b-cell-lymphoma-dlbcl-patients-with-specific-gene-expression/2025-12-12T19:32:42+00:00https://lymphoma-stg.clarovantdigital.com/library/final-analysis-of-the-phase-iii-ghsg-hd21-trial-pet-guided-brecadd-vs-ebeacopp-in-advanced-stage-classical-hodgkin-lymphoma/2025-12-12T19:32:42+00:00https://lymphoma-stg.clarovantdigital.com/library/3-year-follow-up-of-the-s1826-study-confirms-improved-progression-free-survival-with-nivolumab-avd-compared-to-brentuximab-vedotin-avd-in-advanced-stage-classic-hodgkin-lymphoma/2025-12-12T19:32:42+00:00https://lymphoma-stg.clarovantdigital.com/library/real-world-evaluation-of-ctdna-for-risk-stratification-across-the-spectrum-of-both-aggressive-and-indolent-lymphomas/2025-12-12T19:32:42+00:00https://lymphoma-stg.clarovantdigital.com/library/epcoritamab-r-mini-chop-results-in-2-year-remissions-and-high-mrd-negativity-rates-in-elderly-patients-with-newly-diagnosed-dlbcl-results-from-the-epcore-nhl-2-trial/2026-01-14T18:32:48+00:00https://lymphoma-stg.clarovantdigital.com/library/fixed-duration-epcoritamab-monotherapy-induces-high-response-and-mrd-negativity-rates-in-elderly-patients-with-newly-diagnosed-large-b-cell-lymphoma-lbcl-and-comorbidities-results-from-epcore-dlbcl/2026-01-14T18:32:12+00:00https://lymphoma-stg.clarovantdigital.com/library/trends-in-cardiovascular-mortality-in-hodgkin-and-non-hodgkin-lymphoma-a-nationwide-analysis-from-1999-to-2020/2025-12-12T19:32:43+00:00https://lymphoma-stg.clarovantdigital.com/library/real-world-incidence-of-treatment-emergent-cardiovascular-events-among-chronic-lymphocytic-leukemia-small-lymphocytic-lymphoma-patients-receiving-acalabrutinib-or-zanubrutinib-monotherapy/2025-12-12T19:32:43+00:00https://lymphoma-stg.clarovantdigital.com/library/venetoclax-and-ibrutinib-two-partners-for-the-front-line-treatment-of-chronic-lymphocytic-leukemia/2025-12-12T19:32:43+00:00https://lymphoma-stg.clarovantdigital.com/library/outcomes-of-diffuse-large-b-cell-lymphoma-and-high-grade-b-cell-lymphoma-in-elderly-patients-aged-80-years-old-treated-in-first-line-therapy-an-analysis-of-the-bra-dlbcl-multicenter-real-world-reg/2025-12-12T19:32:43+00:00https://lymphoma-stg.clarovantdigital.com/library/patients-with-relapsed-refractory-r-r-diffuse-large-b-cell-lymphoma-dlbcl-preferred-fixed-duration-treatments-with-less-frequent-administrations-in-the-era-of-novel-bispecific-antibodies-bsabs/2025-12-12T19:32:43+00:00https://lymphoma-stg.clarovantdigital.com/library/odronextamab-plus-chemotherapy-in-patients-with-previously-untreated-diffuse-large-b-cell-lymphoma-dlbcl-first-results-from-part-1-of-the-phase-3-olympia-3-study/2025-12-12T19:32:44+00:00https://lymphoma-stg.clarovantdigital.com/library/fixed-treatment-duration-subcutaneous-mosunetuzumab-monotherapy-in-elderly-unfit-patients-with-previously-untreated-diffuse-large-b-cell-lymphoma-interim-results-from-the-phase-ii-morningsun-study/2025-12-12T19:32:44+00:00https://lymphoma-stg.clarovantdigital.com/library/three-year-efficacy-and-longitudinal-safety-of-lisocabtagene-maraleucel-liso-cel-in-patients-with-third-line-or-later-3l-follicular-lymphoma-fl-from-transcend-fl/2025-12-15T19:35:18+00:00https://lymphoma-stg.clarovantdigital.com/library/rituximab-plus-lenalidomide-r2-versus-standard-therapies-in-follicular-lymphoma-a-systematic-review-and-meta-analysis-of-randomized-controlled-trials/2025-12-12T19:32:44+00:00https://lymphoma-stg.clarovantdigital.com/library/results-of-a-registrational-phase-2-study-of-lisaftoclax-monotherapy-for-treatment-of-patients-pts-with-relapsed-refractory-chronic-lymphocytic-leukemia-small-lymphocytic-lymphoma-cll-sll-who-had/2025-12-12T19:32:44+00:00https://lymphoma-stg.clarovantdigital.com/library/primary-analysis-of-the-smart-stop-trial-lenalidomide-tafasitamab-rituximab-and-acalabrutinib-alone-and-with-combination-chemotherapy-in-newly-diagnosed-diffuse-large-b-cell-lymphoma/2025-12-12T19:32:44+00:00https://lymphoma-stg.clarovantdigital.com/library/acalabrutinib-plus-rituximab-followed-by-brexucabtagene-autoleucel-for-frontline-treatment-of-high-risk-mantle-cell-lymphoma-the-window-3-clinical-trial/2025-12-12T19:32:45+00:00https://lymphoma-stg.clarovantdigital.com/library/fixed-duration-versus-continuous-targeted-treatment-for-previously-untreated-chronic-lymphocytic-leukemia-results-from-the-randomized-cll17-trial/2025-12-12T19:32:45+00:00https://lymphoma-stg.clarovantdigital.com/library/sustained-clinical-benefit-of-glofitamab-plus-gemcitabine-and-oxaliplatin-gemox-versus-rituximab-plus-gemox-r-gemox-in-patients-with-relapsed-refractory-r-r-diffuse-large-b-cell-lymphoma-dlbcl/2025-12-12T19:32:45+00:00https://lymphoma-stg.clarovantdigital.com/library/response-adapted-treatment-with-mosunetuzumab-with-or-without-obinutuzumab-and-polatuzumab-vedotin-in-treatment-naive-follicular-and-marginal-zone-lymphoma-final-results-and-phased-seq-mrd-analysis/2025-12-12T19:32:45+00:00https://lymphoma-stg.clarovantdigital.com/library/mosunetuzumab-with-response-driven-lenalidomide-augmentation-achieves-high-response-rates-and-immune-reprogramming-in-untreated-follicular-and-marginal-zone-lymphoma-a-multicenter-phase-2-trial/2025-12-12T19:32:45+00:00https://lymphoma-stg.clarovantdigital.com/library/pembrolizumab-in-relapsed-or-refractory-hodgkin-lymphoma-a-post-hoc-analysis-of-keynote-204-by-prior-lines-of-therapy/2025-12-12T19:32:45+00:00https://lymphoma-stg.clarovantdigital.com/library/real-world-characteristics-and-outcomes-of-patients-with-relapsed-refractory-r-r-diffuse-large-b-cell-lymphoma-dlbcl-who-received-second-line-therapy-stratified-by-stem-cell-transplant-status/2025-12-12T19:32:46+00:00https://lymphoma-stg.clarovantdigital.com/library/treatment-patterns-and-survival-outcomes-in-patients-with-mantle-cell-lymphoma-interim-report-of-the-asia-pacific-multinational-prospective-registry-study/2025-12-12T19:32:46+00:00https://lymphoma-stg.clarovantdigital.com/library/golcadomide-golca-a-potential-first-in-class-oral-celmod-agent-rituximab-r-in-patients-with-relapsed-refractory-r-r-diffuse-large-b-cell-lymphoma-dlbcl-phase-1-2-study-extended-follow/2025-12-12T19:32:46+00:00https://lymphoma-stg.clarovantdigital.com/library/golcadomide-golca-a-potential-first-in-class-oral-celmod-agent-plus-r-chop-in-patients-pts-with-previously-untreated-aggressive-b-cell-lymphoma-a-bcl-24-month-efficacy-results/2025-12-12T19:32:46+00:00https://lymphoma-stg.clarovantdigital.com/library/mosunetuzumab-mosun-or-glofitamab-glofit-in-combination-with-golcadomide-golca-demonstrates-a-manageable-safety-profile-and-encouraging-efficacy-in-patients-with-relapsed-or-refractory-r-r-b-c/2025-12-12T19:32:46+00:00https://lymphoma-stg.clarovantdigital.com/library/golcadomide-golca-a-potential-first-in-class-oral-celmod-agent-rituximab-r-in-patients-with-relapsed-refractory-follicular-lymphoma-r-r-fl-phase-1-2-study-extended-follow-up-results/2025-12-12T19:32:47+00:00https://lymphoma-stg.clarovantdigital.com/library/pirtobrutinib-vs-bendamustine-plus-rituximab-br-in-patients-with-cll-sll-first-results-from-a-randomized-phase-iii-study-examining-a-non-covalent-btk-inhibitor-in-untreated-patients/2025-12-12T19:32:47+00:00https://lymphoma-stg.clarovantdigital.com/library/fixed-duration-subcutaneous-sc-mosunetuzumab-with-maintenance-therapy-in-patients-pts-with-previously-untreated-high-tumor-burden-follicular-lymphoma-htb-fl-longer-follow-up-and-exploratory-c/2025-12-12T19:32:47+00:00https://lymphoma-stg.clarovantdigital.com/library/real-world-effectiveness-and-safety-outcomes-by-age-comorbidity-frailty-and-treatments-prior-to-infusion-in-relapsed-or-refractory-r-r-follicular-lymphoma-patients-treated-with-axicabtagene-cilol/2025-12-12T19:32:47+00:00https://lymphoma-stg.clarovantdigital.com/library/delivering-car-t-and-bites-outpatient-a-safe-and-resource-conscious-model-for-t-cell-redirecting-therapies/2025-12-12T19:32:47+00:00https://lymphoma-stg.clarovantdigital.com/library/long-term-outcomes-of-dexamethasone-prophylaxis-after-axicabtagene-ciloleucel-for-non-hodgkin-lymphoma-a-single-center-retrospective-study/2025-12-12T19:32:48+00:00https://lymphoma-stg.clarovantdigital.com/library/sustained-efficacy-of-zanubrutinib-zanu-vs-bendamustine-rituximab-br-in-treatment-tx-naive-chronic-lymphocytic-leukemia-small-lymphocytic-lymphoma-tn-sll-cll-and-continued-favorable-survival/2025-12-12T19:32:48+00:00https://lymphoma-stg.clarovantdigital.com/library/zanubrutinib-venetoclax-for-treatment-naive-chronic-lymphocytic-leukemia-small-lymphocytic-lymphoma-cll-sll-including-patients-with-del17p-and-or-tp53-mutation-and-unmutated-immunoglobulin-heav/2025-12-12T19:32:48+00:00https://lymphoma-stg.clarovantdigital.com/library/time-to-third-line-treatment-after-bendamustine-rituximab-with-or-without-acalabrutinib-in-patients-with-previously-untreated-mantle-cell-lymphoma-updated-analysis-of-the-phase-3-echo-trial-after-50/2025-12-12T19:32:48+00:00https://lymphoma-stg.clarovantdigital.com/library/real-world-outcomes-of-frontline-polatuzumab-rchp-and-impact-of-frailty-in-older-adults-with-diffuse-large-b-cell-lymphoma/2025-12-12T19:32:48+00:00https://lymphoma-stg.clarovantdigital.com/library/pirtobrutinib-in-post-cbtki-cll-sll-final-update-from-the-phase-1-2-bruin-study-with-more-than-5-years-follow-up/2025-12-12T19:32:48+00:00https://lymphoma-stg.clarovantdigital.com/library/pirtobrutinib-vs-ibrutinib-in-treatment-naive-and-relapsed-refractory-cll-sll-results-from-the-first-randomized-phase-iii-study-comparing-a-non-covalent-and-covalent-btk-inhibitor/2025-12-12T19:32:49+00:00https://lymphoma-stg.clarovantdigital.com/library/pirtobrutinib-venetoclax-and-obinutuzumab-for-patients-with-richter-transformation-a-phase-2-trial/2025-12-12T19:32:49+00:00https://lymphoma-stg.clarovantdigital.com/library/the-role-of-time-to-first-progression-and-fitness-status-in-elderly-patients-with-mantle-cell-lymphoma-results-from-the-elderly-mantle-first-study/2025-12-12T19:32:49+00:00https://lymphoma-stg.clarovantdigital.com/library/synchronous-breast-and-kidney-carcinomas-following-treatment-for-hodgkins-lymphoma-in-young-adulthood-a-case-report-and-literature-review/2025-12-12T19:32:49+00:00https://lymphoma-stg.clarovantdigital.com/library/surrogate-endpoints-as-prognostic-factors-for-long-term-outcomes-among-patients-receiving-axicabtagene-ciloleucel-in-frontline-high-risk-large-b-cell-lymphoma/2025-12-12T19:32:49+00:00https://lymphoma-stg.clarovantdigital.com/library/sonrotoclax-bgb-11417-monotherapy-in-patients-with-relapsed-refractory-r-r-mantle-cell-lymphoma-mcl-previously-treated-with-a-bruton-tyrosine-kinase-btk-inhibitor-early-results-from-a-phase-1/2026-07-05T16:22:36+00:00https://lymphoma-stg.clarovantdigital.com/library/bruin-cll-313-randomized-phase-iii-trial-of-pirtobrutinib-versus-bendamustine-plus-rituximab-in-untreated-patients-with-chronic-lymphocytic-leukemia-small-lymphocytic-lymphoma/2026-01-22T22:06:48+00:00https://lymphoma-stg.clarovantdigital.com/library/comparison-of-axicabtagene-ciloleucel-to-standard-regimens-as-second-line-treatment-for-large-b-cell-lymphoma-in-real-life-a-lysa-study-from-descar-t-and-realysa-registries/2025-12-12T19:32:50+00:00https://lymphoma-stg.clarovantdigital.com/library/patient-journey-with-axicabtagene-ciloleucel-for-relapsed-or-refractory-large-b-cell-lymphoma-in-canada-manufacturing-experience-and-impact-of-patient-location-to-treatment-centre/2025-12-12T19:32:50+00:00https://lymphoma-stg.clarovantdigital.com/library/axicabtagene-ciloleucel-in-relapsed-or-refractory-indolent-non-hodgkin-lymphoma-in-chinese-population-a-single-arm-multicenter-phase-2-trial/2025-12-12T19:32:50+00:00https://lymphoma-stg.clarovantdigital.com/library/real-world-evaluation-of-health-care-resource-utilization-clinical-effectiveness-and-safety-of-lisocabtagene-maraleucel-and-axicabtagene-ciloleucel-administered-in-the-outpatient-op-setting-for-r/2025-12-12T19:32:50+00:00https://lymphoma-stg.clarovantdigital.com/library/mosunetuzumab-and-polatuzumab-combined-with-axicabtagene-ciloleucel-induce-high-complete-response-rates-at-day-90-in-relapsed-refractory-large-b-cell-lymphoma/2025-12-12T19:32:50+00:00https://lymphoma-stg.clarovantdigital.com/library/venetoclax-plus-obinutuzumab-improves-quality-of-life-in-treatment-naive-cll-prospective-real-world-insights-from-the-verve-study/2025-12-12T19:32:51+00:00https://lymphoma-stg.clarovantdigital.com/library/a-comprehensive-geriatric-assessment-to-evaluate-individual-frailty-status-and-quality-of-life-in-patients-with-waldenstrom-macroglobulinemia-a-prospective-italian-study/2025-12-12T19:32:51+00:00https://lymphoma-stg.clarovantdigital.com/library/improvements-in-health-related-quality-of-life-hrqol-in-the-sunmo-study-subcutaneous-sc-mosunetuzumab-plus-polatuzumab-vedotin-mosun-pola-vs-rituximab-gemcitabine-and-oxaliplatin-r-gemox-in/2025-12-12T19:32:51+00:00https://lymphoma-stg.clarovantdigital.com/library/health-related-quality-of-life-hrqol-in-real-world-patients-with-cutaneous-t-cell-lymphoma-ctcl-evaluation-of-patient-reported-outcomes-using-the-skindex-16-in-a-multidisciplinary-ctcl-clinic/2025-12-12T19:32:51+00:00https://lymphoma-stg.clarovantdigital.com/library/health-related-quality-of-life-trajectories-of-patients-with-aggressive-b-cell-lymphomas-treated-with-car-t-cell-therapy-results-from-a-prospective-observational-study/2025-12-12T19:32:51+00:00https://lymphoma-stg.clarovantdigital.com/library/patient-reported-outcomes-and-quality-of-life-over-time-in-relapsed-refractory-diffuse-b-cell-lymphoma-dlbcl-patients-treated-with-car-t-cells-therapy-in-clinical-practice/2025-12-12T19:32:51+00:00https://lymphoma-stg.clarovantdigital.com/library/fixed-duration-subcutaneous-mosunetuzumab-continues-to-demonstrate-high-rates-of-durable-responses-in-patients-with-relapsed-refractory-follicular-lymphoma-after-2-prior-therapies-3-year-follow-up-f/2025-12-12T19:32:52+00:00https://lymphoma-stg.clarovantdigital.com/library/real-world-outcomes-of-mosunetuzumab-use-in-indolent-and-aggressive-lymphomas/2025-12-12T19:32:52+00:00https://lymphoma-stg.clarovantdigital.com/library/long-term-follow-up-with-sustained-progression-free-survival-pfs-benefit-after-subcutaneous-sc-mosunetuzumab-in-combination-with-polatuzumab-vedotin-compared-with-rituximab-plus-polatuzumab-vedoti/2026-01-14T17:51:50+00:00https://lymphoma-stg.clarovantdigital.com/library/fixed-duration-subcutaneous-mosunetuzumab-demonstrates-sustained-clinically-meaningful-outcomes-in-patients-with-previously-untreated-low-tumor-burden-follicular-lymphoma/2025-12-12T19:32:52+00:00https://lymphoma-stg.clarovantdigital.com/library/fixed-duration-intravenous-mosunetuzumab-plus-polatuzumab-vedotin-combination-therapy-continues-to-demonstrate-durable-responses-in-patients-with-large-b-cell-lymphoma-3-year-follow-up-from-a-phase-i/2025-12-12T19:32:52+00:00https://lymphoma-stg.clarovantdigital.com/library/combined-mosunetuzumab-and-zanubrutinib-for-the-treatment-of-patients-with-newly-diagnosed-high-burden-follicular-lymphoma-first-results-of-the-multicenter-phase-2-mithic-fl2-trial/2025-12-12T19:32:53+00:00https://lymphoma-stg.clarovantdigital.com/library/a-randomized-phase-2-investigator-led-trial-of-glofitamab-r-chop-or-glofitamab-polatuzumab-vedotin-r-chp-coalition-in-younger-patients-with-high-burden-high-risk-large-b-cell-lymphoma-demonstrates-2/2025-12-12T19:32:53+00:00https://lymphoma-stg.clarovantdigital.com/library/monoclonal-gammopathy-defines-distinct-clinical-subsets-in-chronic-lymphocytic-leukemia-across-therapeutic-eras-2/2025-12-12T19:32:53+00:00https://lymphoma-stg.clarovantdigital.com/library/outcomes-following-disease-progression-after-epcoritamab-or-glofitamab-in-the-real-world-outcomes-of-bispecific-t-cell-engagers-realbite-multi-center-retrospective-cohort-study/2026-01-14T18:31:34+00:00https://lymphoma-stg.clarovantdigital.com/library/real-world-outcomes-of-patients-with-aggressive-b-cell-lymphoma-treated-with-epcoritamab-or-glofitamab/2026-01-14T18:30:34+00:00https://lymphoma-stg.clarovantdigital.com/library/outcomes-and-treatment-strategies-following-cd20-cd3-bispecific-antibody-failure-in-non-hodgkins-lymphoma-a-retrospective-single-center-study/2025-12-12T19:32:53+00:00https://lymphoma-stg.clarovantdigital.com/library/camidanlumab-tesirine-for-relapsed-or-refractory-classic-hodgkin-lymphoma-a-phase-2-study/2025-12-12T19:32:54+00:00https://lymphoma-stg.clarovantdigital.com/library/glofitamab-and-obinutuzumab-globin-as-first-line-therapy-for-patients-with-high-tumor-burden-follicular-lymphoma-first-results-of-a-multicenter-phase-ii-trial/2025-12-12T19:32:54+00:00https://lymphoma-stg.clarovantdigital.com/library/interim-analysis-of-the-phase-ii-study-of-glofitamab-lenaliomide-and-venetoclax-glove-in-untreated-patients-w-high-risk-mantle-cell-lymphoma-response-and-safety-outcomes-after-the-completion-of-s/2025-12-12T19:32:54+00:00https://lymphoma-stg.clarovantdigital.com/library/glofitamab-in-combination-with-polatuzumab-vedotin-demonstrates-high-and-durable-efficacy-in-patients-with-relapsed-refractory-r-r-large-b-cell-lymphoma-lbcl-in-the-second-line-2l-and-third-line/2025-12-12T19:32:54+00:00https://lymphoma-stg.clarovantdigital.com/library/glofitamab-plus-gemcitabine-and-oxaliplatin-gemox-vs-rituximab-r-gemox-in-patients-with-relapsed-refractory-r-r-diffuse-large-b-cell-lymphoma-dlbcl-efficacy-and-safety-in-patient-subgroups/2025-12-12T19:32:54+00:00https://lymphoma-stg.clarovantdigital.com/library/real-world-outcomes-of-glofitamab-glofit-plus-gemcitabine-and-oxaliplatin-gemox-in-relapsed-refractory-r-r-aggressive-b-cell-lymphoma-bcl-a-multicenter-retrospective-study-from-the-united-sta/2025-12-12T19:32:54+00:00https://lymphoma-stg.clarovantdigital.com/library/epcoritamab-with-rituximab-lenalidomide-r2-and-epcoritamab-maintenance-deliver-deep-and-durable-remissions-in-previously-untreated-1l-follicular-lymphoma-fl-3-year-outcomes-from-epcore-nhl-2/2026-01-14T18:30:06+00:00https://lymphoma-stg.clarovantdigital.com/library/effectiveness-of-epcoritamab-in-a-heterogeneous-population-with-relapsed-refractory-r-r-diffuse-large-b-cell-lymphoma-dlbcl-including-post-chimeric-antigen-receptor-t-cell-therapy-car-t-patients/2026-01-14T18:29:31+00:00https://lymphoma-stg.clarovantdigital.com/library/toxicity-profile-of-epcoritamab-and-glofitamab-in-aggressive-b-cell-lymphoma-a-real-world-analysis-of-crs-and-icans-in-a-single-center-cohort/2026-01-14T18:28:43+00:00https://lymphoma-stg.clarovantdigital.com/library/fixed-duration-epcoritamab-in-combination-with-bendamustine-rituximab-br-for-first-line-1l-treatment-of-follicular-lymphoma-fl-3-year-results-from-epcore-nhl-2-arm-3-demonstrate-deep-and-dura/2026-01-14T18:27:53+00:00https://lymphoma-stg.clarovantdigital.com/library/rituximab-and-epcoritamab-as-first-line-therapy-for-patients-with-high-tumor-burden-follicular-lymphoma-results-of-a-multicenter-phase-ii-trial/2026-01-14T18:27:27+00:00https://lymphoma-stg.clarovantdigital.com/library/sustained-remissions-beyond-4-years-with-epcoritamab-monotherapy-long-term-follow-up-results-from-the-pivotal-epcore-nhl-1-trial-in-patients-with-relapsed-or-refractory-large-b-cell-lymphoma/2026-01-14T18:26:27+00:00https://lymphoma-stg.clarovantdigital.com/library/epcoritamab-monotherapy-demonstrates-promising-efficacy-in-patients-with-richter-transformation-rt-2-year-follow-up-results-from-arm-2a-of-the-phase-1b-2-epcore-cll-1-trial/2026-01-14T18:25:36+00:00https://lymphoma-stg.clarovantdigital.com/library/health-related-quality-of-life-hrqol-in-patients-with-relapsed-refractory-follicular-lymphoma-treated-with-epcoritamab-in-combination-with-rituximab-plus-lenalidomide-er2-primary-results-of-the-2/2026-01-14T18:25:03+00:00https://lymphoma-stg.clarovantdigital.com/library/phase-3-study-inmind-of-tafasitamab-plus-lenalidomide-and-rituximab-for-relapsed-or-refractory-follicular-lymphoma-clinical-characteristics-and-outcomes-by-age/2025-12-12T19:32:56+00:00https://lymphoma-stg.clarovantdigital.com/library/outpatient-op-use-of-lisocabtagene-maraleucel-liso-cel-in-patients-pts-with-relapsed-or-refractory-r-r-large-b-cell-lymphoma-lbcl-real-world-data-from-the-cibmtr-registry/2025-12-12T19:32:56+00:00https://lymphoma-stg.clarovantdigital.com/library/prebiopsy-steroids-and-diagnostic-yield-in-patients-with-diffuse-large-b-cell-lymphoma/2025-12-12T19:32:56+00:00https://lymphoma-stg.clarovantdigital.com/library/patient-reported-outcomes-in-patients-with-hematologic-malignancies-treated-with-car-t-cell-therapy-in-europe/2025-12-12T19:32:56+00:00https://lymphoma-stg.clarovantdigital.com/library/superior-real-world-outcomes-of-lisocabtagene-maraleucel-in-chronic-lymphocytic-leukemia/2025-12-12T19:32:57+00:00https://lymphoma-stg.clarovantdigital.com/library/real-world-data-of-lisocabtagene-maraleucel-as-second-line-therapy-for-patients-with-large-b-cell-lymphoma-updated-results-of-the-french-descar-t-registry-by-lysa/2025-12-12T19:32:57+00:00https://lymphoma-stg.clarovantdigital.com/library/patient-reported-outcomes-pros-with-lisocabtagene-maraleucel-liso-cel-in-patients-with-third-line-or-later-3l-r-r-mzl-from-the-phase-2-transcend-fl-study/2025-12-12T19:32:57+00:00https://lymphoma-stg.clarovantdigital.com/library/primary-analysis-of-a-multicenter-open-label-phase-2-study-of-sonrotoclax-bgb-11417-monotherapy-in-patients-with-relapsed-refractory-r-r-chronic-lymphocytic-leukemia-or-small-lymphocytic-lymphom/2026-07-05T16:22:00+00:00https://lymphoma-stg.clarovantdigital.com/library/severe-infections-after-cd19-directed-chimeric-antigen-receptor-t-cell-therapy-for-relapsed-refractory-large-b-cell-lymphoma-a-retrospective-real-life-study-from-the-descar-t-registry-lysa/2025-12-12T19:32:57+00:00https://lymphoma-stg.clarovantdigital.com/library/car-t-cell-therapy-versus-autologous-hsct-in-patients-with-large-b-cell-lymphoma-in-complete-remission-an-analysis-from-the-ebmt-lymphoma-working-party/2025-12-12T19:32:58+00:00https://lymphoma-stg.clarovantdigital.com/library/real-world-chimeric-antigen-receptor-t-cell-therapy-outcomes-in-t-cell-histiocyte-rich-large-b-cell-lymphoma-the-australian-experience/2025-12-12T19:32:58+00:00https://lymphoma-stg.clarovantdigital.com/library/genetic-lesions-in-nodular-lymphocyte-predominant-hodgkin-lymphoma-and-t-cell-histiocyte-rich-large-b-cell-lymphoma-identified-by-whole-genome-sequencing/2025-12-12T19:32:58+00:00https://lymphoma-stg.clarovantdigital.com/library/mortality-trends-of-chronic-lymphocytic-leukemia-and-pneumonia-in-the-united-states-1999-2023-a-cdc-wonder-analysis/2025-12-19T17:47:36+00:00https://lymphoma-stg.clarovantdigital.com/library/early-time-to-relapse-as-a-survival-prognosticator-in-mature-t-cell-nk-cell-lymphomas-results-from-the-petal-consortium/2025-12-18T19:34:51+00:00https://lymphoma-stg.clarovantdigital.com/library/continuous-tobacco-smoking-increases-mortality-in-diffuse-large-b-cell-lymphoma-but-not-follicular-lymphoma-a-finnish-population-based-study/2025-12-18T19:34:03+00:00https://lymphoma-stg.clarovantdigital.com/library/health-related-quality-of-life-and-symptom-burden-in-patients-with-diffuse-large-b-cell-lymphoma-before-treatment-with-tafasitamab-and-lenalidomide-an-ad-hoc-analysis-of-italian-real-world-data-from/2025-12-19T19:23:23+00:00https://lymphoma-stg.clarovantdigital.com/library/anti-cd19-car-t-cells-for-mantle-cell-lymphoma-with-central-nervous-system-involvement-a-study-of-the-french-descart-registry/2025-12-19T19:23:23+00:00https://lymphoma-stg.clarovantdigital.com/library/early-clearance-of-circulating-tumor-dna-and-association-with-odronextamab-response-in-relapsed-refractory-fl-and-dlbcl/2025-12-19T19:23:23+00:00https://lymphoma-stg.clarovantdigital.com/library/real-world-effectiveness-of-polatuzumab-vedotin-plus-rituximab-cyclophosphamide-doxorubicin-and-prednisone-r-chp-compared-with-rituximab-cyclophosphamide-doxorubicin-vincristine-and-prednisone/2025-12-19T19:23:23+00:00https://lymphoma-stg.clarovantdigital.com/library/nivolumab-plus-brentuximab-vedotin-for-relapsed-refractory-diffuse-large-b-cell-lymphoma/2025-12-19T19:23:24+00:00https://lymphoma-stg.clarovantdigital.com/library/machine-learning-model-of-clinical-laboratory-data-for-30-day-mortality-of-patients-with-hodgkins-lymphoma-in-icu-a-retrospective-study-based-on-mimic-iv-database/2025-12-19T19:23:24+00:00https://lymphoma-stg.clarovantdigital.com/library/prospective-validation-of-circulating-tumor-dna-measurable-residual-disease-after-first-line-therapy-in-large-b-cell-lymphoma/2025-12-19T19:23:24+00:00https://lymphoma-stg.clarovantdigital.com/library/safety-and-efficacy-of-brexucabtagene-autoleucel-in-elderly-patients-with-relapsed-or-refractory-mantle-cell-lymphoma-a-retrospective-multicenter-international-study/2025-12-19T19:23:24+00:00https://lymphoma-stg.clarovantdigital.com/library/real-world-effectiveness-and-safety-outcomes-by-age-comorbidities-and-frailty-among-relapsed-or-refractory-r-r-mantle-cell-lymphoma-mcl-patients-treated-with-brexucabtagene-autoleucel-brexu-cel/2025-12-19T19:23:24+00:00https://lymphoma-stg.clarovantdigital.com/library/zuma-25-preliminary-analysis-a-phase-2-study-of-brexucabtagene-autoleucel-brexu-cel-in-patients-pts-with-relapsed-refractory-r-r-burkitt-lymphoma-bl-substudy-c/2025-12-19T19:23:24+00:00https://lymphoma-stg.clarovantdigital.com/library/real-world-outcomes-of-brexucabtagene-autoleucel-for-relapsed-or-refractory-mantle-cell-lymphoma-a-cibmtr-analysis/2025-12-19T19:23:25+00:00https://lymphoma-stg.clarovantdigital.com/library/patient-characteristics-and-treatment-outcomes-with-pola-r-chp-a-real-world-study-of-patients-with-previously-untreated-diffuse-large-b-cell-lymphoma-dlbcl-in-the-united-states-us/2025-12-19T19:23:25+00:00https://lymphoma-stg.clarovantdigital.com/library/promising-response-rates-and-manageable-safety-with-mosunetuzumab-plus-lenalidomide-mosun-len-in-patients-with-relapsed-refractory-r-r-follicular-lymphoma-fl-us-extension-cohort-from-the-phase/2025-12-19T19:23:25+00:00https://lymphoma-stg.clarovantdigital.com/library/improvements-in-health-related-quality-of-life-hrqol-in-the-sunmo-study-subcutaneous-sc-mosunetuzumab-plus-polatuzumab-vedotin-mosun-pola-vs-rituximab-gemcitabine-and-oxaliplatin-r-gemox-in-2/2025-12-19T19:23:25+00:00https://lymphoma-stg.clarovantdigital.com/library/outcomes-of-car-t-cell-therapies-after-prior-treatment-with-fixed-duration-mosunetuzumab-in-patients-with-relapsed-refractory-b-cell-non-hodgkin-lymphoma/2025-12-19T19:23:25+00:00https://lymphoma-stg.clarovantdigital.com/library/differences-in-patient-reported-time-toxicity-between-bispecific-antibody-bsab-options-impact-of-treatment-duration-and-dosing-frequency-on-patient-reported-time-burden-in-relapsed-refractory-r-r/2026-01-14T18:23:15+00:00https://lymphoma-stg.clarovantdigital.com/library/orelabrutinib-combined-with-bendamustine-rituximab-or-obinutuzumab-followed-by-orelabrutinib-maintenance-in-untreated-marginal-zone-lymphoma-optimize-a-multicenter-single-arm-phase-ii-study/2025-12-19T19:23:26+00:00https://lymphoma-stg.clarovantdigital.com/library/preliminary-study-results-of-orelabrutinib-in-combination-with-rituximab-for-treatment-naive-marginal-zone-lymphoma-a-prospective-single-arm-clinical-trial/2025-12-19T19:23:26+00:00https://lymphoma-stg.clarovantdigital.com/library/polatuzumab-vedotin-combined-with-orelabrutinib-and-rituximab-pro-regimen-as-frontline-therapy-in-elderly-and-frail-patients-with-diffuse-large-b-cell-lymphoma-dlbcl-results-from-a-phase-ii-study/2025-12-19T19:23:26+00:00https://lymphoma-stg.clarovantdigital.com/library/polatuzumab-vedotin-and-glofitamab-for-relapsed-refractory-diffuse-large-b-cell-lymphoma-in-the-compassionate-use-program-in-italy/2025-12-19T19:23:26+00:00https://lymphoma-stg.clarovantdigital.com/library/hematologic-malignancies-among-adults-in-southeast-asia-incidence-mortality-and-regional-contexts/2025-12-19T19:23:26+00:00https://lymphoma-stg.clarovantdigital.com/library/dynamics-of-circulating-tumour-dna-in-relapsed-refractory-diffuse-large-b-cell-lymphoma-patients/2025-12-19T19:23:27+00:00https://lymphoma-stg.clarovantdigital.com/library/mosunetuzumab-plus-polatuzumab-vedotin-in-transplant-ineligible-refractory-relapsed-large-b-cell-lymphoma-primary-results-of-the-phase-iii-sunmo-trial/2025-12-19T19:23:27+00:00https://lymphoma-stg.clarovantdigital.com/library/risk-of-central-nervous-system-versus-systemic-relapse-in-patients-with-diffuse-large-b-cell-lymphoma-treated-with-r-chop-what-should-we-focus-on/2025-12-19T19:23:27+00:00https://lymphoma-stg.clarovantdigital.com/library/fixed-duration-epcoritamab-r-chop-in-patients-with-newly-diagnosed-dlbcl-and-high-ipi-scores-3-5-led-to-sustained-remissions-and-disease-free-survival-beyond-3-years-results-from-the-epcore-nhl-2/2026-01-14T18:22:41+00:00https://lymphoma-stg.clarovantdigital.com/library/crs-and-icans-in-car-t-cell-therapy-for-large-b-cell-lymphoma/2025-12-31T16:14:18+00:00https://lymphoma-stg.clarovantdigital.com/library/prognostic-and-immunomodulatory-roles-of-cd30-in-diffuse-large-b-cell-lymphoma-a-cell-of-origin-and-microenvironment-dependent-paradigm/2025-12-31T16:17:07+00:00https://lymphoma-stg.clarovantdigital.com/library/the-influence-of-gcb-and-non-gcb-subtypes-based-on-the-hans-algorithm-on-2-year-event-free-survival-in-diffuse-large-b-cell-lymphoma-patients-who-received-rchop-therapy/2026-01-04T15:02:32+00:00https://lymphoma-stg.clarovantdigital.com/library/hypercalcemia-as-a-rare-complication-of-chronic-lymphocytic-leukemia/2026-01-04T15:02:13+00:00https://lymphoma-stg.clarovantdigital.com/library/clinical-characteristics-and-prognostic-analysis-of-three-hundred-and-nineteen-cases-of-primary-gastrointestinal-diffuse-large-b-cell-lymphoma/2026-01-04T15:08:00+00:00https://lymphoma-stg.clarovantdigital.com/library/prophylaxis-of-central-nervous-system-relapse-in-diffuse-large-b-cell-lymphoma-advances-and-challenges/2026-01-04T15:12:20+00:00https://lymphoma-stg.clarovantdigital.com/library/efficacy-and-safety-of-capivasertib-azd5363-a-potent-oral-pan-akt-inhibitor-in-patients-with-relapsed-or-refractory-b-cell-non-hodgkin-lymphoma-capital/2026-01-04T15:17:12+00:00https://lymphoma-stg.clarovantdigital.com/library/value-of-ultrasound-assessment-of-sarcopenia-in-patients-with-diffuse-large-b-cell-lymphoma-a-prospective-study/2026-01-05T15:49:33+00:00https://lymphoma-stg.clarovantdigital.com/library/impact-of-prior-bendamustine-exposure-on-bispecific-antibody-outcomes-in-relapsed-refractory-follicular-lymphoma/2026-03-29T19:56:32+00:00https://lymphoma-stg.clarovantdigital.com/library/real-world-experience-with-tisagenlecleucel-for-the-treatment-of-relapsed-or-refractory-diffuse-large-b-cell-lymphoma-in-korea/2026-04-24T19:47:45+00:00https://lymphoma-stg.clarovantdigital.com/library/clinical-outcomes-in-patients-with-cll-treated-with-btki-at-a-large-us-cancer-center/2026-01-09T21:09:32+00:00https://lymphoma-stg.clarovantdigital.com/library/ipilimumab-with-and-without-nivolumab-in-patients-with-classic-hodgkin-lymphoma-with-progression-after-pd-1-blockade/2026-01-09T21:09:32+00:00https://lymphoma-stg.clarovantdigital.com/library/the-importance-of-assessing-the-fitness-of-older-patients-with-newly-diagnosed-diffuse-large-b-cell-lymphoma-and-classic-hodgkin-lymphoma/2026-01-09T21:09:32+00:00https://lymphoma-stg.clarovantdigital.com/library/a-real-world-study-evaluating-drug-tolerability-and-health-care-resource-use-with-acalabrutinib-vs-ibrutinib-in-patients-with-relapsed-refractory-chronic-lymphocytic-leukemia-small-lymphocytic-lymphom/2026-01-09T21:09:32+00:00https://lymphoma-stg.clarovantdigital.com/library/current-landscape-of-frontline-and-relapsed-follicular-lymphoma-trials/2026-01-09T21:09:32+00:00https://lymphoma-stg.clarovantdigital.com/library/healthcare-resource-utilization-and-costs-in-patients-with-chronic-lymphocytic-leukemia-or-small-lymphocytic-leukemia-treated-with-covalent-brutons-tyrosine-kinase-inhibitors-real-world-impact-of-car/2026-01-09T21:09:32+00:00https://lymphoma-stg.clarovantdigital.com/library/multi-centre-real-world-outcome-of-patients-with-richter-transformation-receiving-cd19-directed-commercial-car-t-cell-therapy-in-australia/2026-01-09T21:09:33+00:00https://lymphoma-stg.clarovantdigital.com/library/chemotherapy-sparing-strategies-in-follicular-lymphoma-emerging-targeted-and-immune-based-approaches/2026-01-09T21:09:33+00:00https://lymphoma-stg.clarovantdigital.com/library/measurable-residual-disease-after-venetoclax-treatment-for-relapsed-or-refractory-chronic-lymphocytic-leukemia-in-japan/2026-01-09T21:09:33+00:00https://lymphoma-stg.clarovantdigital.com/library/validation-of-prognostic-scores-in-patients-with-hiv-related-diffuse-large-b-cell-lymphoma-the-value-of-peripheral-blood-parameters-a-study-from-the-spanish-lymphoma-group-geltamo/2026-01-09T21:09:33+00:00https://lymphoma-stg.clarovantdigital.com/library/the-heterogeneity-of-relapsed-refractory-diffuse-large-b-cell-lymphoma-patients-who-achieved-therapies-response-and-received-autologous-stem-cell-transplantation-in-the-era-of-new-targeted-drugs/2026-01-09T21:09:33+00:00https://lymphoma-stg.clarovantdigital.com/library/clinical-features-of-neurotoxicity-after-cd19-car-t-cell-therapy-in-mantle-cell-lymphoma/2026-01-09T21:09:33+00:00https://lymphoma-stg.clarovantdigital.com/library/clinical-impact-of-ibrutinib-plus-r-chop-in-untreated-dlbcl-coexpressing-bcl2-and-myc-in-the-phase-3-phoenix-trial/2026-01-09T21:09:34+00:00https://lymphoma-stg.clarovantdigital.com/library/outcomes-of-car-t-cell-therapy-in-high-grade-b-cell-lymphomas-compared-to-dlbcl-a-weighted-comparison-analysis/2026-01-09T21:09:34+00:00https://lymphoma-stg.clarovantdigital.com/library/genomic-determinants-of-response-and-resistance-to-pirtobrutinib-in-relapsed-refractory-chronic-lymphocytic-leukemia/2026-01-09T21:09:34+00:00https://lymphoma-stg.clarovantdigital.com/library/improved-outcomes-of-high-risk-relapsed-hodgkin-lymphoma-patients-after-high-dose-chemotherapy-a-15-year-analysis/2026-01-09T21:09:34+00:00https://lymphoma-stg.clarovantdigital.com/library/astct-clinical-practice-recommendations-for-transplantation-in-classical-hodgkin-lymphoma/2026-01-09T21:09:34+00:00https://lymphoma-stg.clarovantdigital.com/library/a-familiar-foe-revisited-examining-the-relationship-between-endemic-burkitt-lymphoma-and-changing-malaria-admissions-in-the-coastal-region-of-kenya/2026-01-09T21:09:34+00:00https://lymphoma-stg.clarovantdigital.com/library/secondary-malignancy-of-t-cell-origin-after-car-t-cell-therapy-ema-conclusions-from-the-evaluation-of-38-suspected-cases/2026-01-09T21:09:35+00:00https://lymphoma-stg.clarovantdigital.com/library/patterns-of-brutons-tyrosine-kinase-inhibitor-btki-usage-in-b-cell-lymphomas-in-india-a-questionnaire-based-study/2026-01-09T21:09:35+00:00https://lymphoma-stg.clarovantdigital.com/library/progression-free-survival-is-strongly-associated-with-overall-survival-in-relapsed-refractory-diffuse-large-b-cell-lymphoma-in-the-car-t-cell-era/2026-01-09T21:09:35+00:00https://lymphoma-stg.clarovantdigital.com/library/real-world-cardiac-events-and-outcomes-in-cbtki-treated-chronic-lymphocytic-leukemia-patients/2026-01-09T21:09:35+00:00https://lymphoma-stg.clarovantdigital.com/library/external-nasal-reconstruction-in-patients-with-extranodal-natural-killer-nk-t-cell-lymphoma-nasal-type/2026-01-09T21:09:35+00:00https://lymphoma-stg.clarovantdigital.com/library/the-role-of-artificial-intelligence-in-palliative-oncology-zeroing-in-on-hematologic-malignancies/2026-01-09T21:09:35+00:00https://lymphoma-stg.clarovantdigital.com/library/use-of-glucarpidase-for-methotrexate-induced-nephrotoxicity-during-the-treatment-of-primary-central-nervous-system-lymphoma/2026-01-09T21:09:35+00:00https://lymphoma-stg.clarovantdigital.com/library/axicabtagene-ciloleucel-in-combination-with-rituximab-for-refractory-large-b-cell-lymphoma-the-phase-2-single-arm-zuma-14-trial/2026-01-09T21:09:36+00:00https://lymphoma-stg.clarovantdigital.com/library/clinical-efficacy-and-safety-of-umbralisib-a-dual-pi3k-ck1-inhibitor-in-treatment-of-hematologic-malignancies/2026-01-09T21:09:36+00:00https://lymphoma-stg.clarovantdigital.com/library/brentuximab-vedotin-addition-to-gemcitabine-in-relapsed-or-refractory-peripheral-t-cell-lymphoma-a-lysa-phase-2-study/2026-01-09T21:09:36+00:00https://lymphoma-stg.clarovantdigital.com/library/central-nervous-system-involvement-in-patients-with-richter-transformation-of-chronic-lymphocytic-leukemia-cll-the-mayo-clinic-experience/2026-01-09T21:09:36+00:00https://lymphoma-stg.clarovantdigital.com/library/statin-therapy-with-cd19-directed-car-t-therapy-improves-outcomes-in-relapsed-or-refractory-large-b-cell-lymphoma/2026-01-09T21:09:36+00:00https://lymphoma-stg.clarovantdigital.com/library/cytomegalovirus-infection-and-clinical-outcomes-in-hospitalized-chimeric-antigen-receptor-t-cell-therapy-recipients/2026-01-09T21:09:36+00:00https://lymphoma-stg.clarovantdigital.com/library/role-of-radiotherapy-in-the-management-of-elderly-patients-with-lymphoma/2026-01-09T21:09:37+00:00https://lymphoma-stg.clarovantdigital.com/library/how-patients-can-contribute-to-the-assessments-of-health-technologies/2026-01-09T21:09:37+00:00https://lymphoma-stg.clarovantdigital.com/library/shaping-the-future-of-hta-in-italy-insights-from-the-italian-health-policy-forum/2026-01-09T21:09:37+00:00https://lymphoma-stg.clarovantdigital.com/library/enhancing-patient-engagement-in-hta-using-consensus-research-to-overcome-pico-scoping-challenges-under-the-eu-htar-2/2026-01-09T21:09:37+00:00https://lymphoma-stg.clarovantdigital.com/library/prognostic-factors-associated-with-recurrent-covid-19-and-impact-of-sars-cov-2-vaccine-on-patients-with-chronic-lymphocytic-leukemia/2026-01-22T22:05:53+00:00https://lymphoma-stg.clarovantdigital.com/library/real-world-safety-and-effectiveness-of-zanubrutinib-versus-ibrutinib-in-cll-the-cll-zanu2024-italian-cohort/2026-05-26T15:35:52+00:00https://lymphoma-stg.clarovantdigital.com/library/palliative-care-for-patients-with-hematologic-malignancies-challenges-and-perspectives/2026-01-13T15:19:43+00:00https://lymphoma-stg.clarovantdigital.com/library/brentuximab-vedotin-and-nivolumab-in-combination-with-chemotherapy-for-nonbulky-early-stage-classical-hodgkin-lymphoma/2026-04-28T13:10:50+00:00https://lymphoma-stg.clarovantdigital.com/library/survival-in-mantle-cell-lymphoma-patients-burdened-by-a-second-primary-malignancy/2026-01-16T19:28:13+00:00https://lymphoma-stg.clarovantdigital.com/library/can-modified-lymphodepletion-before-tisagenlecleucel-improve-outcome-in-high-risk-patients-with-large-b-cell-lymphoma/2026-01-16T19:28:13+00:00https://lymphoma-stg.clarovantdigital.com/library/chronic-myeloid-and-lymphocytic-leukemias-in-the-elderly-public-health-challenges-in-early-detection-and-long-term-care/2026-01-16T19:28:13+00:00https://lymphoma-stg.clarovantdigital.com/library/risk-of-type-ii-diabetes-mellitus-among-b-cell-non-hodgkins-lymphoma-survivors/2026-01-16T19:28:13+00:00https://lymphoma-stg.clarovantdigital.com/library/matching-adjusted-indirect-treatment-comparison-of-aavd-vs-pet-guided-abvd-in-newly-diagnosed-advanced-hodgkin-lymphoma/2026-01-16T19:28:13+00:00https://lymphoma-stg.clarovantdigital.com/library/real-world-outcomes-of-polatuzumab-vedotin-plus-r-chp-versus-r-chop-based-regimens-in-japanese-patients-with-untreated-diffuse-large-b-cell-lymphoma/2026-01-16T19:28:14+00:00https://lymphoma-stg.clarovantdigital.com/library/outcome-of-patients-with-mantle-cell-lymphoma-after-failure-of-anti-cd19-car-t-cell-therapy-a-descar-t-study-by-lysa-group-2/2026-01-16T19:28:14+00:00https://lymphoma-stg.clarovantdigital.com/library/patients-with-follicular-lymphoma-should-be-treated-according-to-baseline-pet-ct-findings-with-targeted-re-biopsy/2026-01-16T19:28:14+00:00https://lymphoma-stg.clarovantdigital.com/library/efficacy-and-safety-of-subcutaneous-mosunetuzumab-in-combination-with-lenalidomide-and-as-a-monotherapy-in-japanese-patients-with-relapsed-refractory-follicular-lymphoma/2026-01-16T19:28:14+00:00https://lymphoma-stg.clarovantdigital.com/library/baseline-tumor-informed-circulating-tumor-dna-concentration-predicts-early-chemoimmunotherapy-failure-in-diffuse-large-b-cell-lymphoma/2026-01-16T19:28:14+00:00https://lymphoma-stg.clarovantdigital.com/library/talos-fill-the-gap-tafasitamab-and-lenalidomide-in-diffuse-large-b-cell-lymphoma-in-the-real-life-patient-journey/2026-01-16T19:28:14+00:00https://lymphoma-stg.clarovantdigital.com/library/risk-adapted-combined-modality-therapy-in-early-stage-extranodal-natural-killer-t-cell-lymphoma-a-markov-model-based-cost-effectiveness-analysis/2026-01-16T19:28:15+00:00https://lymphoma-stg.clarovantdigital.com/library/high-leptin-levels-independent-of-body-mass-index-are-associated-with-inflammation-and-poorer-treatment-response-in-patients-with-diffuse-large-b-cell-lymphoma/2026-01-16T19:28:15+00:00https://lymphoma-stg.clarovantdigital.com/library/radiotherapy-in-cutaneous-lymphomas-recommendations-from-the-eortc-cutaneous-lymphoma-tumour-group/2026-01-16T19:28:15+00:00https://lymphoma-stg.clarovantdigital.com/library/results-of-brexucabtagene-autoleucel-for-patients-with-relapsed-refractory-mantle-cell-lymphoma-in-the-routine-setting-in-germany-and-switzerland/2026-01-16T19:28:15+00:00https://lymphoma-stg.clarovantdigital.com/library/behind-the-swelling-primary-mediastinal-large-b-cell-lymphoma-masquerading-as-an-infection/2026-01-20T16:08:26+00:00https://lymphoma-stg.clarovantdigital.com/library/treatment-outcomes-and-prognostic-factors-in-diffuse-large-b-cell-lymphoma-with-extranodal-involvement/2026-01-20T19:46:38+00:00https://lymphoma-stg.clarovantdigital.com/library/a-retrospective-study-of-treatment-and-outcomes-in-synchronous-systemic-and-central-nervous-system-large-b-cell-lymphoma/2026-01-23T19:21:46+00:00https://lymphoma-stg.clarovantdigital.com/library/distribution-and-prognostic-impact-of-lymphgen-subtypes-in-korean-diffuse-large-b-cell-lymphoma-using-clinical-ngs-panel/2026-04-24T19:47:11+00:00https://lymphoma-stg.clarovantdigital.com/library/contraceptives-in-chronic-lymphocytic-leukemia-cll-a-narrative-review/2026-01-23T19:21:47+00:00https://lymphoma-stg.clarovantdigital.com/library/chidamide-exploration-of-maintenance-therapy-for-patients-with-dlbcl-with-hbv-infection/2026-01-23T19:21:47+00:00https://lymphoma-stg.clarovantdigital.com/library/prognostic-role-of-pet-ct-volumetric-parameters-in-paediatric-hodgkin-lymphoma-a-systematic-review-and-expert-recommendations-from-the-international-search-for-cayahl-group/2026-01-23T19:21:47+00:00https://lymphoma-stg.clarovantdigital.com/library/three-year-follow-up-of-epcoritamab-therapy-in-japanese-patients-with-relapsed-refractory-follicular-lymphoma-in-epcore-nhl-3/2026-01-23T19:21:47+00:00https://lymphoma-stg.clarovantdigital.com/library/intermediate-dose-tbi-fludarabine-conditioning-for-allogeneic-hematopoietic-cell-transplantation-in-patients-with-cutaneous-t-cell-lymphoma/2026-01-23T19:21:47+00:00https://lymphoma-stg.clarovantdigital.com/library/clinical-impact-of-immunoglobulin-heavy-chain-repertoire-in-mantle-cell-lymphoma-a-study-from-the-fondazione-italiana-linfomi-fil-phase-iii-mcl0208-trial/2026-01-23T19:21:47+00:00https://lymphoma-stg.clarovantdigital.com/library/real-world-treatment-patterns-and-characteristics-of-patients-with-diffuse-large-b-cell-lymphoma-dlbcl-a-retrospective-analysis-of-us-commercial-and-medicare-claims-2017-2024/2026-01-23T19:21:48+00:00https://lymphoma-stg.clarovantdigital.com/library/efficacy-of-btk-inhibitor-combined-with-rituximab-and-lenalidomide-in-newly-diagnosed-diffuse-large-b-cell-lymphoma-a-single-center-retrospective-study/2026-01-23T19:21:48+00:00https://lymphoma-stg.clarovantdigital.com/library/antihypertensive-past-adherence-trajectories-and-risk-of-cardiotoxicity-among-adults-initiating-anthracycline-treatment/2026-01-23T19:21:48+00:00https://lymphoma-stg.clarovantdigital.com/library/tafasitamab-as-monotherapy-or-in-combination-in-japanese-patients-with-b-cell-non-hodgkin-lymphoma-results-from-the-phase-1b-j-mind-study/2026-01-23T19:21:48+00:00https://lymphoma-stg.clarovantdigital.com/library/classical-hodgkin-lymphoma-associated-with-immune-deficiency-and-dysregulation-exhibits-a-prognosis-similar-to-sporadic-cases-but-with-distinct-predictive-markers/2026-01-23T19:21:48+00:00https://lymphoma-stg.clarovantdigital.com/library/tp53-mutation-heterogeneity-reveals-distinct-prognoses-in-mantle-cell-lymphoma/2026-01-23T19:21:48+00:00https://lymphoma-stg.clarovantdigital.com/library/safety-and-efficacy-of-a-pre-phase-with-dexamethasone-followed-by-fractionated-r-chop-in-diffuse-large-b-cell-lymphoma-patients-with-gastrointestinal-involvement-at-diagnosis/2026-01-23T19:21:49+00:00https://lymphoma-stg.clarovantdigital.com/library/primary-refractory-disease-in-large-b-cell-lymphoma-definition-and-outcomes-from-a-secondary-analysis-of-the-ly-12-clinical-trial/2026-02-06T18:38:58+00:00https://lymphoma-stg.clarovantdigital.com/library/the-predictive-value-of-interleukin-2-receptor-and-prognostic-nutritional-index-in-patients-with-diffuse-large-b-cell-lymphoma/2026-02-06T18:46:42+00:00https://lymphoma-stg.clarovantdigital.com/library/sintilimab-combined-with-avd-for-the-treatment-of-composite-hodgkin-lymphoma-and-follicular-lymphoma-a-case-report-and-literature-review/2026-02-06T18:46:42+00:00https://lymphoma-stg.clarovantdigital.com/library/guidelines-for-diagnosis-treatment-and-follow-up-of-patients-with-follicular-lymphoma-spanish-lymphoma-group-geltamo-2025/2026-02-06T18:46:42+00:00https://lymphoma-stg.clarovantdigital.com/library/long-term-outcomes-of-older-patients-with-classical-hodgkin-lymphoma-an-analysis-of-the-texas-cancer-registry/2026-02-06T18:46:42+00:00https://lymphoma-stg.clarovantdigital.com/library/clinical-characteristics-treatment-patterns-and-survival-in-mantle-cell-lymphoma-a-real-world-cohort/2026-02-06T18:46:42+00:00https://lymphoma-stg.clarovantdigital.com/library/clinical-practice-guidelines-for-the-diagnosis-and-management-of-chronic-lymphocytic-leukemia-in-saudi-arabia-consensus-statement-by-an-expert-panel/2026-02-06T18:46:43+00:00https://lymphoma-stg.clarovantdigital.com/library/car-t-therapy-in-adult-dlbcl-patients-in-slovenia-evaluation-of-predictive-scores-for-outcomes-and-adverse-events/2026-02-06T18:46:43+00:00https://lymphoma-stg.clarovantdigital.com/library/tp53-mutation-predict-poor-prognosis-in-diffuse-large-b-cell-lymphoma-a-single-center-study/2026-02-06T18:46:43+00:00https://lymphoma-stg.clarovantdigital.com/library/patient-reported-outcomes-among-patients-with-mantle-cell-lymphoma-or-chronic-lymphocytic-leukemia-receiving-pirtobrutinib-in-the-bruin-phase-1-2-study-final-analysis/2026-02-06T18:46:43+00:00https://lymphoma-stg.clarovantdigital.com/library/cd19-car-t-cell-therapy-in-primary-cutaneous-diffuse-large-b-cell-lymphoma-leg-type/2026-02-06T18:46:43+00:00https://lymphoma-stg.clarovantdigital.com/library/bispecific-antibodies-versus-chimeric-antigen-receptor-t-cell-therapy-in-relapsed-refractory-diffuse-large-b-cell-lymphoma-a-comparative-narrative-review-of-efficacy-safety-and-accessibility/2026-02-06T18:46:43+00:00https://lymphoma-stg.clarovantdigital.com/library/incidence-prevalence-survival-and-mortality-of-chronic-lymphocytic-leukaemia-small-lymphocytic-lymphoma-and-waldenstrom-macroglobulinaemia-in-australia/2026-02-19T14:51:21+00:00https://lymphoma-stg.clarovantdigital.com/library/failure-patterns-and-clinical-indications-in-early-stage-follicular-lymphoma-a-study-from-the-national-cancer-center-in-china/2026-02-06T18:46:44+00:00https://lymphoma-stg.clarovantdigital.com/library/awareness-and-real-world-practices-in-chronic-lymphocytic-leukemia-insights-from-a-nationwide-survey-of-korean-hematologists/2026-04-24T19:46:42+00:00https://lymphoma-stg.clarovantdigital.com/library/prognostic-and-predictive-impact-of-notch1-mutations-in-patients-with-chronic-lymphocytic-leukemia-a-tertiary-single-center-experience/2026-02-06T18:46:44+00:00https://lymphoma-stg.clarovantdigital.com/library/systemic-immune-alterations-in-paediatric-classical-hodgkin-lymphoma-with-ccl17-and-mcp-4-as-diagnostic-and-predictive-biomarkers/2026-02-06T18:46:44+00:00https://lymphoma-stg.clarovantdigital.com/library/hodgkin-lymphoma-the-effect-of-chemotherapy-on-gonadal-function-and-fertility-is-strongly-related-to-the-treatment-regimen-age-and-sex-a-systematic-review-and-meta-analysis/2026-02-06T18:46:44+00:00https://lymphoma-stg.clarovantdigital.com/library/impact-of-marital-status-on-survival-in-patients-with-follicular-lymphoma/2026-02-06T18:46:44+00:00https://lymphoma-stg.clarovantdigital.com/library/global-regional-and-national-patterns-of-change-in-the-burden-of-hodgkin-lymphoma-from-1990-to-2021-an-analysis-of-the-global-burden-of-disease-study-2021-and-projections-to-2035/2026-03-13T13:40:13+00:00https://lymphoma-stg.clarovantdigital.com/library/a-case-of-transformation-of-waldenstroms-macroglobulinemia-to-diffuse-large-b-cell-lymphoma/2026-02-06T18:46:45+00:00https://lymphoma-stg.clarovantdigital.com/library/efficacy-and-safety-of-epcoritamab-in-relapsed-or-refractory-large-b-cell-lymphoma-3-year-update-from-the-epcore-nhl-1-trial/2026-02-06T18:46:45+00:00https://lymphoma-stg.clarovantdigital.com/library/brecadd-vs-beacopp-and-health-related-quality-of-life-in-advanced-stage-hodgkin-lymphoma/2026-02-06T18:46:45+00:00https://lymphoma-stg.clarovantdigital.com/library/balancing-safety-and-efficacy-of-bendamustine-plus-anti-cd20-regimens-in-elderly-patients-70-y-with-follicular-lymphoma-a-tertiary-academic-center-experience/2026-02-06T18:46:45+00:00https://lymphoma-stg.clarovantdigital.com/library/introducing-car-t-cell-therapy-into-clinical-practice-for-mantle-cell-lymphoma-real-world-experience-from-poland/2026-02-13T17:48:31+00:00https://lymphoma-stg.clarovantdigital.com/library/burkitt-lymphoma-a-guide-to-biological-features-diagnosis-and-differential-diagnosis/2026-02-13T17:54:02+00:00https://lymphoma-stg.clarovantdigital.com/library/guided-by-target-selection-inotuzumab-ozogamicin-successfully-salvaged-a-patient-with-refractory-follicular-lymphoma-after-anti-cd19-and-anti-cd22-car-t-cell-therapy-a-case-report-and-literature-rev/2026-02-13T17:54:03+00:00https://lymphoma-stg.clarovantdigital.com/library/investigating-rituximab-induced-infusion-related-reactions-in-patients-with-non-hodgkin-lymphoma-with-a-focus-on-follicular-lymphoma-a-retrospective-observational-study/2026-02-13T17:54:03+00:00https://lymphoma-stg.clarovantdigital.com/library/retreatment-with-r-chop-like-therapy-in-patients-with-late-relapse-of-diffuse-large-b-cell-lymphoma/2026-02-13T17:54:03+00:00https://lymphoma-stg.clarovantdigital.com/library/population-based-validation-of-the-car-hematotox-for-hematotoxicity-infections-and-survival-after-cart-in-r-r-lbcl/2026-02-13T17:54:03+00:00https://lymphoma-stg.clarovantdigital.com/library/prospective-cohort-study-testing-interventions-to-reduce-diagnosis-delay-and-treatment-abandonment-of-children-with-burkitt-lymphoma-in-kenya/2026-03-13T13:40:49+00:00https://lymphoma-stg.clarovantdigital.com/library/chidamide-a-histone-deacetylase-inhibitor-combined-with-r-gemox-in-relapsed-refractory-diffuse-large-b-cell-lymphoma-trust-a-multicenter-single-arm-phase-2-trial/2026-02-13T17:54:03+00:00https://lymphoma-stg.clarovantdigital.com/library/clonal-haematopoiesis-in-t-follicular-helper-cell-lymphoma-a-prognostic-biomarker-and-early-event-in-lymphoma-evolution/2026-02-13T17:54:04+00:00https://lymphoma-stg.clarovantdigital.com/library/characteristics-and-prognosis-of-epstein-barr-virus-positive-diffuse-large-b-cell-lymphoma-a-retrospective-single-center-study/2026-02-13T17:54:04+00:00https://lymphoma-stg.clarovantdigital.com/library/predictive-value-of-natural-killer-nk-cells-in-bone-marrow-for-relapse-in-diffuse-large-b-cell-lymphoma-integrating-antibody-dependent-cell-mediated-cytotoxicity-adcc-based-immunotherapy/2026-02-13T17:54:04+00:00https://lymphoma-stg.clarovantdigital.com/library/impact-of-best-response-to-ibrutinib-plus-bendamustine-and-rituximab-on-pfs-in-mcl-a-secondary-analysis-of-shine/2026-02-13T17:54:04+00:00https://lymphoma-stg.clarovantdigital.com/library/long-term-follow-up-demonstrates-the-curative-potential-of-dual-cd19-cd22-car-t-cell-therapy-alone-or-combined-with-autologous-stem-cell-transplantation-in-tp53-altered-relapsed-refractory-b-cell-non/2026-02-13T17:54:04+00:00https://lymphoma-stg.clarovantdigital.com/library/prognostic-value-of-tumor-bulk-in-modern-management-of-common-lymphoma-subtypes-an-australasian-lymphoma-and-related-diseases-registry-study/2026-02-17T23:45:03+00:00https://lymphoma-stg.clarovantdigital.com/library/advances-in-liquid-diagnostics-for-primary-central-nervous-system-lymphoma-a-narrative-review/2026-02-17T23:51:18+00:00https://lymphoma-stg.clarovantdigital.com/library/real-world-treatment-utilization-patterns-discontinuation-and-healthcare-resource-utilization-of-first-line-bruton-tyrosine-kinase-inhibitors-among-elderly-patients-65-years-in-chronic-lymphocytic-l/2026-02-20T18:56:39+00:00https://lymphoma-stg.clarovantdigital.com/library/real-world-selection-of-venetoclax-obinutuzumab-versus-btk-inhibitor-therapy-for-treatment-naive-chronic-lymphocytic-leukemia-small-lymphocytic-lymphoma/2026-02-20T18:56:40+00:00https://lymphoma-stg.clarovantdigital.com/library/circulating-tumor-dna-determinants-of-response-and-outcome-in-relapsed-refractory-mantle-cell-lymphoma/2026-02-20T18:56:40+00:00https://lymphoma-stg.clarovantdigital.com/library/richter-transformation-to-classical-hodgkin-lymphoma-following-recurrent-disseminated-histoplasmosis-in-chronic-lymphocytic-leukemia-a-case-report/2026-02-20T18:56:40+00:00https://lymphoma-stg.clarovantdigital.com/library/prognostic-significance-of-ki-67-in-grade-3a-follicular-lymphoma-and-development-of-a-novel-pfs-nomogram/2026-02-20T18:56:40+00:00https://lymphoma-stg.clarovantdigital.com/library/primary-thyroid-lymphoma-a-report-of-three-cases-and-a-review-of-the-literature/2026-02-20T18:56:40+00:00https://lymphoma-stg.clarovantdigital.com/library/real-world-outcomes-of-intravitreal-and-systemic-therapy-in-primary-and-secondary-vitreoretinal-lymphoma/2026-02-20T18:56:40+00:00https://lymphoma-stg.clarovantdigital.com/library/ibrutinib-exposure-correlates-with-improved-efficacy-of-car-t-cells-in-patients-with-mantle-cell-lymphoma/2026-02-20T18:56:41+00:00https://lymphoma-stg.clarovantdigital.com/library/efficacy-of-the-five-element-music-therapy-combined-with-mindfulness-meditation-on-the-fatigue-anxiety-and-depression-of-diffuse-large-b-cell-lymphoma-patients-who-are-undergoing-chemotherapy/2026-02-20T18:56:41+00:00https://lymphoma-stg.clarovantdigital.com/library/case-report-of-two-patients-with-refractory-hiv-related-b-cell-lymphoma-treated-with-the-monoclonal-antibody-glofitamab-for-secondary-central-nervous-system-involvement/2026-02-20T18:56:41+00:00https://lymphoma-stg.clarovantdigital.com/library/dissecting-clonal-hematopoiesis-in-the-myeloid-compartment-of-chronic-lymphocytic-leukemia-and-richter-transformation/2026-02-20T18:56:41+00:00https://lymphoma-stg.clarovantdigital.com/library/horizon-scan-of-the-clinical-development-landscape-of-biosimilar-products-in-the-uk-and-eu/2026-02-20T18:56:41+00:00https://lymphoma-stg.clarovantdigital.com/library/advancing-the-use-of-artificial-intelligence-in-health-technology-assessment-activities-insights-and-next-steps-from-the-2025-htai-global-policy-forum/2026-02-20T18:56:41+00:00https://lymphoma-stg.clarovantdigital.com/library/innovating-hta-a-call-for-capacity-building-and-standardization/2026-02-20T18:56:41+00:00https://lymphoma-stg.clarovantdigital.com/library/pericardial-effusion-and-bruton-tyrosine-kinase-inhibitors-in-b-cell-malignant-disease/2026-02-20T18:56:42+00:00https://lymphoma-stg.clarovantdigital.com/library/fitness-beyond-age-multidisciplinary-expert-opinion-on-redefining-fitness-for-targeted-therapies-in-chronic-lymphocytic-leukemia/2026-02-20T18:56:42+00:00https://lymphoma-stg.clarovantdigital.com/library/venetoclax-plus-rituximab-for-relapse-refractory-chronic-lymphocytic-leukemia-a-systematic-review-and-network-meta-analysis-of-treatments-available-in-brazil/2026-02-27T18:14:16+00:00https://lymphoma-stg.clarovantdigital.com/library/the-biology-and-evolution-of-richter-transformation-in-chronic-lymphocytic-leukemia/2026-02-27T18:14:16+00:00https://lymphoma-stg.clarovantdigital.com/library/historic-real-world-outcomes-and-future-benchmarks-for-patients-with-diffuse-large-b-cell-lymphoma-receiving-first-and-second-line-therapy-in-austria-a-large-single-center-experience/2026-02-27T18:14:16+00:00https://lymphoma-stg.clarovantdigital.com/library/efficacy-of-pirtobrutinib-monotherapy-in-treatment-naive-chronic-lymphocytic-leukemia-a-bayesian-network-meta-analysis-of-randomized-controlled-trials/2026-02-27T18:14:16+00:00https://lymphoma-stg.clarovantdigital.com/library/rare-non-hodgkin-lymphomas-in-childhood-and-adolescence-from-rare-to-recognized-entities/2026-02-27T18:14:16+00:00https://lymphoma-stg.clarovantdigital.com/library/prognostic-significance-of-pod24-in-primary-central-nervous-system-diffuse-large-b-cell-lymphoma-a-retrospective-study/2026-02-27T18:14:16+00:00https://lymphoma-stg.clarovantdigital.com/library/pseudo-richter-transformation-following-btki-interruption-in-cll-a-systematic-review-of-clinical-biological-and-pathologic-features/2026-02-27T18:14:16+00:00https://lymphoma-stg.clarovantdigital.com/library/inclusion-characteristics-and-reporting-of-older-patients-in-recent-registration-trials-for-dlbcl/2026-02-27T18:14:17+00:00https://lymphoma-stg.clarovantdigital.com/library/large-b-cell-lymphoma-with-irf4-rearrangment-lbcl-irf4-among-children-adolescents-and-young-adults-caya-a-narrative-review/2026-02-27T18:14:17+00:00https://lymphoma-stg.clarovantdigital.com/library/case-report-car-t-therapy-for-relapsed-diffuse-large-b-cell-lymphoma-in-a-patient-with-pre-existing-parkinson-disease-unfolding-clinical-challenges/2026-02-27T18:14:17+00:00https://lymphoma-stg.clarovantdigital.com/library/treatment-of-follicular-lymphoma-with-chop-and-anti-cd20-therapy/2026-02-27T18:14:17+00:00https://lymphoma-stg.clarovantdigital.com/library/economic-evaluation-of-brutons-tyrosine-kinase-inhibitors-for-chronic-lymphocytic-leukaemia-in-south-africa/2026-03-13T13:25:22+00:00https://lymphoma-stg.clarovantdigital.com/library/a-multicenter-phase-1-2-trial-of-lenalidomide-and-dose-adjusted-epoch-r-in-myc-associated-dlbcl/2026-02-27T18:14:17+00:00https://lymphoma-stg.clarovantdigital.com/library/prognosis-in-marginal-zone-lymphoma-a-comprehensive-review/2026-03-05T19:01:03+00:00https://lymphoma-stg.clarovantdigital.com/library/real-world-outcomes-after-car-t-versus-standard-therapy-in-third-line-or-later-relapsed-or-refractory-follicular-lymphoma-in-the-united-states/2026-03-06T16:59:20+00:00https://lymphoma-stg.clarovantdigital.com/library/nivolumab-doxorubicin-vinblastine-and-dacarbazine-in-hiv-associated-advanced-stage-classic-hodgkin-lymphoma/2026-03-06T16:59:20+00:00https://lymphoma-stg.clarovantdigital.com/library/phase-2-study-of-relmacabtagene-autoleucel-cd19-car-t-for-relapsed-refractory-mantle-cell-lymphoma-in-chinese-adults/2026-03-06T16:59:20+00:00https://lymphoma-stg.clarovantdigital.com/library/the-surgery-for-the-patients-with-intestinal-nonhodgkin-lymphomas-a-nationwide-study/2026-03-06T16:59:21+00:00https://lymphoma-stg.clarovantdigital.com/library/bruton-tyrosine-kinase-inhibition-in-combination-with-bispecific-antibodies-for-richter-syndrome-a-report-of-two-cases-and-mini-review/2026-03-06T16:59:21+00:00https://lymphoma-stg.clarovantdigital.com/library/risk-factors-for-febrile-neutropenia-in-patients-with-newly-diagnosed-diffuse-large-b-cell-lymphoma-undergoing-initial-r-chop-treatment/2026-03-06T16:59:21+00:00https://lymphoma-stg.clarovantdigital.com/library/primary-pulmonary-non-hodgkin-lymphoma-a-report-of-two-cases-and-a-review-of-the-literature-emphasizing-the-role-of-radiotherapy/2026-03-06T16:59:21+00:00https://lymphoma-stg.clarovantdigital.com/library/hta-submission-strategies-and-their-associations-with-rollout-times-and-type-of-hta-recommendation-in-australia-and-canada/2026-03-06T16:59:21+00:00https://lymphoma-stg.clarovantdigital.com/library/characteristics-of-published-mini-and-rapid-health-technology-assessments-reports-a-cross-sectional-analysis/2026-03-06T16:59:21+00:00https://lymphoma-stg.clarovantdigital.com/library/advancing-hospital-based-health-technology-and-impact-assessments-institutionalizing-strategic-decision-making-in-innovation-adoption/2026-03-06T16:59:21+00:00https://lymphoma-stg.clarovantdigital.com/library/efficacy-of-standard-dose-versus-low-dose-nivolumab-in-relapsed-refractory-hodgkin-lymphoma-a-retrospective-analysis/2026-03-06T16:59:22+00:00https://lymphoma-stg.clarovantdigital.com/library/the-impact-of-fitness-and-dose-intensity-on-clinical-outcomes-with-venetoclax-obinutuzumab-in-cll/2026-03-06T16:59:22+00:00https://lymphoma-stg.clarovantdigital.com/library/prognostic-value-of-the-cally-index-in-diffuse-large-b-cell-lymphoma-linking-inflammation-nutrition-and-tumor-biology/2026-03-06T16:59:22+00:00https://lymphoma-stg.clarovantdigital.com/library/real-world-single-center-experience-with-pixantrone-in-dlbcl-prior-to-its-withdrawal-clinical-outcomes-and-exploratory-immunologic-observations/2026-03-06T16:59:22+00:00https://lymphoma-stg.clarovantdigital.com/library/patient-characteristics-and-treatment-outcomes-in-marginal-zone-lymphoma-results-of-the-prospective-german-mzl-registry/2026-03-06T16:59:22+00:00https://lymphoma-stg.clarovantdigital.com/library/epcoritamab-plus-rituximab-dexamethasone-cytarabine-oxaliplatin-carboplatin-induces-deep-and-durable-responses-in-transplant-eligible-patients-with-relapsed-or-refractory-diffuse-large-b-cell-lymph/2026-03-12T15:31:57+00:00https://lymphoma-stg.clarovantdigital.com/library/potential-clinical-applications-of-circulating-tumor-dna-in-patients-with-diffuse-large-b-cell/2026-03-12T15:39:32+00:00https://lymphoma-stg.clarovantdigital.com/library/causes-of-excess-non-lymphoma-death-in-58000-patients-with-dlbcl-diagnosed-during-1997-2020-and-followed-for-up-to-25-years/2026-03-12T15:46:53+00:00https://lymphoma-stg.clarovantdigital.com/library/clinical-practice-guidelines-for-the-diagnosis-and-management-of-hodgkin-lymphoma-in-countries-with-restricted-resources/2026-03-13T13:32:13+00:00https://lymphoma-stg.clarovantdigital.com/library/fixed-duration-veno-vs-fcr-br-in-fit-patients-with-untreated-cll-primary-analysis-of-the-phase-3-cristallo-trial/2026-07-07T00:58:32+00:00https://lymphoma-stg.clarovantdigital.com/library/a-pilot-randomized-trial-of-supervised-resistance-training-plus-home-based-activity-in-chronic-lymphocytic-leukaemia-patients/2026-03-13T17:32:01+00:00https://lymphoma-stg.clarovantdigital.com/library/management-of-primary-refractory-diffuse-large-b-cell-lymphoma-in-patients-unsuitable-for-car-t-cell-therapy/2026-03-13T17:32:01+00:00https://lymphoma-stg.clarovantdigital.com/library/reduced-dose-bendamustine-as-a-first-line-treatment-of-follicular-lymphoma-is-associated-with-poorer-prognosis/2026-03-13T17:32:01+00:00https://lymphoma-stg.clarovantdigital.com/library/bridging-practices-prior-to-brexucabtagene-autoleucel-for-mantle-cell-lymphoma-in-the-united-kingdom-an-analysis-of-modality-response-toxicity-and-survival/2026-03-13T17:32:01+00:00https://lymphoma-stg.clarovantdigital.com/library/a-single-center-retrospective-study-suggests-a-potential-benefit-of-btk-inhibitor-based-therapy-in-patients-with-histologic-transformation-of-waldenstrom-macroglobulinemia/2026-03-13T17:32:02+00:00https://lymphoma-stg.clarovantdigital.com/library/a-meta-analysis-investigating-response-rates-with-continuous-bruton-tyrosine-kinase-inhibitor-monotherapies-in-the-treatment-of-b-cell-lymphomas/2026-03-13T17:32:02+00:00https://lymphoma-stg.clarovantdigital.com/library/real-world-outcomes-of-allogeneic-stem-cell-transplantation-in-relapsed-hodgkin-lymphoma-a-single-center-experience-from-india/2026-03-13T17:32:02+00:00https://lymphoma-stg.clarovantdigital.com/library/incidence-of-severe-covid-19-in-patients-with-chronic-lymphocytic-leukaemia-or-indolent-b-cell-non-hodgkin-lymphoma-who-received-vaccination-and-pre-exposure-prophylaxis-with-tixagevimab-and-cilgavima/2026-03-13T17:32:02+00:00https://lymphoma-stg.clarovantdigital.com/library/cutaneous-adverse-events-following-car-t-cell-therapy-in-hematologic-malignancies/2026-03-13T17:32:02+00:00https://lymphoma-stg.clarovantdigital.com/library/bruton-tyrosine-kinase-inhibitors-in-combination-with-chemoimmunotherapy-is-an-effective-treatment-for-patients-with-richters-syndrome/2026-03-13T17:32:02+00:00https://lymphoma-stg.clarovantdigital.com/library/presenting-clinical-features-of-vitreoretinal-lymphoma/2026-03-13T17:32:03+00:00https://lymphoma-stg.clarovantdigital.com/library/prognostic-factors-and-nomogram-development-for-adult-diffuse-large-b-cell-lymphoma-a-single-center-retrospective-cohort-study/2026-03-13T17:32:03+00:00https://lymphoma-stg.clarovantdigital.com/library/cd20-negativity-at-the-start-of-second-line-therapy-predicts-a-shorter-overall-survival-in-b-cell-lymphomas/2026-04-27T18:23:41+00:00https://lymphoma-stg.clarovantdigital.com/library/venetoclax-retreatment-in-chronic-lymphocytic-leukemia-is-biologically-rational-and-clinically-effective/2026-09-10T19:39:47+00:00https://lymphoma-stg.clarovantdigital.com/library/immunoglobulin-replacement-therapy-and-infection-risk-in-chronic-lymphocytic-leukemia-a-systematic-review-and-meta-analysis/2026-03-25T20:35:34+00:00https://lymphoma-stg.clarovantdigital.com/library/predictors-and-responses-to-varying-durations-of-btk-inhibitor-bridging-therapy-before-anti-cd19-car-t-cell-therapy-in-patients-with-relapsed-refractory-dlbcl/2026-03-29T20:53:22+00:00https://lymphoma-stg.clarovantdigital.com/library/association-of-proteinuria-with-disease-stage-and-treatment-response-in-patients-with-lymphoma-a-prospective-cohort-study/2026-03-29T20:53:22+00:00https://lymphoma-stg.clarovantdigital.com/library/fixed-duration-subcutaneous-mosunetuzumab-in-relapsed-refractory-follicular-lymphoma-pivotal-phase-2-primary-analysis/2026-03-29T20:53:22+00:00https://lymphoma-stg.clarovantdigital.com/library/u-shaped-association-of-red-cell-distribution-width-to-platelet-count-ratio-and-prognosis-in-diffuse-large-b-cell-lymphoma-treated-with-rituximab-based-therapy/2026-03-29T20:53:22+00:00https://lymphoma-stg.clarovantdigital.com/library/patient-perspective-on-chemotherapy-induced-peripheral-neuropathy-cipn-in-advanced-stage-classical-hodgkin-lymphoma-treated-with-multiagent-chemotherapy-regimens-in-the-hd21-trial/2026-03-29T20:53:22+00:00https://lymphoma-stg.clarovantdigital.com/library/limited-diagnostic-utility-of-bone-marrow-sampling-in-pet-defined-limited-stage-follicular-lymphoma/2026-03-29T20:53:22+00:00https://lymphoma-stg.clarovantdigital.com/library/dueling-malignancies-a-rare-case-of-concurrent-chronic-lymphocytic-leukemia-cll-and-chronic-myeloid-leukemia-cml-in-a-multimorbid-elderly-patient/2026-03-29T20:53:22+00:00https://lymphoma-stg.clarovantdigital.com/library/five-year-survival-and-determinants-of-diffuse-large-b-cell-lymphoma-in-resource-limited-settings-the-impact-of-hiv-aids-in-a-multi-center-cohort-study/2026-03-29T20:53:23+00:00https://lymphoma-stg.clarovantdigital.com/library/liquid-biopsy-for-the-diagnosis-of-ebv-positive-burkitt-lymphoma-in-endemic-areas/2026-09-02T15:59:21+00:00https://lymphoma-stg.clarovantdigital.com/library/novel-immunotherapeutic-strategies-for-diffuse-large-b-cell-lymphoma-a-comprehensive-review/2026-03-29T20:53:23+00:00https://lymphoma-stg.clarovantdigital.com/library/comparative-effectiveness-of-odronextamab-monotherapy-versus-real-world-systemic-therapies-in-r-r-follicular-lymphoma/2026-03-29T20:53:23+00:00https://lymphoma-stg.clarovantdigital.com/library/penpulimab-in-combination-with-lenalidomide-and-r-gemox-regimen-r2-gemox-pd1i-in-relapsed-or-refractory-diffuse-large-b-cell-lymphoma-a-multicenter-single-arm-phase-2-trial/2026-03-29T20:53:23+00:00https://lymphoma-stg.clarovantdigital.com/library/brutons-tyrosine-kinase-inhibitors-in-diffuse-large-b-cell-lymphoma-therapy-critical-considerations-and-future-innovations/2026-03-29T20:53:23+00:00https://lymphoma-stg.clarovantdigital.com/library/ebv-associated-histological-transformation-of-marginal-zone-lymphomas-two-case-reports-and-a-literature-review/2026-03-29T20:53:23+00:00https://lymphoma-stg.clarovantdigital.com/library/optimizing-the-role-of-checkpoint-inhibitors-in-the-management-of-hodgkin-lymphoma/2026-03-29T20:53:23+00:00https://lymphoma-stg.clarovantdigital.com/library/health-related-quality-of-life-after-second-line-axi-cel-in-transplant-ineligible-patients-with-large-b-cell-lymphoma/2026-03-29T20:53:23+00:00https://lymphoma-stg.clarovantdigital.com/library/recurrent-acute-pancreatitis-revealing-pancreatic-infiltration-by-cd20-positive-b-cell-lymphoma-a-diagnostic-pitfall-in-extranodal-lymphoma/2026-03-29T20:53:24+00:00https://lymphoma-stg.clarovantdigital.com/library/clinicopathologic-patterns-and-treatment-outcomes-of-pediatric-classic-hodgkin-lymphoma-in-ethiopian-newly-opened-cancer-treatment-centers/2026-03-29T20:53:24+00:00https://lymphoma-stg.clarovantdigital.com/library/choosing-between-nivo-avd-and-brecadd-hodgkin-lymphomas-new-era/2026-03-29T20:53:24+00:00https://lymphoma-stg.clarovantdigital.com/library/efficacy-and-safety-of-zanubrutinib-combined-with-age-adapted-bendamustine-and-rituximab-followed-by-zanubrutinib-maintenance-therapy-in-elderly-patients-with-mantle-cell-lymphoma-a-retrospective-ana/2026-03-29T20:53:24+00:00https://lymphoma-stg.clarovantdigital.com/library/epidemiology-clinicopathological-profile-treatment-patterns-and-survival-outcomes-of-non-hodgkin-lymphoma-a-10-year-single-institution-retrospective-study/2026-03-31T18:24:02+00:00https://lymphoma-stg.clarovantdigital.com/library/the-validation-of-advanced-stage-hodgkin-lymphoma-international-prognostic-index-a-hipi-in-turkish-patients-with-classical-hodgkin-lymphoma/2026-04-02T19:18:53+00:00https://lymphoma-stg.clarovantdigital.com/library/prognostic-value-of-the-aggregate-inflammation-systemic-index-aisi-in-patients-with-diffuse-large-b-cell-lymphoma-a-multicenter-retrospective-study/2026-04-02T19:18:54+00:00https://lymphoma-stg.clarovantdigital.com/library/early-ibrutinib-dose-modifications-in-cll-a-post-hoc-analysis-of-the-real-world-evidence-study/2026-04-02T19:18:54+00:00https://lymphoma-stg.clarovantdigital.com/library/real-world-data-of-r-mini-chop-therapy-in-elderly-hispanic-population-with-diffuse-large-b-cell-lymphoma-and-high-grade-follicular-lymphoma/2026-04-02T19:18:54+00:00https://lymphoma-stg.clarovantdigital.com/library/synergistic-adverse-prognostic-impact-of-cd30-and-epstein-barr-virus-in-peripheral-t-cell-lymphoma-cd30-identifies-a-high-risk-subgroup-in-epstein-barr-virus-encoded-rna-positive-patients/2026-04-02T19:18:54+00:00https://lymphoma-stg.clarovantdigital.com/library/a-new-era-for-transplant-ineligible-r-r-lbcl-patients-whats-changing/2026-04-02T19:18:54+00:00https://lymphoma-stg.clarovantdigital.com/library/propensity-matched-study-of-liposomal-doxorubicin-vs-doxorubicin-in-first-line-dlbcl-treatment-efficacy-and-safety/2026-04-02T19:18:54+00:00https://lymphoma-stg.clarovantdigital.com/library/risk-of-skin-cancer-among-patients-with-chronic-lymphocytic-leukemia/2026-04-02T19:18:55+00:00https://lymphoma-stg.clarovantdigital.com/library/assessing-overall-survival-benefits-in-advanced-cancers-the-role-of-external-comparator-cohort-studies-with-real-world-data/2026-04-02T19:18:55+00:00https://lymphoma-stg.clarovantdigital.com/library/real-world-comparison-of-btk-inhibitors-and-lenalidomide-as-first-line-maintenance-in-primary-cns-lymphoma-a-multi-center-retrospective-study/2026-04-02T19:18:55+00:00https://lymphoma-stg.clarovantdigital.com/library/identifying-clustering-in-patterns-of-late-effects-among-survivors-of-adolescent-and-young-adult-hodgkin-lymphoma/2026-04-02T19:18:55+00:00https://lymphoma-stg.clarovantdigital.com/library/final-phase-2-study-results-of-acalabrutinib-in-treatment-naive-and-relapsed-refractory-chronic-lymphocytic-leukemia/2026-04-07T16:50:32+00:00https://lymphoma-stg.clarovantdigital.com/library/real-world-data-of-autologous-stem-cell-transplantation-for-patients-with-mantle-cell-lymphoma-in-argentina/2026-04-10T19:05:33+00:00https://lymphoma-stg.clarovantdigital.com/library/real-world-treatment-switching-and-sequencing-to-next-line-of-therapy-of-zanubrutinib-acalabrutinib-and-ibrutinib-in-chronic-lymphocytic-leukemia-or-small-lymphocytic-lymphoma/2026-04-10T19:05:34+00:00https://lymphoma-stg.clarovantdigital.com/library/neurotoxicity-in-older-patients-with-relapsed-or-refractory-large-b-cell-lymphoma-treated-with-car-t-cell-therapy-a-multicenter-study/2026-04-10T19:05:34+00:00https://lymphoma-stg.clarovantdigital.com/library/advances-in-biomarkers-for-mantle-cell-lymphoma-in-the-era-of-targeted-therapies/2026-04-10T19:05:34+00:00https://lymphoma-stg.clarovantdigital.com/library/real-world-evidence-of-treatment-outcomes-in-mantle-cell-lymphoma-a-single-center-experience-in-southern-taiwan/2026-04-10T19:05:34+00:00https://lymphoma-stg.clarovantdigital.com/library/cost-efficiency-modeling-of-conversion-to-biosimilar-rituximab-based-r-chop-in-diffuse-large-b-cell-lymphoma-in-medicare/2026-04-10T19:05:34+00:00https://lymphoma-stg.clarovantdigital.com/library/clinical-characteristics-and-outcome-of-diffuse-large-b-cell-lymphoma-real-world-data-from-saudi-arabia/2026-04-10T19:05:34+00:00https://lymphoma-stg.clarovantdigital.com/library/concomitant-recurrent-follicular-lymphoma-and-prostate-adenocarcinoma-detected-during-routine-urologic-follow-up-a-rare-case-report/2026-04-10T19:05:35+00:00https://lymphoma-stg.clarovantdigital.com/library/trends-and-disparities-in-non-hodgkin-lymphoma-related-mortality-in-the-united-states-1999-2020/2026-04-10T19:05:35+00:00https://lymphoma-stg.clarovantdigital.com/library/pirtobrutinib-a-highly-selective-noncovalent-reversible-btki-in-r-r-marginal-zone-lymphoma-phase-1-2-bruin-study/2026-04-10T19:05:35+00:00https://lymphoma-stg.clarovantdigital.com/library/a-real-world-study-of-tafasitamab-for-the-treatment-of-relapsed-or-refractory-diffuse-large-b-cell-lymphoma-in-the-united-states/2026-04-10T19:05:35+00:00https://lymphoma-stg.clarovantdigital.com/library/primary-refractory-disease-in-large-b-cell-lymphoma-definition-and-outcomes-from-a-secondary-analysis-of-the-ly-12-clinical-trial-2/2026-04-10T19:05:35+00:00https://lymphoma-stg.clarovantdigital.com/library/new-diagnosis-of-b-cell-follicular-lymphoma-temporally-associated-with-routine-vaccination-a-report-of-two-cases/2026-04-10T19:05:35+00:00https://lymphoma-stg.clarovantdigital.com/library/clinical-biological-and-treatment-related-predictors-of-central-nervous-system-relapse-in-diffuse-large-b-cell-lymphoma-a-retrospective-cohort-study/2026-04-10T19:05:36+00:00https://lymphoma-stg.clarovantdigital.com/library/outcomes-in-patients-with-refractory-relapsed-cns-lymphoma-treated-in-complete-remission-autologous-transplantation-vs-car-t-therapy/2026-04-10T19:05:36+00:00https://lymphoma-stg.clarovantdigital.com/library/primary-bone-lymphoma-in-adults-a-report-of-two-cases-and-review-of-the-literature-highlighting-the-role-of-radiotherapy/2026-04-10T19:05:36+00:00https://lymphoma-stg.clarovantdigital.com/library/zanubrutinib-based-regimen-as-the-salvage-or-bridging-treatment-of-cart-therapy-in-relapsed-or-refractory-non-germinal-center-b-cell-like-diffuse-large-b-cell-lymphoma-a-retrospective-multicenter-co/2026-04-10T19:09:23+00:00https://lymphoma-stg.clarovantdigital.com/library/primary-gastrointestinal-lymphoma-epidemiological-clinicopathological-and-prognostic-characteristics/2026-04-17T19:27:25+00:00https://lymphoma-stg.clarovantdigital.com/library/long-term-survival-with-lisocabtagene-maraleucel-in-second-line-large-b-cell-lymphoma-from-transform/2026-04-17T19:26:59+00:00https://lymphoma-stg.clarovantdigital.com/library/encouraging-response-rates-and-high-mobilization-success-with-brentuximab-vedotin-plus-gdp-in-adult-relapsed-refractory-classical-hodgkin-lymphoma-a-real-world-study/2026-04-17T20:12:04+00:00https://lymphoma-stg.clarovantdigital.com/library/burden-of-early-mortality-attributable-to-hodgkin-lymphoma-in-young-adults-a-united-states-study-based-on-cdc-wonder-data-2018-2023/2026-04-17T20:12:04+00:00https://lymphoma-stg.clarovantdigital.com/library/subsequent-primary-neoplasm-risk-among-survivors-of-cancer-in-adolescence-and-young-adulthood-a-population-based-study-from-alberta-canada/2026-04-17T20:12:04+00:00https://lymphoma-stg.clarovantdigital.com/library/pseudo-autologous-stem-cell-transplant-for-the-treatment-of-secondary-central-nervous-system-lymphoma/2026-04-17T20:12:04+00:00https://lymphoma-stg.clarovantdigital.com/library/real-world-treatment-patterns-and-safety-outcomes-of-targeted-therapies-in-a-single-center-chronic-lymphocytic-leukemia-cohort/2026-04-17T20:12:04+00:00https://lymphoma-stg.clarovantdigital.com/library/treatment-choice-for-chronic-lymphocytic-leukemia-after-covalent-btki-therapy-a-patient-and-oncologist-preference-study/2026-04-17T20:12:04+00:00https://lymphoma-stg.clarovantdigital.com/library/penpulimab-combined-with-rituximab-high-dose-methotrexate-and-cytarabine-pen-rma-in-newly-diagnosed-primary-central-nervous-system-lymphoma-pcnsl-a-phase-2-trial/2026-04-17T20:12:05+00:00https://lymphoma-stg.clarovantdigital.com/library/primary-cutaneous-kinase-negative-anaplastic-large-cell-lymphoma-presenting-as-a-subcutaneous-abdominal-wall-mass-in-a-young-adult-a-case-report-and-literature-review/2026-04-17T20:12:05+00:00https://lymphoma-stg.clarovantdigital.com/library/improved-survival-and-health-care-use-with-car-t-vs-historical-care-in-relapsed-refractory-large-b-cell-lymphoma/2026-04-17T20:12:05+00:00https://lymphoma-stg.clarovantdigital.com/library/molecularly-adapted-antitumor-therapy-for-newly-diagnosed-diffuse-large-b-cell-lymphoma-two-year-follow-up-results/2026-04-17T20:12:05+00:00https://lymphoma-stg.clarovantdigital.com/library/evolving-therapeutic-strategies-in-mantle-cell-lymphoma-advancements-and-future-directions/2026-04-17T20:12:05+00:00https://lymphoma-stg.clarovantdigital.com/library/treatment-and-survival-outcomes-for-patients-with-follicular-lymphoma-and-pod24-a-systematic-review-and-meta-analysis/2026-04-17T20:12:05+00:00https://lymphoma-stg.clarovantdigital.com/library/establishing-a-consumer-panel-to-inform-health-technology-assessment-processes-and-policy-impact-and-insights-from-singapore-experience/2026-04-17T20:12:06+00:00https://lymphoma-stg.clarovantdigital.com/library/advancing-health-technology-assessment-in-the-middle-east-and-north-africa-insights-and-outcomes-from-the-2025-htai-regional-meeting/2026-04-17T20:12:06+00:00https://lymphoma-stg.clarovantdigital.com/library/factors-influencing-front-line-treatment-of-chronic-lymphocytic-leukemia-a-french-real-world-study/2026-04-17T20:12:06+00:00https://lymphoma-stg.clarovantdigital.com/library/health-related-quality-of-life-with-odronextamab-monotherapy-for-relapsed-refractory-follicular-lymphoma-in-the-elm-2-study/2026-04-17T20:12:06+00:00https://lymphoma-stg.clarovantdigital.com/library/first-line-treatment-of-ighv-unmutated-chronic-lymphocytic-leukemia-a-network-meta-analysis-of-targeted-and-chemoimmunotherapy-regimens/2026-09-02T14:50:03+00:00https://lymphoma-stg.clarovantdigital.com/library/allogeneic-hct-as-consolidation-in-b-cell-lymphomas-after-exposure-to-bispecific-antibodies-a-geth-tc-study/2026-04-17T20:12:06+00:00https://lymphoma-stg.clarovantdigital.com/library/cytokine-release-syndrome-compatible-fever-after-initiation-of-local-radiotherapy-during-late-phase-epcoritamab-therapy-in-relapsed-refractory-diffuse-large-b-cell-lymphoma-a-case-report/2026-04-17T20:12:07+00:00https://lymphoma-stg.clarovantdigital.com/library/car-t-cell-therapy-for-chronic-lymphocytic-leukemia-a-promising-immunotherapy-approach/2026-04-24T13:00:12+00:00https://lymphoma-stg.clarovantdigital.com/library/rituximab-acalabrutinib-and-durvalumab-for-primary-central-nervous-system-lymphoma-a-single-arm-phase-1b-multi-center-study/2026-04-24T16:22:31+00:00https://lymphoma-stg.clarovantdigital.com/library/brentuximab-vedotin-and-bendamustine-for-relapsed-or-refractory-hodgkin-lymphoma-the-lysa-real-world-experience/2026-04-24T16:32:28+00:00https://lymphoma-stg.clarovantdigital.com/library/circulating-tumor-dna-at-baseline-as-a-prognostic-marker-in-untreated-follicular-lymphoma/2026-04-24T16:35:48+00:00https://lymphoma-stg.clarovantdigital.com/library/occult-obstructive-sleep-apnea-in-survivors-of-hodgkin-lymphoma-following-radiation-therapy-an-atypical-and-under-recognized-phenotype/2026-04-24T18:07:34+00:00https://lymphoma-stg.clarovantdigital.com/library/incidence-of-hodgkin-and-non-hodgkin-lymphomas-comparison-of-the-military-and-general-population/2026-04-24T18:07:34+00:00https://lymphoma-stg.clarovantdigital.com/library/solving-the-puzzle-of-hans-algorithm-ha-methodological-shortcomings-canadian-harmonization-of-hans-algorithm-for-diffuse-large-b-cell-lymphoma-dlbcl-and-development-of-fit-for-purpose-modified-ha/2026-04-24T18:07:34+00:00https://lymphoma-stg.clarovantdigital.com/library/ebstein-bar-virus-ebv-positive-diffuse-large-b-cell-vitreoretinal-lymphoma-two-cases-without-overt-immunocompromise-and-review-of-the-literature/2026-09-02T15:58:48+00:00https://lymphoma-stg.clarovantdigital.com/library/therapy-driven-clonal-dynamics-in-chronic-lymphocytic-leukemia/2026-04-24T18:07:34+00:00https://lymphoma-stg.clarovantdigital.com/library/richter-like-transformation-of-cll-sll-after-a-temporary-hold-of-ibrutinib-a-case-report/2026-04-24T18:07:34+00:00https://lymphoma-stg.clarovantdigital.com/library/tucidinostat-plus-r-chop-vs-r-chop-in-myc-bcl2-double-expressor-diffuse-large-b-cell-lymphoma/2026-04-24T18:07:35+00:00https://lymphoma-stg.clarovantdigital.com/library/clinical-characteristics-and-prognostic-prediction-of-secondary-solid-malignancies-in-patients-with-diffuse-large-b-cell-lymphoma-and-follicular-lymphoma/2026-04-24T18:07:35+00:00https://lymphoma-stg.clarovantdigital.com/library/a-targeted-circulating-tumor-dna-landscape-of-copy-number-aberrations-in-large-b-cell-lymphomas/2026-04-24T18:07:35+00:00https://lymphoma-stg.clarovantdigital.com/library/primary-cardiac-diffuse-large-b-cell-lymphoma-a-diagnostic-pitfall-with-overlapping-imaging-features/2026-04-24T18:07:35+00:00https://lymphoma-stg.clarovantdigital.com/library/molecular-international-prognostic-index-prognostic-model-in-diffuse-large-b-cell-lymphoma/2026-04-24T18:07:35+00:00https://lymphoma-stg.clarovantdigital.com/library/synchronous-breast-carcinoma-and-diffuse-large-b-cell-lymphoma-a-case-report-and-literature-review-on-diagnostic-challenges-and-management-implications/2026-04-24T18:07:35+00:00https://lymphoma-stg.clarovantdigital.com/library/cd5-positive-diffuse-large-b-cell-lymphoma-of-the-uterus-a-case-report-with-cytologic-findings-from-uterine-cavity-drainage-and-literature-review/2026-04-24T18:07:35+00:00https://lymphoma-stg.clarovantdigital.com/library/expression-and-prognostic-impact-of-cd73-in-classical-hodgkin-lymphoma/2026-04-24T18:07:35+00:00https://lymphoma-stg.clarovantdigital.com/library/checkpoint-inhibitors-obinutuzumab-plus-pet-adapted-ultra-low-dose-nodal-radiotherapy-yield-high-efficacy-in-treatment-naive-follicular-lymphoma-results-from-the-phase-ii-fluoro-study/2026-04-24T18:07:36+00:00https://lymphoma-stg.clarovantdigital.com/library/impact-of-peri-transplant-consolidative-radiotherapy-in-patients-with-relapsed-or-refractory-classical-hodgkin-lymphoma/2026-04-24T18:07:36+00:00https://lymphoma-stg.clarovantdigital.com/library/evaluation-of-incidence-and-outcomes-of-transformed-nodular-lymphocyte-predominant-hodgkin-lymphoma-in-the-united-states-a-population-based-cohort-study/2026-04-24T18:07:36+00:00https://lymphoma-stg.clarovantdigital.com/library/pathways-to-care-analysis-of-non-hodgkin-lymphoma-in-ethiopia-a-mixed-methods-study/2026-04-24T18:07:36+00:00https://lymphoma-stg.clarovantdigital.com/library/predictors-of-sensitivity-to-immune-therapies-in-classic-hodgkin-lymphoma/2026-04-24T18:07:36+00:00https://lymphoma-stg.clarovantdigital.com/library/real-world-clinical-outcomes-of-tisagenlecleucel-in-relapsed-or-refractory-diffuse-large-b-cell-lymphoma-a-single-center-retrospective-study/2026-04-24T19:13:35+00:00https://lymphoma-stg.clarovantdigital.com/library/clinical-utility-of-18f-fdg-pet-ct-in-the-assessment-of-mantle-cell-lymphoma-with-intraorbital-involvement-a-case-report-and-literature-review/2026-05-01T18:08:07+00:00https://lymphoma-stg.clarovantdigital.com/library/diffuse-large-b-cell-lymphoma-at-the-base-of-the-tongue-a-rare-diagnostic-entity-in-imaging/2026-05-01T18:08:07+00:00https://lymphoma-stg.clarovantdigital.com/library/real-world-efficacy-of-bruton-tyrosine-kinase-inhibitor-based-maintenance-therapy-in-diffuse-large-b-cell-lymphoma-a-multicenter-retrospective-cohort-study-with-external-historical-control/2026-05-01T18:08:07+00:00https://lymphoma-stg.clarovantdigital.com/library/abexinostat-a-histone-deacetylases-inhibitor-for-patients-with-relapsed-or-refractory-follicular-lymphoma-a-multi-center-single-arm-phase-2-study/2026-05-01T18:08:08+00:00https://lymphoma-stg.clarovantdigital.com/library/multidisciplinary-diagnosis-and-treatment-of-thyroid-diffuse-large-b-cell-lymphoma-with-tracheal-invasion-a-case-report/2026-05-01T18:08:08+00:00https://lymphoma-stg.clarovantdigital.com/library/circulating-tumor-dna-assessment-of-disease-response-in-large-b-cell-lymphoma-lisocabtagene-maraleucel-versus-autologous-stem-cell-transplantation-standard-therapy/2026-05-01T18:08:08+00:00https://lymphoma-stg.clarovantdigital.com/library/a-recently-recognized-and-underdiagnosed-entity-of-splenic-diffuse-red-pulp-small-b-cell-lymphoma-a-report-of-two-cases/2026-05-01T18:08:08+00:00https://lymphoma-stg.clarovantdigital.com/library/outpatient-versus-inpatient-axicabtagene-ciloleucel-car-t-cell-therapy-in-non-hodgkins-lymphoma-insights-from-a-us-multicenter-transplant-and-cellular-therapy-network/2026-05-01T18:08:08+00:00https://lymphoma-stg.clarovantdigital.com/library/improving-chimeric-antigen-receptor-t-access-in-latin-america-promises-barriers-and-a-call-to-action/2026-05-01T18:08:09+00:00https://lymphoma-stg.clarovantdigital.com/library/spontaneous-regression-of-stage-iv-advanced-diffuse-large-b-cell-lymphoma-in-an-person-living-with-hiv-a-case-report-and-literature-review/2026-05-01T18:08:09+00:00https://lymphoma-stg.clarovantdigital.com/library/adult-t-cell-leukemia-lymphoma-and-targeted-maternal-screening/2026-05-01T18:08:09+00:00https://lymphoma-stg.clarovantdigital.com/library/persistence-of-pet-scan-positivity-after-chemoimmunotherapy-for-dlbcl/2026-05-01T18:08:09+00:00https://lymphoma-stg.clarovantdigital.com/library/dissecting-minimal-residual-disease-dynamics-to-improve-outcome-prediction-in-mantle-cell-lymphoma-data-from-the-fondazione-italiana-linfomi-fil-mcl0208-clinical-trial/2026-05-01T18:08:09+00:00https://lymphoma-stg.clarovantdigital.com/library/the-efficacy-and-toxicity-of-cns-prophylaxis-in-diffuse-large-b-cell-lymphoma-clsg-cns-01-a-randomized-multicenter-prospective-phase-3-trial/2026-05-01T18:08:09+00:00https://lymphoma-stg.clarovantdigital.com/library/unfinished-business-in-chronic-lymphocytic-leukemia-translational-and-clinical-priorities-for-a-cure/2026-05-07T13:55:08+00:00https://lymphoma-stg.clarovantdigital.com/library/chronic-lymphoid-leukemia-in-togo-a-study-of-34-cases-collected-at-the-campus-teaching-hospital-of-lome-from-2012-to-2022/2026-05-07T14:01:47+00:00https://lymphoma-stg.clarovantdigital.com/library/extracorporeal-blood-purification-in-the-management-of-cytokine-release-syndrome-and-immune-effector-cellassociated-neurotoxicity-syndrome-following-chimeric-antigen-receptor-t-cell-therapy-a-case-re/2026-05-07T14:10:23+00:00https://lymphoma-stg.clarovantdigital.com/library/the-development-and-preliminary-validation-of-the-ctcl-pro-20-a-novel-quality-of-life-survey-for-patients-with-cutaneous-t-cell-lymphoma/2026-05-08T18:01:50+00:00https://lymphoma-stg.clarovantdigital.com/library/optimizing-bone-health-in-lymphoma-survivors-denosumab-superiority-to-alendronate-for-r-chop-like-therapy/2026-05-08T18:10:55+00:00https://lymphoma-stg.clarovantdigital.com/library/fixed-duration-obinutuzumab-ibrutinib-venetoclax-for-richters-transformation-results-from-the-phase-ii-givers-trial/2026-05-08T18:18:41+00:00https://lymphoma-stg.clarovantdigital.com/library/safety-and-efficacy-of-allogeneic-cd19-directed-car-t-therapy-ctx110-in-relapsed-refractory-b-cell-non-hodgkin-lymphoma/2026-05-08T18:46:07+00:00https://lymphoma-stg.clarovantdigital.com/library/intravenous-immunoglobulin-reduces-infections-for-patients-with-chronic-lymphocytic-leukemia-a-single-center-retrospective-analysis/2026-05-08T19:28:50+00:00https://lymphoma-stg.clarovantdigital.com/library/histologic-transformation-in-follicular-lymphoma-real-world-outcomes-with-rituximab-vs-obinutuzumab-based-combinations/2026-05-08T19:32:50+00:00https://lymphoma-stg.clarovantdigital.com/library/outcomes-of-patients-over-70-years-treated-with-brexu-cel-for-r-r-mantle-cell-lymphoma-a-study-from-the-ctiwp-of-ebmt/2026-05-08T19:32:50+00:00https://lymphoma-stg.clarovantdigital.com/library/real-world-effectiveness-of-zanubrutinib-plus-salvage-chemotherapy-in-relapsed-or-refractory-double-expressor-dlbcl/2026-05-08T19:32:50+00:00https://lymphoma-stg.clarovantdigital.com/library/prognostic-value-of-nutritional-and-functional-screening-instruments-for-mortality-in-patients-with-hematologic-malignancies/2026-05-08T19:32:50+00:00https://lymphoma-stg.clarovantdigital.com/library/psychological-distress-and-quality-of-life-in-patients-with-indolent-non-hodgkin-lymphoma/2026-05-08T19:32:50+00:00https://lymphoma-stg.clarovantdigital.com/library/efficacy-toxicity-and-prognostic-factors-of-rituximab-plus-cyclophosphamide-doxorubicin-vincristine-and-prednisone-in-elderly-patients-with-diffuse-large-b-cell-lymphoma-a-single-center-retrospe/2026-05-08T19:32:50+00:00https://lymphoma-stg.clarovantdigital.com/library/zamtocabtagene-autoleucel-in-relapsed-refractory-b-nhl-5-year-follow-up-of-a-cd20-19-tandem-car-t-cell-phase-1-trial/2026-05-08T19:32:51+00:00https://lymphoma-stg.clarovantdigital.com/library/a-phase-ii-study-of-daratumumab-and-ibrutinib-for-relapsed-refractory-chronic-lymphocytic-leukemia/2026-05-08T19:32:51+00:00https://lymphoma-stg.clarovantdigital.com/library/racial-and-clinical-determinants-of-response-in-2304-large-b-cell-lymphomas-treated-with-cd19-car-t-in-clinical-trials/2026-05-08T19:32:51+00:00https://lymphoma-stg.clarovantdigital.com/library/cns-prophylaxis-in-patients-with-diffuse-large-b-cell-lymphoma/2026-05-14T20:42:50+00:00https://lymphoma-stg.clarovantdigital.com/library/mosunetuzumab-plus-polatuzumab-vedotin-in-relapsed-refractory-mcl-after-btk-inhibitor-therapy-a-phase-2-study/2026-05-14T20:48:12+00:00https://lymphoma-stg.clarovantdigital.com/library/glofitamab-and-epcoritamab-for-large-b-cell-lymphoma-a-real-world-retrospective-uk-analysis-of-efficacy-tolerability-and-impact-of-treatment-sequencing/2026-05-14T20:51:39+00:00https://lymphoma-stg.clarovantdigital.com/library/cd20-re-emergence-in-a-patient-with-diffuse-large-b-cell-lymphoma-who-experienced-a-cd20-negative-relapse-after-glofitamab-treatment/2026-05-14T20:58:33+00:00https://lymphoma-stg.clarovantdigital.com/library/frailty-and-chronic-lymphocytic-leukemia-navigating-challenges-to-improve-outcomes/2026-05-15T19:41:46+00:00https://lymphoma-stg.clarovantdigital.com/library/ai-enhanced-quantitative-ihc-analysis-for-prognostic-stratification-in-marginal-zone-lymphoma-development-of-a-revised-mzl-ipi-model/2026-05-15T19:41:46+00:00https://lymphoma-stg.clarovantdigital.com/library/clinical-implications-of-immune-dysfunction-in-chronic-lymphocytic-leukemia/2026-05-15T19:41:46+00:00https://lymphoma-stg.clarovantdigital.com/library/improved-outcomes-for-relapsed-refractory-hodgkin-lymphoma-after-autologous-transplantation-in-the-era-of-novel-agents/2026-05-15T19:41:46+00:00https://lymphoma-stg.clarovantdigital.com/library/autologous-stem-cell-transplantation-after-anti-pd-1-therapy-for-multiply-relapsed-or-refractory-hodgkin-lymphoma/2026-05-15T19:41:47+00:00https://lymphoma-stg.clarovantdigital.com/library/treatment-adherence-survival-outcomes-and-barriers-to-care-of-non-hodgkin-lymphoma-in-northwest-ethiopia-a-mixed-methods-study/2026-05-15T19:41:47+00:00https://lymphoma-stg.clarovantdigital.com/library/primary-cutaneous-diffuse-large-b-cell-lymphoma-presenting-as-a-non-healing-axillary-ulcer/2026-05-15T19:41:47+00:00https://lymphoma-stg.clarovantdigital.com/library/a-comprehensive-review-of-the-role-of-zanubrutinib-for-patients-with-chronic-lymphocytic-leukemia/2026-05-15T19:41:47+00:00https://lymphoma-stg.clarovantdigital.com/library/a-decade-of-ibrutinib-for-cll-with-and-without-tp53-aberration-final-report-on-an-investigator-sponsored-phase-2-study/2026-05-15T19:41:47+00:00https://lymphoma-stg.clarovantdigital.com/library/a-rare-presentation-of-a-17-year-old-female-with-primary-colon-lymphoma-presenting-as-intussusception-a-case-report/2026-05-15T19:41:47+00:00https://lymphoma-stg.clarovantdigital.com/library/advancing-health-technology-assessment-in-taiwan-over-15-years-of-evidence-based-reform-innovation-and-patient-partnership/2026-05-15T19:41:47+00:00https://lymphoma-stg.clarovantdigital.com/library/what-the-future-holds-the-growing-role-of-real-world-evidence-in-health-technology-assessment-in-malaysia/2026-05-15T19:41:48+00:00https://lymphoma-stg.clarovantdigital.com/library/beyond-efficiency-reimagining-health-technology-assessment-in-the-age-of-artificial-intelligence/2026-05-15T19:41:48+00:00https://lymphoma-stg.clarovantdigital.com/library/addition-of-autologous-stem-cell-transplantation-to-an-ibrutinib-containing-first-line-treatment-in-patients-aged-18-65-years-with-mantle-cell-lymphoma-triangle-4-5-year-follow-up-of-a-three-arm-r/2026-05-15T19:41:48+00:00https://lymphoma-stg.clarovantdigital.com/library/prolonged-survival-with-glofitamab-in-non-diffuse-large-b-cell-lymphoma-after-car-t-cell-therapy-relapse/2026-05-22T13:38:17+00:00https://lymphoma-stg.clarovantdigital.com/library/a-phase-2-open-label-multicenter-study-of-the-safety-and-efficacy-of-tak-007-in-adult-patients-with-relapsed-refractory-b-cell-non-hodgkin-lymphoma/2026-05-22T17:28:41+00:00https://lymphoma-stg.clarovantdigital.com/library/mecapegfilgrastim-for-prophylaxis-of-immunochemotherapy-induced-neutropenia-in-patients-with-diffuse-large-b-cell-lymphoma-a-multicenter-pilot-trial/2026-05-22T17:36:29+00:00https://lymphoma-stg.clarovantdigital.com/library/metabolic-vulnerabilities-and-therapeutic-opportunities-in-diffuse-large-b-cell-lymphoma/2026-05-22T17:36:30+00:00https://lymphoma-stg.clarovantdigital.com/library/tailored-approaches-in-mantle-cell-lymphoma-refining-treatment-paradigms-with-an-expert-panel-opinion/2026-05-22T17:36:30+00:00https://lymphoma-stg.clarovantdigital.com/library/an-international-real-world-study-of-primary-vitreoretinal-lymphoma-from-the-australasian-lymphoma-alliance-and-collaborators/2026-05-22T17:36:30+00:00https://lymphoma-stg.clarovantdigital.com/library/marked-variation-in-eligibility-criteria-across-registrational-trials-for-relapsed-diffuse-large-b-cell-lymphoma-limits-applicability-to-clinical-practice/2026-05-22T17:36:30+00:00https://lymphoma-stg.clarovantdigital.com/library/single-cell-profiling-reveals-malignant-states-and-immune-landscapes-in-pcnsl-and-systemic-dlbcl/2026-05-22T17:36:30+00:00https://lymphoma-stg.clarovantdigital.com/library/family-history-of-haematological-malignancy-and-prognosis-across-non-hodgkin-lymphoma-subtypes/2026-05-22T17:36:30+00:00https://lymphoma-stg.clarovantdigital.com/library/patient-reported-health-related-quality-of-life-in-previously-untreated-chronic-lymphocytic-leukaemia-results-from-the-randomised-phase-3-flair-trial-comparing-ibrutinib-rituximab-versus-fludarabine/2026-05-22T17:36:30+00:00https://lymphoma-stg.clarovantdigital.com/library/clinical-outcomes-and-spatial-transcriptomic-profiles-of-cd19-20-car-t-therapy-in-relapsed-or-refractory-b-cell-non-hodgkins-lymphoma/2026-05-22T17:36:31+00:00https://lymphoma-stg.clarovantdigital.com/library/a-rare-case-of-primary-thyroid-lymphoma/2026-05-22T17:36:31+00:00https://lymphoma-stg.clarovantdigital.com/library/hairy-cell-leukemia-clinical-characteristics-and-outcomes-from-a-single-center-in-the-middle-east-and-north-africa/2026-05-22T17:36:31+00:00https://lymphoma-stg.clarovantdigital.com/library/real-world-evidence-for-pembrolizumab-gemcitabine-vinorelbine-and-liposomal-doxorubicin-in-classical-hodgkin-lymphoma/2026-05-22T17:36:31+00:00https://lymphoma-stg.clarovantdigital.com/library/occult-primary-prostate-lymphoma-in-a-young-male-a-case-report/2026-05-22T17:36:31+00:00https://lymphoma-stg.clarovantdigital.com/library/dynamics-of-complete-responses-crs-in-patients-with-relapsed-or-refractory-follicular-lymphoma-r-r-fl-treated-with-odronextamab-in-the-elm-2-study/2026-05-22T17:36:31+00:00https://lymphoma-stg.clarovantdigital.com/library/imaging-features-of-pediatric-primary-orbital-lymphomas-a-rare-case-with-histopathological-correlation-and-systematic-literature-review/2026-05-22T17:36:31+00:00https://lymphoma-stg.clarovantdigital.com/library/clinical-outcomes-of-cd3xcd20-bispecific-antibodies-in-patients-with-central-nervous-system-involvement-by-lymphoma/2026-05-22T17:36:32+00:00https://lymphoma-stg.clarovantdigital.com/library/the-in-vivo-revolution-in-car-t-therapy-medicinal-products-challenges-and-regulatory-prospects/2026-05-22T17:36:32+00:00https://lymphoma-stg.clarovantdigital.com/library/burden-and-management-of-infectious-diseases-in-patients-treated-by-chimeric-antigen-receptor-t-car-t-cell-therapy-for-refractory-or-relapsing-diffuse-large-b-cell-lymphoma-or-multiple-myeloma/2026-05-22T17:36:32+00:00https://lymphoma-stg.clarovantdigital.com/library/brentuximab-vedotin-as-a-bridge-to-transplant-in-hodgkin-lymphoma-patients-experience-from-treated-patients-in-north-macedonia/2026-05-25T17:20:33+00:00https://lymphoma-stg.clarovantdigital.com/library/locally-manufactured-versus-commercial-car-t-therapy-for-large-b-cell-lymphoma-a-multicenter-propensity-scorematched-analysis/2026-05-25T17:26:53+00:00https://lymphoma-stg.clarovantdigital.com/library/attenuated-antibody-responses-to-respiratory-syncytial-virus-vaccination-in-hematologic-malignancies-impact-of-anti-cd20-therapy/2026-05-25T17:34:42+00:00https://lymphoma-stg.clarovantdigital.com/library/hiv-related-plasmablastic-lymphoma-with-different-therapeutic-approaches-two-case-reports/2026-05-27T16:05:18+00:00https://lymphoma-stg.clarovantdigital.com/library/favezelimab-plus-pembrolizumab-for-anti-pd-1-refractory-classic-hodgkin-lymphoma-an-open-label-phase-1-2-study/2026-05-27T16:07:50+00:00https://lymphoma-stg.clarovantdigital.com/library/nivolumab-with-or-without-vinblastine-for-first-line-treatment-of-elderly-patients-with-hodgkin-lymphoma-and-coexisting-medical-conditions-the-niviniho-phase-ii-lysa-study/2026-05-29T18:05:07+00:00https://lymphoma-stg.clarovantdigital.com/library/outcomes-of-critically-ill-patients-with-newly-diagnosed-burkitts-lymphoma-a-monocentric-retrospective-study/2026-05-29T18:24:46+00:00https://lymphoma-stg.clarovantdigital.com/library/enhancing-immunotherapy-in-diffuse-large-b-cell-lymphoma-the-synergistic-potential-of-metabolic-checkpoint-inhibitors-and-immunomodulation/2026-05-29T18:24:47+00:00https://lymphoma-stg.clarovantdigital.com/library/survival-and-prognostic-features-of-early-stage-diffuse-large-b-cell-lymphoma-in-older-adults/2026-05-29T18:24:47+00:00https://lymphoma-stg.clarovantdigital.com/library/artificial-intelligence-enhancement-of-flow-cytometry-data-accelerates-the-identification-of-measurable-residual-chronic-lymphocytic-leukemia/2026-05-29T18:24:47+00:00https://lymphoma-stg.clarovantdigital.com/library/type-2-diabetes-and-risk-of-non-hodgkin-lymphoma-and-multiple-myeloma-a-pooled-analysis/2026-05-29T18:24:47+00:00https://lymphoma-stg.clarovantdigital.com/library/epcoritamab-monotherapy-as-outpatient-treatment-for-patients-with-relapsed-refractory-diffuse-large-b-cell-lymphoma-interim-results-from-epcore-nhl-6/2026-05-29T18:24:47+00:00https://lymphoma-stg.clarovantdigital.com/library/significant-variations-in-first-line-mantle-cell-lymphoma-care-an-australasian-lymphoma-and-related-diseases-registry-study/2026-05-29T18:24:47+00:00https://lymphoma-stg.clarovantdigital.com/library/safety-and-efficacy-of-azer-cel-an-allogeneic-cd19-car-t-for-the-treatment-of-patients-with-relapsed-refractory-non-hodgkin-lymphoma-and-chronic-lymphocytic-leukemia-not-previously-exposed-to-autolog/2026-06-01T11:45:46+00:00https://lymphoma-stg.clarovantdigital.com/library/plasmablastic-lymphoma-2026-update-on-diagnosis-risk-stratification-and-management/2026-05-29T18:24:48+00:00https://lymphoma-stg.clarovantdigital.com/library/treatment-evolution-and-survival-impact-of-consolidation-therapies-in-mantle-cell-lymphoma-insights-from-an-asia-pacific-real-world-registry/2026-05-29T18:24:48+00:00https://lymphoma-stg.clarovantdigital.com/library/prospective-phase-ii-study-of-frontline-helicobacter-pylori-eradication-therapy-for-early-stage-extragastric-mucosa-associated-lymphoid-tissue-lymphoma/2026-05-29T18:24:48+00:00https://lymphoma-stg.clarovantdigital.com/library/classic-hodgkin-lymphoma-beyond-the-lymph-node-a-systemic-immunobiological-paradigm/2026-06-04T21:54:59+00:00https://lymphoma-stg.clarovantdigital.com/library/mosunetuzumab-plus-polatuzumab-vedotin-mosun-pola-versus-rituximab-gemcitabine-and-oxaliplatin-r-gemox-in-patients-with-relapsed-refractory-large-b-cell-lymphoma-r-r-lbcl-updated-efficacy-and/2026-06-04T21:54:59+00:00https://lymphoma-stg.clarovantdigital.com/library/cd20-negative-primary-intestinal-diffuse-large-b-cell-lymphoma-with-tp53-mutation-in-poorly-controlled-celiac-disease-a-diagnostic-challenge/2026-06-04T21:55:00+00:00https://lymphoma-stg.clarovantdigital.com/library/regulatory-definitions-and-classification-of-biosimilar-medications-across-the-6-regions-of-the-world-health-organization/2026-06-04T21:55:00+00:00https://lymphoma-stg.clarovantdigital.com/library/accessing-btk-inhibitors-and-other-novel-therapies-for-mantle-cell-lymphoma-are-we-all-invited-to-the-party/2026-06-04T21:55:00+00:00https://lymphoma-stg.clarovantdigital.com/library/fixed-duration-glofitamab-monotherapy-in-relapsed-refractory-r-r-mantle-cell-lymphoma-mcl-with-without-prior-brutons-tyrosine-kinase-inhibitor-btki-exposure-updated-data-after-a-3-5-year-follow/2026-06-04T21:55:00+00:00https://lymphoma-stg.clarovantdigital.com/library/glofitamab-monotherapy-in-patients-with-heavily-pretreated-relapsed-refractory-r-r-mantle-cell-lymphoma-mcl-updated-analysis-from-a-phase-i-ii-study-2/2026-06-04T21:55:00+00:00https://lymphoma-stg.clarovantdigital.com/library/integrating-btk-inhibition-into-r-da-epoch-for-hiv-related-dlbcl/2026-06-04T21:55:01+00:00https://lymphoma-stg.clarovantdigital.com/library/tafasitamab-plus-lenalidomide-and-r-chop-versus-r-chop-for-first-line-treatment-of-patients-with-high-risk-diffuse-large-b-cell-lymphoma-frontmind-a-global-phase-3-randomised-double-blind-place/2026-06-04T21:55:01+00:00https://lymphoma-stg.clarovantdigital.com/library/comparative-efficacy-and-safety-of-systemic-therapies-in-transplant-eligible-and-ineligible-relapsed-refractory-large-b-cell-lymphoma-a-bayesian-network-meta-analysis/2026-06-04T21:55:01+00:00https://lymphoma-stg.clarovantdigital.com/library/rare-leukemic-phase-of-follicular-lymphoma-with-a-high-risk-follicular-lymphoma-international-prognostic-index-flipi-score-treated-with-bendamustine-rituximab/2026-06-04T21:55:01+00:00https://lymphoma-stg.clarovantdigital.com/library/real-world-outcomes-of-axicabtagene-ciloleucel-car-t-therapy-in-large-b-cell-lymphoma-a-single-center-observational-study/2026-06-04T21:55:01+00:00https://lymphoma-stg.clarovantdigital.com/library/real-world-outcomes-of-bispecific-antibodies-in-relapsed-refractory-r-r-follicular-lymphoma-fl/2026-06-04T21:55:01+00:00https://lymphoma-stg.clarovantdigital.com/library/geospatial-access-to-car-t-clinical-trials-for-non-hodgkin-lymphoma-for-persons-with-hiv/2026-06-04T21:55:02+00:00https://lymphoma-stg.clarovantdigital.com/library/chidamide-in-combination-with-chop-in-previously-untreated-peripheral-t-cell-lymphoma-with-t-follicular-helper-phenotype-results-of-the-phase-ii-swift-trial/2026-06-04T21:55:02+00:00https://lymphoma-stg.clarovantdigital.com/library/phase-2-trial-of-epcoritamab-in-combination-with-rituximab-mini-cvp-for-older-unfit-frail-or-anthracycline-ineligible-adult-patients-with-newly-diagnosed-diffuse-large-b-cell-lymphoma-interim-futilit/2026-06-04T21:55:02+00:00https://lymphoma-stg.clarovantdigital.com/library/golcadomide-golca-a-potential-first-in-class-oral-celmod-pola-rchp-in-patients-pts-with-newly-diagnosed-aggressive-b-cell-lymphoma-a-bcl-safety-and-12-month-mo-efficacy-results/2026-06-04T21:55:02+00:00https://lymphoma-stg.clarovantdigital.com/library/real-world-toxicity-of-bispecific-antibodies-versus-car-t-cell-therapy-in-diffuse-large-b-cell-lymphoma-and-follicular-lymphoma/2026-06-04T21:55:03+00:00https://lymphoma-stg.clarovantdigital.com/library/measurable-residual-disease-mrd-by-circulating-tumor-ct-dna-in-patients-pt-with-r-r-follicular-lymphoma-fl-treated-with-lisocabtagene-maraleucel-liso-cel-in-transcend-fl/2026-06-04T21:55:03+00:00https://lymphoma-stg.clarovantdigital.com/library/newly-diagnosed-extranodal-nk-t-cell-lymphoma-nasal-type-at-the-injected-left-arm-after-bnt162b2-mrna-covid-19-vaccination/2026-06-04T21:55:03+00:00https://lymphoma-stg.clarovantdigital.com/library/tumor-lysis-syndrome-risk-in-burkitt-lymphoma-versus-mantle-cell-lymphoma-during-alkylating-therapy-a-propensity-matched-trinetx-comparative-outcome-analysis/2026-06-04T21:55:03+00:00https://lymphoma-stg.clarovantdigital.com/library/efficacy-and-safety-of-bruton-tyrosine-kinase-inhibitors-in-waldenstrom-macroglobulinemia-a-single-center-retrospective-analysis/2026-06-04T21:55:03+00:00https://lymphoma-stg.clarovantdigital.com/library/survival-trends-in-the-era-of-novel-therapies-identify-unmet-needs-in-peripheral-t-cell-lymphoma-a-national-cancer-database-analysis/2026-06-04T21:55:03+00:00https://lymphoma-stg.clarovantdigital.com/library/real-world-impact-of-atrial-fibrillation-afib-on-cardiovascular-cv-outcomes-and-healthcare-resource-utilization-hcru-in-patients-with-chronic-lymphocytic-leukemia-cll/2026-06-04T21:55:04+00:00https://lymphoma-stg.clarovantdigital.com/library/next-generation-models-for-lymphoid-malignancies-the-rise-of-3d-culture-systems-in-translational-hematology/2026-06-04T21:55:04+00:00https://lymphoma-stg.clarovantdigital.com/library/inequities-in-access-to-rituximab-and-survival-in-non-hodgkin-lymphoma-a-20-year-cohort-study-from-nigeria/2026-06-04T22:05:43+00:00https://lymphoma-stg.clarovantdigital.com/library/chronic-lymphocytic-leukemia-through-the-spectrum-frontline-therapy-sequencing-with-subsequent-therapy-and-treatment-of-double-refractory-patients/2026-06-04T22:11:31+00:00https://lymphoma-stg.clarovantdigital.com/library/comparative-toxicity-and-survival-outcomes-of-lmb-96-chemotherapy-protocol-with-or-without-rituximab-in-pediatric-high-risk-b-cell-non-hodgkin-lymphoma/2026-06-09T14:08:26+00:00https://lymphoma-stg.clarovantdigital.com/library/levels-of-physical-activity-and-sedentary-lifestyle-in-patients-with-hematological-cancer-treated-with-monoclonal-antibodies-as-a-monotherapy-or-combination-therapy-immunochemotherapy-a-comparative/2026-06-09T14:09:44+00:00https://lymphoma-stg.clarovantdigital.com/library/real-world-treatment-patterns-of-patients-with-large-b-cell-lymphoma-over-time-and-into-a-post-car-t-approval-era/2026-06-09T14:17:01+00:00https://lymphoma-stg.clarovantdigital.com/library/anti-programmed-cell-death-protein-1-based-salvage-therapy-for-relapsed-refractory-hodgkin-lymphoma-a-multicenter-real-world-analysis/2026-06-11T20:46:45+00:00https://lymphoma-stg.clarovantdigital.com/library/brentuximab-vedotin-after-allosct-for-relapsed-refractory-hodgkin-lymphoma-ghsg-bv-allo-phase-ii-trial/2026-06-11T20:51:30+00:00https://lymphoma-stg.clarovantdigital.com/library/allogeneic-hematopoietic-cell-transplantation-for-relapsed-refractory-hodgkin-lymphoma-a-multicenter-real-world-experience/2026-06-11T20:56:45+00:00https://lymphoma-stg.clarovantdigital.com/library/atypical-cutaneous-manifestation-leading-to-the-diagnosis-of-chronic-lymphocytic-leukemia/2026-06-19T18:51:35+00:00https://lymphoma-stg.clarovantdigital.com/library/healthy-birth-after-chemotherapy-for-diffuse-large-b-cell-lymphoma-with-superior-vena-cava-syndrome-in-late-pregnancy-a-case-report/2026-06-19T18:51:35+00:00https://lymphoma-stg.clarovantdigital.com/library/pathogenesis-of-diffuse-large-b-cell-lymphoma-proteogenotypes/2026-06-19T18:51:35+00:00https://lymphoma-stg.clarovantdigital.com/library/real-world-outcomes-among-medicare-beneficiaries-treated-with-first-line-1l-bruton-tyrosine-kinase-inhibitors-btkis-for-chronic-lymphocytic-leukemia-cll/2026-06-19T18:51:35+00:00https://lymphoma-stg.clarovantdigital.com/library/precision-medicine-in-non-hodgkin-lymphoma-advances-in-btk-inhibition-cd30-directed-antibody-drug-conjugates-and-hdac-mediated-epigenetic-therapy-with-pirtobrutinib-brentuximab-vedotin-and-belino/2026-06-19T18:51:36+00:00https://lymphoma-stg.clarovantdigital.com/library/dose-adjusted-epoch-r-in-aggressive-b-cell-lymphomas-efficacy-molecular-prognostic-factors-and-real-world-outcomes-from-a-multicenter-turkish-cohort-a-turkish-oncology-group-tog-study/2026-06-19T18:51:36+00:00https://lymphoma-stg.clarovantdigital.com/library/frontmind-phase-3-study-of-tafasitamab-tafa-plus-lenalidomide-len-and-r-chop-for-patients-pts-with-newly-diagnosed-diffuse-large-b-cell-lymphoma-dlbcl/2026-06-19T18:51:36+00:00https://lymphoma-stg.clarovantdigital.com/library/optimizing-car-t-therapy-delivery-in-the-italian-healthcare-system-economic-and-organizational-insights-in-follicular-lymphoma/2026-06-19T18:51:36+00:00https://lymphoma-stg.clarovantdigital.com/library/phase-2-multicenter-maintenance-study-of-golidocitinib-a-jak1-selective-inhibitor-in-patients-with-peripheral-t-cell-lymphomas-after-first-line-systemic-therapy-jackpot26/2026-06-19T18:51:36+00:00https://lymphoma-stg.clarovantdigital.com/library/microcosting-of-childhood-hodgkin-lymphoma-treatment-across-resource-levels-using-the-adapted-resource-and-implementation-application-guidelines-in-the-us/2026-06-19T18:51:37+00:00https://lymphoma-stg.clarovantdigital.com/library/clinical-spectrum-and-treatment-of-thyroid-lymphoma-results-of-a-cohort-study-of-61-patients/2026-06-19T18:51:37+00:00https://lymphoma-stg.clarovantdigital.com/library/real-world-overall-survival-and-time-to-next-treatment-among-medicare-beneficiaries-with-chronic-lymphocytic-leukemia-in-the-frontline-setting/2026-06-19T18:51:37+00:00https://lymphoma-stg.clarovantdigital.com/library/high-dose-methotrexate-as-cns-prophylaxis-in-ultra-high-risk-large-b-cell-lymphoma-an-international-multicenter-analysis/2026-06-19T18:51:37+00:00https://lymphoma-stg.clarovantdigital.com/library/allogeneic-hematopoietic-cell-transplantation-for-t-cell-histiocyte-rich-large-b-cell-lymphoma-an-ebmt-lymphoma-working-party-study/2026-06-19T18:51:37+00:00https://lymphoma-stg.clarovantdigital.com/library/updated-efficacy-and-safety-results-of-rocbrutinib-from-the-phase-2-rock-1-study-in-patients-with-relapsed-or-refractory-mantle-cell-lymphoma-and-previously-treated-with-btk-inhibitor/2026-06-19T18:51:37+00:00https://lymphoma-stg.clarovantdigital.com/library/pembrolizumab-in-children-and-young-adults-with-high-risk-classic-hodgkin-lymphoma-with-slow-early-response-to-front-line-chemotherapy-updated-results-from-keynote-667/2026-06-19T18:51:38+00:00https://lymphoma-stg.clarovantdigital.com/library/the-association-between-financial-toxicity-and-mortality-in-hematologic-malignancies-a-systematic-review-and-meta-analysis/2026-06-19T18:51:38+00:00https://lymphoma-stg.clarovantdigital.com/library/primary-bone-diffuse-large-b-cell-lymphoma-dlbcl-in-a-young-adult-a-case-report/2026-06-19T18:51:38+00:00https://lymphoma-stg.clarovantdigital.com/library/real-world-impact-of-atrial-fibrillation-on-cardiovascular-outcomes-and-healthcare-resource-utilization-in-patients-with-chronic-lymphocytic-leukemia-small-lymphocytic-lymphoma/2026-06-19T18:51:38+00:00https://lymphoma-stg.clarovantdigital.com/library/safety-and-efficacy-of-subcutaneous-mosunetuzumab-plus-lenalidomide-induction-therapy-followed-by-mosunetuzumab-maintenance-in-previously-untreated-follicular-lymphoma/2026-06-19T18:51:38+00:00https://lymphoma-stg.clarovantdigital.com/library/outcomes-of-lisocabtagene-maraleucel-liso-cel-in-patients-pt-with-relapsed-or-refractory-r-r-mantle-cell-lymphoma-mcl-first-real-world-data-from-the-cibmtr/2026-06-19T18:51:38+00:00https://lymphoma-stg.clarovantdigital.com/library/coformulated-favezelimab-pembrolizumab-versus-chemotherapy-in-participants-with-relapsed-or-refractory-classic-hodgkin-lymphoma-results-of-the-randomized-phase-2-keyform-008-study/2026-06-19T18:51:39+00:00https://lymphoma-stg.clarovantdigital.com/library/efficacy-and-safety-of-subcutaneous-mosunetuzumab-plus-polatuzumab-vedotin-in-patients-with-relapsed-refractory-large-b-cell-lymphoma-japan-subgroup-analysis-of-the-phase-iii-sunmo-trial/2026-06-19T18:51:39+00:00https://lymphoma-stg.clarovantdigital.com/library/comparison-of-long-term-efficacy-between-the-brecadd-and-navd-regimens-in-advanced-stage-hodgkin-lymphoma-a-matching-adjusted-indirect-treatment-comparison-of-the-hd21-and-swog-s1826-trials/2026-06-19T18:51:39+00:00https://lymphoma-stg.clarovantdigital.com/library/overcoming-chemotherapy-resistance-in-diffuse-large-b-cell-lymphoma-using-multifunctional-nanocarriers-current-advances-and-clinical-challenges/2026-06-19T18:51:39+00:00https://lymphoma-stg.clarovantdigital.com/library/comparative-outcomes-of-lisocabtagene-maraleucel-versus-an-external-control-arm-in-third-line-or-later-relapsed-or-refractory-follicular-lymphoma/2026-06-19T18:51:39+00:00https://lymphoma-stg.clarovantdigital.com/library/safety-data-and-initial-pooled-efficacy-data-from-the-nordic-lymphoma-group-phase-3-polar-bear-trial-in-elderly-or-frail-patients-with-diffuse-large-cell-lymphoma-r-pola-mini-chp-vs-r-mini-chop/2026-06-19T18:51:39+00:00https://lymphoma-stg.clarovantdigital.com/library/real-world-outcomes-of-bispecific-antibody-therapy-after-chimeric-antigen-receptor-t-cell-therapy-in-follicular-lymphoma/2026-06-19T18:51:40+00:00https://lymphoma-stg.clarovantdigital.com/library/comparative-prognostic-performance-of-nutritional-and-inflammatory-indices-in-diffuse-large-b-cell-lymphoma/2026-06-19T18:51:40+00:00https://lymphoma-stg.clarovantdigital.com/library/a-prospective-population-based-study-of-chimeric-antigen-receptor-t-cell-therapy-for-patients-with-diffuse-large-b-cell-lymphoma/2026-06-19T18:51:40+00:00https://lymphoma-stg.clarovantdigital.com/library/clinical-and-pathological-features-that-predict-high-grade-b-cell-lymphomas-hgbcls-with-myc-and-bcl2-or-bcl6-translocations-double-hit-lymphoma-a-systematic-review-and-meta-analysis/2026-06-19T18:51:40+00:00https://lymphoma-stg.clarovantdigital.com/library/impact-of-spleen-volume-and-volume-change-in-non-hodgkin-lymphoma-treated-with-chimeric-antigen-receptor-t-cell-therapy/2026-06-19T18:51:40+00:00https://lymphoma-stg.clarovantdigital.com/library/updated-efficacy-and-safety-data-from-an-ongoing-phase-1a-b-trial-of-the-btk-degrader-bexobrutideg-nx-5948-in-patients-with-cll-across-lines-of-therapy/2026-07-31T16:41:39+00:00https://lymphoma-stg.clarovantdigital.com/library/polatuzumab-vedotin-plus-rituximab-ifosfamide-carboplatin-etoposide-pola-r-ice-vs-r-ice-as-second-line-treatment-in-large-b-cell-lymphoma-lbcl-final-analysis-of-a-randomized-phase-3-study/2026-06-19T18:51:41+00:00https://lymphoma-stg.clarovantdigital.com/library/lenalidomide-plus-rituximab-for-previously-untreated-advanced-follicular-lymphoma-the-10-year-relevance-trial-analysis/2026-06-19T18:51:41+00:00https://lymphoma-stg.clarovantdigital.com/library/surovatamig-azd0486-plus-rituximab-in-previously-untreated-follicular-lymphoma-fl-initial-safety-data-from-the-phase-3-soundtrack-f1-trial/2026-06-19T18:51:41+00:00https://lymphoma-stg.clarovantdigital.com/library/early-surgical-intervention-in-a-case-of-primary-cardiac-lymphoma-in-an-immunocompetent-56-year-old-male/2026-06-19T18:51:41+00:00https://lymphoma-stg.clarovantdigital.com/library/fixed-duration-pirtobrutinib-plus-venetoclax-rituximab-versus-venetoclax-rituximab-for-patients-with-previously-treated-cll-sll-a-phase-3-randomized-trial-bruin-cll-322-2/2026-06-19T19:01:50+00:00https://lymphoma-stg.clarovantdigital.com/library/glofitamab-plus-gemcitabine-and-oxaliplatin-for-relapsed-refractory-dlbcl-3-year-follow-up-of-starglo/2026-06-19T19:27:21+00:00https://lymphoma-stg.clarovantdigital.com/library/extranodal-non-hodgkin-lymphoma-of-the-head-and-neck-region-a-review-of-55-cases/2026-06-25T17:00:10+00:00https://lymphoma-stg.clarovantdigital.com/library/car-t-cell-therapy-versus-salvage-chemotherapy-in-relapsed-refractory-dlbcl-a-systematic-review-and-meta-analysis-integrating-radiologic-laboratory-and-histopathologic-correlates/2026-06-26T20:09:40+00:00https://lymphoma-stg.clarovantdigital.com/library/atrial-fibrillation-secondary-to-diffuse-large-b-cell-lymphoma-responding-to-corticosteroid-treatment-a-case-report/2026-06-26T20:19:53+00:00https://lymphoma-stg.clarovantdigital.com/library/clinico-epidemiological-histopathological-and-cytogenetic-profiling-of-non-hodgkin-lymphoma-at-a-tertiary-care-hospital-in-maharashtra-india-a-4-year-combined-prospective-and-retrospective-observa/2026-06-26T20:19:54+00:00https://lymphoma-stg.clarovantdigital.com/library/concurrent-chronic-myeloid-leukemia-and-chronic-lymphocytic-leukemia-at-initial-presentation-a-case-report-and-review-of-the-literature/2026-06-26T20:19:54+00:00https://lymphoma-stg.clarovantdigital.com/library/immunotherapy-of-diffuse-large-b-cell-lymphoma-from-monoclonal-antibodies-to-cellular-therapies-a-narrative-review/2026-06-26T20:19:54+00:00https://lymphoma-stg.clarovantdigital.com/library/outcomes-and-salvage-strategies-for-large-b-cell-lymphoma-progressing-after-second-line-car-t-cell-therapy-a-descar-t-study-from-the-lysa-group/2026-06-26T20:19:54+00:00https://lymphoma-stg.clarovantdigital.com/library/durability-benchmarking-of-contemporary-second-line-and-later-therapies-for-relapsed-or-refractory-follicular-lymphoma-using-reconstructed-individual-patient-data-from-published-kaplan-meier-curves/2026-06-26T20:19:54+00:00https://lymphoma-stg.clarovantdigital.com/library/circulating-tumor-dna-testing-in-solid-tumors-and-lymphoma-asco-guideline/2026-06-26T20:19:54+00:00https://lymphoma-stg.clarovantdigital.com/library/safety-and-efficacy-of-dose-modified-approaches-of-fixed-duration-fd-ibrutinibvenetoclax-iv-in-patients-with-previously-untreated-cll-primary-analysis-of-the-prospective-phase-2-tailor-study/2026-06-26T20:19:54+00:00https://lymphoma-stg.clarovantdigital.com/library/polatuzumab-r-chp-vs-r-chop-in-older-dlbcl-survival-benefit-infectious-toxicity-and-cost-implications-in-middle-income-health-systems/2026-06-26T20:19:55+00:00https://lymphoma-stg.clarovantdigital.com/library/genomic-heterogeneity-in-primary-cutaneous-follicular-center-lymphomas-reveals-different-clinicopathological-subgroups/2026-06-26T20:19:55+00:00https://lymphoma-stg.clarovantdigital.com/library/pet-guided-early-identification-of-car-t-candidates-in-diffuse-large-b-cell-lymphoma-a-multidisciplinary-expert-consensus/2026-06-26T20:19:55+00:00https://lymphoma-stg.clarovantdigital.com/library/results-from-epcore-dlbcl-1-randomized-phase-3-study-of-epcoritamab-epcor-vs-investigators-choice-chemoimmunotherapy-cit-in-patients-with-relapsed-refractory-large-b-cell-lymphoma-r-r-l/2026-06-26T20:23:17+00:00https://lymphoma-stg.clarovantdigital.com/library/current-findings-in-the-resistance-mechanism-of-anti-cd19-car-t-cell-therapy-in-b-cell-malignancies-a-literature-review/2026-07-05T16:30:01+00:00https://lymphoma-stg.clarovantdigital.com/library/anti-cd47-antibody-magrolimab-with-pembrolizumab-in-patients-with-relapsed-refractory-classic-hodgkin-lymphoma/2026-07-05T16:33:58+00:00https://lymphoma-stg.clarovantdigital.com/library/outcome-of-classic-hodgkin-lymphoma-treated-with-abvd-regimen-a-single-center-experience/2026-07-05T16:38:39+00:00https://lymphoma-stg.clarovantdigital.com/library/outcome-of-ibrutinib-in-chronic-lymphocytic-leukemia-real-world-experience-from-a-developing-country/2026-07-05T16:44:11+00:00https://lymphoma-stg.clarovantdigital.com/library/a-novel-dose-dense-strategy-for-cd19-directed-car-t-cell-therapy-is-associated-with-durable-responses-without-increased-toxicity-in-patients-with-b-cell-non-hodgkin-lymphoma/2026-07-05T17:07:15+00:00https://lymphoma-stg.clarovantdigital.com/library/the-prognostic-implications-of-autoimmune-hemolytic-anemia-in-chronic-lymphocytic-leukemia-across-treatment-eras/2026-07-05T17:11:04+00:00https://lymphoma-stg.clarovantdigital.com/library/incidence-and-mortality-rates-of-hodgkins-lymphoma-in-the-western-region-of-libya/2026-07-05T17:13:52+00:00https://lymphoma-stg.clarovantdigital.com/library/pattern-of-histological-subtypes-of-non-hodgkin-lymphoma-a-hospital-based-study-from-nepal/2026-07-05T17:18:18+00:00https://lymphoma-stg.clarovantdigital.com/library/dual-resistance-to-asparaginase-and-pd-1-blockade-in-extranodal-natural-killer-t-cell-lymphoma-dismal-outcomes-from-a-multicenter-cohort/2026-07-10T15:28:31+00:00https://lymphoma-stg.clarovantdigital.com/library/real-world-outcomes-of-glofitamab-therapy-in-car-t-naive-patients-with-relapsed-refractory-large-b-cell-lymphoma/2026-07-10T15:33:07+00:00https://lymphoma-stg.clarovantdigital.com/library/misdiagnosis-analysis-and-multidisciplinary-collaborative-treatment-of-primary-cutaneous-diffuse-large-b-cell-lymphoma-case-report/2026-07-10T17:16:28+00:00https://lymphoma-stg.clarovantdigital.com/library/use-and-reporting-of-patient-reported-outcomes-in-randomized-controlled-trials-in-non-hodgkin-lymphoma-a-scoping-review/2026-07-10T17:16:28+00:00https://lymphoma-stg.clarovantdigital.com/library/clinical-follow-up-using-patient-reported-outcome-pro-for-patients-with-lymphoma-and-chronic-lymphocytic-leukemia-in-a-hematological-outpatient-clinic-a-danish-prospective-study/2026-07-10T17:16:28+00:00https://lymphoma-stg.clarovantdigital.com/library/extranodal-natural-killer-t-cell-lymphoma-from-fatal-to-curable/2026-09-02T15:58:15+00:00https://lymphoma-stg.clarovantdigital.com/library/current-landscape-of-academic-and-point-of-care-car-t-cell-therapy-in-low-middle-income-countries/2026-07-10T17:16:28+00:00https://lymphoma-stg.clarovantdigital.com/library/clinical-decision-support-in-hematological-malignancies-using-a-case-grounded-ai-agent/2026-07-10T17:16:28+00:00https://lymphoma-stg.clarovantdigital.com/library/effects-of-home-based-exercise-with-telehealth-guidance-in-lymphoma-survivors-entering-cardio-oncology-rehabilitation-a-randomized-controlled-trial/2026-07-10T17:16:29+00:00https://lymphoma-stg.clarovantdigital.com/library/long-term-clinical-outcomes-from-the-smart-start-trial-rituximab-lenalidomide-and-ibrutinib-in-patients-with-newly-diagnosed-large-b-cell-lymphoma/2026-07-10T17:16:29+00:00https://lymphoma-stg.clarovantdigital.com/library/feasibility-and-outcomes-of-decentralized-point-of-care-cd19-car-t-cell-for-relapsed-large-b-cell-lymphoma-in-resource-limited-settings/2026-07-10T17:16:29+00:00https://lymphoma-stg.clarovantdigital.com/library/obinutuzumab-lenalidomide-and-venetoclax-for-the-initial-treatment-of-patients-with-advanced-stage-follicular-lymphoma-results-of-the-phase-ib-ii-leverage-study/2026-07-10T17:16:29+00:00https://lymphoma-stg.clarovantdigital.com/library/effects-of-chronic-lymphocytic-leukaemia-cll-directed-therapy-on-diffuse-large-b-cell-lymphoma-dlbcl-type-richter-transformation-compared-to-de-novo-dlbcl-in-a-nationwide-cohort/2026-07-10T17:16:29+00:00https://lymphoma-stg.clarovantdigital.com/library/clinicopathological-characteristics-and-prediction-of-overall-survival-and-death-within-2-years-in-diffuse-large-b-cell-lymphoma-based-on-histological-images-and-deep-learning/2026-07-10T17:16:29+00:00https://lymphoma-stg.clarovantdigital.com/library/updated-real-world-outcomes-with-brentuximab-vedotin-in-chinese-lymphoma-patients-a-multicenter-retrospective-study/2026-07-10T17:16:30+00:00https://lymphoma-stg.clarovantdigital.com/library/the-complex-interplay-of-malaria-and-ebv-in-burkitt-lymphoma/2026-09-02T15:57:31+00:00https://lymphoma-stg.clarovantdigital.com/library/oral-manifestations-and-dental-management-in-patients-undergoing-car-t-cell-therapy-a-retrospective-observational-study/2026-07-10T17:16:30+00:00https://lymphoma-stg.clarovantdigital.com/library/phase-i-ii-study-of-sonrotoclax-bgb-11417-monotherapy-in-patients-with-mantle-cell-lymphoma-previously-treated-with-anti-cd20-therapy-and-a-bruton-tyrosine-kinase-inhibitor/2026-07-10T17:16:30+00:00https://lymphoma-stg.clarovantdigital.com/library/orelabrutinib-versus-chemoimmunotherapy-in-treatment-naive-chronic-lymphocytic-leukemia-small-lymphocytic-lymphoma-a-randomized-phase-3-trial/2026-07-10T17:16:30+00:00https://lymphoma-stg.clarovantdigital.com/library/mantle-cell-lymphoma-artificial-intelligence-prognostic-index-using-hematoxylin-and-eosin-histology/2026-07-10T17:16:30+00:00https://lymphoma-stg.clarovantdigital.com/library/polatuzumab-vedotin-plus-rituximab-gemcitabine-and-oxaliplatin-in-relapsed-or-refractory-diffuse-large-b-cell-lymphoma-results-from-the-phase-iii-randomized-polargo-trial/2026-07-10T17:16:31+00:00https://lymphoma-stg.clarovantdigital.com/library/prevalence-pattern-and-prognosis-of-lung-lesions-in-pediatric-hodgkin-lymphoma/2026-07-10T17:16:31+00:00https://lymphoma-stg.clarovantdigital.com/library/marginal-zone-lymphoma-2026-update-on-diagnosis-and-management/2026-07-10T17:16:31+00:00https://lymphoma-stg.clarovantdigital.com/library/real-world-outcomes-of-venetoclax-in-relapsed-refractory-chronic-lymphocytic-leukemia/2026-07-10T17:16:31+00:00https://lymphoma-stg.clarovantdigital.com/library/sufficient-dose-brentuximab-vedotin-improves-prognosis-in-patients-with-classic-hodgkin-lymphoma-a-single-center-real-world-study-in-china/2026-07-10T17:16:31+00:00https://lymphoma-stg.clarovantdigital.com/library/comparison-of-epcoritamab-lenalidomide-and-rituximab-versus-usual-care-in-relapsed-refractory-follicular-lymphoma/2026-07-10T17:16:31+00:00https://lymphoma-stg.clarovantdigital.com/library/cellular-therapy-in-mantle-cell-lymphoma-recommendations-from-the-ebmt-practice-harmonisation-and-guidelines-committee/2026-07-10T17:16:32+00:00https://lymphoma-stg.clarovantdigital.com/library/what-is-new-in-the-5th-edition-of-the-world-health-organization-classification-of-mature-b-and-t-nk-cell-tumors-and-stromal-neoplasms/2026-09-02T15:57:07+00:00https://lymphoma-stg.clarovantdigital.com/library/a-multi-targeted-strategy-for-relapsed-refractory-b-cell-non-hodgkin-lymphoma-real-world-outcomes-of-the-vipor-regimen/2026-07-10T17:16:32+00:00https://lymphoma-stg.clarovantdigital.com/library/unfinished-business-in-chronic-lymphocytic-leukemia-translational-and-clinical-priorities-for-a-cure-2/2026-07-10T17:16:32+00:00https://lymphoma-stg.clarovantdigital.com/library/histological-response-dynamics-in-gastric-extranodal-marginal-zone-b-cell-lymphoma-of-the-mucosa-associated-lymphoid-tissue-after-helicobacter-pylori-eradication-a-single-center-longitudinal-analysis/2026-07-11T23:41:43+00:00https://lymphoma-stg.clarovantdigital.com/library/bleomycin-omission-in-limited-stage-classic-hodgkin-lymphoma-with-negative-pet-scan-after-two-cycles-of-abvd/2026-07-13T14:09:06+00:00https://lymphoma-stg.clarovantdigital.com/library/limited-efficacy-of-salvage-r-ice-therapy-in-relapsed-diffuse-large-b-cell-lymphoma-a-real-world-study-from-iraq/2026-07-13T14:08:19+00:00https://lymphoma-stg.clarovantdigital.com/library/evaluation-of-cytokine-release-syndrome-in-non-hodgkin-lymphoma-therapy-with-bispecific-antibodies-a-meta-analysis-of-clinical-trials/2026-07-17T17:37:03+00:00https://lymphoma-stg.clarovantdigital.com/library/comparison-and-combination-of-prognostic-scores-for-nodular-lymphocyte-predominant-hodgkin-lymphoma-an-analysis-from-the-german-hodgkin-study-group/2026-07-17T17:41:03+00:00https://lymphoma-stg.clarovantdigital.com/library/mrd-negativity-by-pbmcs-and-ctdna-confirms-deep-and-durable-responses-following-epcoritamab-monotherapy-in-r-r-fl/2026-07-17T17:47:17+00:00https://lymphoma-stg.clarovantdigital.com/library/enteropathy-associated-t-cell-lymphoma-molecular-clonal-evolution-and-its-clinical-consequences/2026-07-17T17:53:17+00:00https://lymphoma-stg.clarovantdigital.com/library/long-term-remission-of-severe-psoriasis-following-cd19-car-t-cell-therapy-for-follicular-lymphoma/2026-07-17T17:58:29+00:00https://lymphoma-stg.clarovantdigital.com/library/the-efficacy-safety-and-rationale-of-orelabrutinib-combined-with-obinutuzumab-o2-as-a-first-line-systemic-treatment-for-marginal-zone-lymphoma/2026-07-17T20:53:47+00:00https://lymphoma-stg.clarovantdigital.com/library/coexistence-of-mycosis-fungoides-and-hodgkin-lymphoma-in-a-pediatric-patient-a-report-of-a-rare-case/2026-07-17T20:53:48+00:00https://lymphoma-stg.clarovantdigital.com/library/ibrutinib-plus-venetoclax-for-relapsed-refractory-mantle-cell-lymphoma-final-analysis-of-the-phase-3-sympatico-study/2026-07-17T20:53:48+00:00https://lymphoma-stg.clarovantdigital.com/library/vitamin-d-supplementation-and-treatment-free-survival-in-early-stage-cll-a-real-world-validation-study/2026-09-02T14:50:49+00:00https://lymphoma-stg.clarovantdigital.com/library/integrating-ethical-analysis-in-health-technology-assessment-opportunities-and-challenges/2026-07-17T20:53:48+00:00https://lymphoma-stg.clarovantdigital.com/library/designing-and-implementing-real-world-patient-reported-outcomes-emerging-recommendations-a-good-practices-report-of-an-ispor-task-force/2026-07-17T20:53:48+00:00https://lymphoma-stg.clarovantdigital.com/library/differences-in-evidentiary-requirements-for-oncology-drug-assessments-across-health-technology-assessment-bodies-in-germany-spain-and-france-the-european-medicines-agency-and-the-eu-health-technol/2026-07-17T20:53:48+00:00https://lymphoma-stg.clarovantdigital.com/library/a-targeted-review-of-available-data-sources-to-support-evidence-informed-decisions-implications-for-health-technology-assessment-in-south-africa/2026-07-17T20:53:48+00:00https://lymphoma-stg.clarovantdigital.com/library/real-world-patterns-of-healthcare-use-costs-and-survival-in-diffuse-large-b-cell-lymphoma-a-nationwide-swedish-register-study/2026-07-17T20:53:49+00:00https://lymphoma-stg.clarovantdigital.com/library/risk-and-survival-outcomes-of-secondary-primary-malignancies-in-chinese-lymphoma-patients-in-the-era-of-modern-targeted-therapies-a-single-center-retrospective-cohort-study/2026-07-17T20:53:49+00:00https://lymphoma-stg.clarovantdigital.com/library/comparison-of-venetoclax-based-treatments-for-patients-with-relapsed-refractory-chronic-lymphocytic-leukemia-a-single-center-real-world-experience/2026-07-17T20:53:49+00:00https://lymphoma-stg.clarovantdigital.com/library/real-world-effectiveness-and-safety-of-acalabrutinib-in-chronic-lymphocytic-leukaemia-multicentre-experience/2026-07-17T20:53:49+00:00https://lymphoma-stg.clarovantdigital.com/library/rituximab-maintenance-added-to-ibrutinib-containing-therapy-in-younger-untreated-patients-with-mantle-cell-lymphoma-results-from-the-triangle-trial/2026-07-17T20:53:49+00:00https://lymphoma-stg.clarovantdigital.com/library/the-danish-lymphoid-cancer-research-daly-care-genetic-cohort-profile/2026-07-17T20:53:49+00:00https://lymphoma-stg.clarovantdigital.com/library/healthy-birth-after-chemotherapy-for-diffuse-large-b-cell-lymphoma-with-superior-vena-cava-syndrome-in-late-pregnancy-a-case-report-2/2026-07-17T20:53:50+00:00https://lymphoma-stg.clarovantdigital.com/library/efficacy-of-high-frequency-low-dose-rituximab-and-acalabrutinib-in-chronic-lymphocytic-leukemia/2026-07-17T20:53:50+00:00https://lymphoma-stg.clarovantdigital.com/library/renal-involvement-in-indolent-and-aggressive-b-cell-neoplasms-a-comparative-study-of-chronic-lymphocytic-leukemia-small-lymphocytic-lymphoma-and-diffuse-large-b-cell-lymphoma/2026-07-17T20:53:50+00:00https://lymphoma-stg.clarovantdigital.com/library/high-histological-entropy-is-correlated-with-poor-overall-survival-and-death-within-the-first-2-years-in-diffuse-large-b-cell-lymphoma/2026-07-17T20:53:50+00:00https://lymphoma-stg.clarovantdigital.com/library/golidocitinib-for-folliculotropic-mycosis-fungoides/2026-07-17T20:53:50+00:00https://lymphoma-stg.clarovantdigital.com/library/englumafusp-alfa-plus-glofitamab-in-b-cell-non-hodgkin-lymphoma-a-phase-1-trial/2026-07-17T20:53:50+00:00https://lymphoma-stg.clarovantdigital.com/library/accounting-for-out-of-field-dose-and-second-cancer-risk-in-classical-hodgkin-lymphoma-a-comprehensive-comparison-of-proton-and-photon-therapy-using-whole-body-phantom/2026-07-17T20:53:50+00:00https://lymphoma-stg.clarovantdigital.com/library/frontline-abvd-remains-an-effective-option-in-advanced-stage-classical-hodgkin-lymphoma-real-world-data-from-turkey/2026-07-17T20:53:51+00:00https://lymphoma-stg.clarovantdigital.com/library/first-line-brutons-tyrosine-kinase-inhibitor-based-regimens-for-mantle-cell-lymphoma/2026-07-17T20:53:51+00:00https://lymphoma-stg.clarovantdigital.com/library/a-novel-severe-toxicity-free-and-progression-free-survival-endpoint-predicts-outcomes-after-cd19-chimeric-antigen-receptor-t-cell-therapy-in-large-b-cell-lymphoma/2026-07-17T20:53:51+00:00https://lymphoma-stg.clarovantdigital.com/library/cytogenetic-characteristics-of-chronic-lymphocytic-leukemia-patients-a-single-center-study-from-morocco/2026-07-17T20:53:51+00:00https://lymphoma-stg.clarovantdigital.com/library/patient-perspectives-on-non-hodgkin-lymphoma-a-qualitative-study-to-guide-selection-of-clinical-trial-endpoints/2026-07-17T20:53:51+00:00https://lymphoma-stg.clarovantdigital.com/library/diffuse-large-b-cell-lymphoma-complicated-by-cytokine-release-syndrome-and-immune-effector-cell-associated-neurotoxicity-on-day-355-of-epcoritamab-therapy-a-case-report/2026-07-24T00:47:27+00:00https://lymphoma-stg.clarovantdigital.com/library/first-line-ibrutinib-plus-venetoclax-for-non-blastoid-mantle-cell-lymphoma-in-patients-%e2%89%a565-years-or-with-tp53-mutations/2026-07-24T00:55:37+00:00https://lymphoma-stg.clarovantdigital.com/library/final-results-of-uk-ncri-phase-ii-trial-of-pembrolizumab-and-radiotherapy-in-cutaneous-t-cell-lymphoma/2026-07-24T01:01:39+00:00https://lymphoma-stg.clarovantdigital.com/library/safety-feasibility-and-efficacy-of-anti-pd-1-therapy-for-the-treatment-of-classical-hodgkin-lymphoma/2026-07-24T01:06:33+00:00https://lymphoma-stg.clarovantdigital.com/library/chidamideaugmented-beam-conditioning-and-maintenance-in-first-remission-tcell-lymphoma-a-singlearm-phase-2-experience/2026-07-31T16:23:39+00:00https://lymphoma-stg.clarovantdigital.com/library/avd-is-an-effective-chemotherapy-backbone-in-first-line-treatment-of-older-patients-with-classical-hodgkin-lymphoma/2026-07-24T18:44:20+00:00https://lymphoma-stg.clarovantdigital.com/library/complex-tp53-alterations-with-del17p-and-del13q-in-chronic-lymphocytic-leukemia-clinical-implications-from-a-case-based-review/2026-07-24T18:44:20+00:00https://lymphoma-stg.clarovantdigital.com/library/prognostic-impact-of-presentation-phenotypes-in-early-stage-favorable-hodgkin-lymphoma/2026-07-24T18:44:20+00:00https://lymphoma-stg.clarovantdigital.com/library/epstein-barr-virus-antibodies-and-risk-of-non-hodgkin-lymphoma-a-pooled-analysis-of-four-prospective-cohorts/2026-09-02T15:55:53+00:00https://lymphoma-stg.clarovantdigital.com/library/ultralow-dose-interleukin-10-expressing-chimeric-antigen-receptor-t-cells-in-relapsed-refractory-diffuse-large-b-cell-lymphoma/2026-07-24T18:44:21+00:00https://lymphoma-stg.clarovantdigital.com/library/multi-modal-ultrasound-based-prognostic-model-for-diffuse-large-b-cell-lymphoma-with-predominantly-superficial-lymph-node-involvement/2026-07-24T18:44:21+00:00https://lymphoma-stg.clarovantdigital.com/library/bacterial-colonization-of-the-upper-respiratory-tract-in-patients-with-chronic-lymphocytic-leukemia-cll-primary-assessment-of-standard-and-alternative-antibacterial-treatments/2026-07-24T18:44:21+00:00https://lymphoma-stg.clarovantdigital.com/library/co-occurrence-of-chronic-lymphocytic-leukemia-small-lymphocytic-lymphoma-and-head-and-neck-squamous-cell-carcinoma-a-single-institution-study/2026-07-24T18:44:21+00:00https://lymphoma-stg.clarovantdigital.com/library/long-term-outcomes-with-continuous-venetoclax-for-relapsed-chronic-lymphocytic-leukemia/2026-07-31T16:06:34+00:00https://lymphoma-stg.clarovantdigital.com/library/fixed-treatment-duration-venetoclax-following-covalent-btki-progression-in-chronic-lymphocytic-leukemia/2026-07-31T16:22:15+00:00https://lymphoma-stg.clarovantdigital.com/library/a53-adapted-decitabine-containing-r-chop-in-newly-diagnosed-diffuse-large-b-cell-lymphoma-defined-by-lymphgen-preliminary-results-of-a-prospective-proof-of-concept-study/2026-07-31T17:57:00+00:00https://lymphoma-stg.clarovantdigital.com/library/artificial-intelligence-in-hematologic-malignancies-opportunities-challenges-and-clinical-integration/2026-07-31T17:57:00+00:00https://lymphoma-stg.clarovantdigital.com/library/cellular-immunity-profile-in-b-cell-non-hodgkin-lymphoma-patients-receiving-rituximab-based-chemotherapy/2026-07-31T17:57:00+00:00https://lymphoma-stg.clarovantdigital.com/library/cardiac-surveillance-for-anthracycline-cardiotoxicity-clinical-yield-in-low-to-intermediate-risk-patients-matrix-study/2026-07-31T17:57:00+00:00https://lymphoma-stg.clarovantdigital.com/library/estimated-cardiac-deaths-associated-with-treating-chronic-lymphocytic-leukemia-with-ibrutinib-versus-zanubrutinib-in-the-united-states/2026-07-31T17:57:00+00:00https://lymphoma-stg.clarovantdigital.com/library/chronic-lymphocytic-leukemia-management-in-india-balancing-evidence-access-and-affordability-in-clinical-practice/2026-07-31T17:57:00+00:00https://lymphoma-stg.clarovantdigital.com/library/fixed-duration-pirtobrutinib-plus-venetoclax-rituximab-versus-venetoclax-rituximab-for-patients-with-previously-treated-chronic-lymphocytic-leukaemia-or-small-lymphocytic-lymphoma-bruin-cll-322-an/2026-07-31T17:57:00+00:00https://lymphoma-stg.clarovantdigital.com/library/interim-positron-emission-tomography-guided-dose-adapted-residual-site-radiation-therapy-improves-survival-in-diffuse-large-b-cell-lymphoma-patients-with-partial-metabolic-response-after-r-chop-a-ret/2026-07-31T17:57:01+00:00https://lymphoma-stg.clarovantdigital.com/library/improved-progression-free-survival-after-axicabtagene-ciloleucel-compared-to-tisagenlecleucel-in-patients-aged-70-years-with-large-b-cell-lymphoma/2026-08-20T16:10:44+00:00https://lymphoma-stg.clarovantdigital.com/library/loncastuximab-tesirine-as-a-successful-bridge-to-allogeneic-hematopoietic-cell-transplantation-in-a-heavily-pretreated-patient-with-t-cell-histiocyte-rich-large-b-cell-lymphoma/2026-08-20T16:18:33+00:00https://lymphoma-stg.clarovantdigital.com/library/comparison-of-pola-r-chp-and-r-chop-for-newly-diagnosed-dlbcl-a-single-center-retrospective-study/2026-08-20T16:24:36+00:00https://lymphoma-stg.clarovantdigital.com/library/prognostic-value-of-the-conut-score-in-newly-diagnosed-diffuse-large-b-cell-lymphoma/2026-08-20T16:31:09+00:00https://lymphoma-stg.clarovantdigital.com/library/lisocabtagene-maraleucel-combined-with-ibrutinib-in-r-r-cll-or-sll-primary-results-from-transcend-cll-004/2026-08-20T16:58:15+00:00https://lymphoma-stg.clarovantdigital.com/library/richter-transformation-emerging-immunologic-strategies-beyond-chemoimmunotherapy/2026-08-21T12:08:10+00:00https://lymphoma-stg.clarovantdigital.com/library/primary-breast-diffuse-large-b-cell-lymphoma-mimicking-breast-carcinoma-a-diagnostic-challenge-case-report/2026-08-21T18:20:16+00:00https://lymphoma-stg.clarovantdigital.com/library/cytokine-release-syndrome-and-immune-effector-cell-associated-neurotoxicity-syndrome-following-axicabtagene-ciloleucel-or-brexucabtagene-autoleucel-chimeric-antigen-receptor-t-cell-therapy-center-for/2026-08-21T18:20:16+00:00https://lymphoma-stg.clarovantdigital.com/library/acalabrutinib-in-combination-with-rituximab-cyclophosphamide-doxorubicin-vincristine-and-prednisolone-as-first-line-therapy-for-patients-with-diffuse-large-b-cell-lymphoma/2026-08-21T18:20:16+00:00https://lymphoma-stg.clarovantdigital.com/library/glofitamab-plus-gemcitabine-and-oxaliplatin-for-relapsed-refractory-dlbcl-3-year-follow-up-of-starglo-2/2026-08-21T18:20:17+00:00https://lymphoma-stg.clarovantdigital.com/library/prognostic-significance-of-baseline-liver-enzyme-patterns-in-chronic-lymphocytic-leukemia-a-nationwide-real-world-cohort-study/2026-08-21T18:20:17+00:00https://lymphoma-stg.clarovantdigital.com/library/acalabrutinib-vs-chlorambucil-plus-rituximab-in-untreated-chronic-lymphocytic-leukemia-a-randomized-phase-3-asian-study/2026-08-21T18:20:17+00:00https://lymphoma-stg.clarovantdigital.com/library/pirtobrutinib-monotherapy-for-first-line-chronic-lymphocytic-leukemia-a-non-anchored-indirect-comparison-using-reconstructed-patient-level-data/2026-08-21T18:20:17+00:00https://lymphoma-stg.clarovantdigital.com/library/atezolizumab-for-relapsed-refractory-extranodal-nk-t-cell-lymphoma-phase-2-of-ncch1903-attack-trial/2026-08-21T18:20:17+00:00https://lymphoma-stg.clarovantdigital.com/library/management-of-systemic-lupus-erythematosus-and-antiphospholipid-syndrome-during-car-t-therapy-insights-from-two-clinical-cases/2026-08-21T18:20:18+00:00https://lymphoma-stg.clarovantdigital.com/library/sustained-complete-remission-after-a-single-cycle-of-r-chop-in-extranodal-diffuse-large-b-cell-lymphoma-of-the-mandible-a-case-report/2026-08-21T18:20:18+00:00https://lymphoma-stg.clarovantdigital.com/library/therapy-related-acute-myeloid-leukemia-with-24-month-latency-after-cd19-car-t-cell-therapy-in-relapsed-refractory-diffuse-large-b-cell-lymphoma-a-case-report/2026-08-21T18:20:18+00:00https://lymphoma-stg.clarovantdigital.com/library/cumulative-incidence-and-factors-associated-with-subsequent-myeloid-neoplasms-in-patients-with-nodal-t-follicular-helper-cell-lymphomas/2026-08-21T18:20:18+00:00https://lymphoma-stg.clarovantdigital.com/library/treatment-monitoring-and-management-of-patients-with-relapsed-refractory-chronic-lymphocytic-leukemia-and-mantle-cell-lymphoma-evidence-from-a-multi-country-needs-assessment/2026-08-21T18:20:19+00:00https://lymphoma-stg.clarovantdigital.com/library/comparison-of-the-mutational-profile-between-bcl2-and-bcl6-rearrangement-positive-follicular-lymphoma/2026-08-21T18:20:19+00:00https://lymphoma-stg.clarovantdigital.com/library/decade-long-persistence-of-cd19-car-t-cells-in-b-cell-lymphomas/2026-08-21T18:20:19+00:00https://lymphoma-stg.clarovantdigital.com/library/mosunetuzumab-a-bispecific-cd20-x-cd3-antibody-for-follicular-lymphoma-with-promising-evidence-in-other-b-nhl-subtypes/2026-08-21T18:20:19+00:00https://lymphoma-stg.clarovantdigital.com/library/clinical-features-outcomes-and-prognostic-factors-of-lymphocyte-depleted-classical-hodgkin-lymphoma-a-population-based-seer-analysis/2026-08-21T18:20:19+00:00https://lymphoma-stg.clarovantdigital.com/library/hodgkin-and-non-hodgkin-lymphomas-in-the-post-antiretroviral-therapy-era-according-to-hiv-virological-suppression/2026-08-21T18:20:19+00:00https://lymphoma-stg.clarovantdigital.com/library/clinical-efficacy-and-safety-of-pembrolizumab-and-nivolumab-in-frontline-treatment-for-classical-hodgkin-lymphoma-systematic-review-and-meta-analysis-of-clinical-trials/2026-08-21T18:20:20+00:00https://lymphoma-stg.clarovantdigital.com/library/reproductive-outcomes-in-women-with-hodgkin-lymphoma-in-a-danish-fertility-preservation-cohort/2026-08-21T18:20:20+00:00https://lymphoma-stg.clarovantdigital.com/library/current-evidence-and-strategies-for-bridging-therapy-in-cd19-directed-chimeric-antigen-receptor-t-cell-therapy-for-relapsed-refractory-large-b-cell-lymphomas/2026-08-21T18:20:20+00:00https://lymphoma-stg.clarovantdigital.com/library/real-world-treatment-patterns-of-patients-with-large-b-cell-lymphoma-over-time-and-into-a-post-car-t-approval-era-2/2026-08-21T18:20:20+00:00https://lymphoma-stg.clarovantdigital.com/library/prognostic-impact-of-extranodal-organ-burden-in-classical-hodgkin-lymphoma-with-extranodal-involvement-a-retrospective-cohort-analysis/2026-08-21T18:20:20+00:00https://lymphoma-stg.clarovantdigital.com/library/prediction-of-lymphoma-bone-marrow-infiltration-by-machine-learning-models-based-on-fluorine-18-fluorodeoxyglucose-positron-emission-computed-tomography/2026-08-21T18:20:20+00:00https://lymphoma-stg.clarovantdigital.com/library/impact-of-prior-bendamustine-exposure-on-chimeric-antigen-receptor-t-cell-therapy-outcomes-in-follicular-lymphoma/2026-08-21T18:20:21+00:00https://lymphoma-stg.clarovantdigital.com/library/long-term-complete-remission-following-treatment-with-polatuzumab-vedotin-rituximab-and-bendamustine-in-a-patient-with-mantle-cell-lymphoma-relapsing-after-car-t-cell-therapy-a-case-report/2026-08-21T18:20:21+00:00https://lymphoma-stg.clarovantdigital.com/library/cost-effectiveness-of-first-line-therapies-for-treatment-naive-chronic-lymphocytic-leukaemia-in-south-africa/2026-08-21T18:20:21+00:00https://lymphoma-stg.clarovantdigital.com/library/hypertension-and-time-to-treatment-failure-with-acalabrutinib-and-ibrutinib-in-treatment-naive-cll-sll/2026-08-21T18:20:21+00:00https://lymphoma-stg.clarovantdigital.com/library/begev-as-salvage-therapy-in-relapsed-refractory-non-hodgkin-lymphoma-real-world-outcomes-and-transplantation-feasibility/2026-08-21T18:20:21+00:00https://lymphoma-stg.clarovantdigital.com/library/comparative-cardiovascular-safety-and-exploratory-bleeding-outcomes-of-ibrutinib-acalabrutinib-and-zanubrutinib-in-mantle-cell-lymphoma-a-propensity-score-matched-real-world-analysis/2026-08-21T18:20:21+00:00https://lymphoma-stg.clarovantdigital.com/library/postoperative-complications-following-total-knee-arthroplasty-in-patients-with-chronic-lymphocytic-leukemia/2026-08-21T18:20:22+00:00https://lymphoma-stg.clarovantdigital.com/library/beyond-the-nodes-atypical-presentations-of-non-hodgkin-lymphoma-across-organs/2026-08-21T18:20:22+00:00https://lymphoma-stg.clarovantdigital.com/library/clinical-characteristics-and-prognostic-analysis-of-ebv-positive-hiv-associated-diffuse-large-b-cell-lymphoma-in-china-a-retrospective-single-center-study/2026-09-02T15:55:15+00:00https://lymphoma-stg.clarovantdigital.com/library/autologous-stem-cell-transplant-for-hiv-associated-lymphoma-a-systematic-review-and-meta-analysis/2026-08-21T18:20:22+00:00https://lymphoma-stg.clarovantdigital.com/library/mechanisms-of-first-line-treatment-resistance-in-diffuse-large-b-cell-lymphoma/2026-08-21T18:20:22+00:00https://lymphoma-stg.clarovantdigital.com/library/health-care-resource-use-in-the-management-of-patients-with-relapsed-refractory-diffuse-large-b-cell-lymphoma-canadian-perspective/2026-08-21T18:20:22+00:00https://lymphoma-stg.clarovantdigital.com/library/advanced-stage-hodgkin-lymphoma-a-review-on-frontline-treatment-advances/2026-08-21T18:20:22+00:00https://lymphoma-stg.clarovantdigital.com/library/treatment-intensity-illness-burden-and-disparities-in-newly-diagnosed-diffuse-large-b-cell-lymphoma-treated-at-an-urban-academic-center/2026-08-21T18:20:23+00:00https://lymphoma-stg.clarovantdigital.com/library/acalabrutinib-versus-venetoclax-plus-obinutuzumab-in-treatment-naive-chronic-lymphocytic-leukemia-a-real-world-propensity-score-matched-study/2026-08-21T18:20:23+00:00https://lymphoma-stg.clarovantdigital.com/library/the-great-debate-car-t-cell-therapy-versus-bispecific-antibodies-in-b-cell-lymphoma/2026-08-21T18:20:23+00:00https://lymphoma-stg.clarovantdigital.com/library/real-world-comparative-effectiveness-of-first-line-btk-inhibitors-in-chronic-lymphocytic-leukemia/2026-08-21T18:20:23+00:00https://lymphoma-stg.clarovantdigital.com/library/primary-classical-hodgkin-lymphoma-of-breast-presenting-as-recurrent-breast-abscess-in-a-non-lactating-woman-a-case-report-and-literature-review/2026-08-21T18:20:23+00:00https://lymphoma-stg.clarovantdigital.com/library/radiation-monotherapy-for-primary-cutaneous-diffuse-large-b-cell-lymphoma-leg-type-a-case-report/2026-08-21T18:20:24+00:00https://lymphoma-stg.clarovantdigital.com/library/treatment-decision-making-for-individuals-with-relapsed-refractory-chronic-lymphocytic-leukemia-in-the-usa/2026-08-21T18:20:24+00:00https://lymphoma-stg.clarovantdigital.com/library/pd-1-pd-l1-immune-checkpoint-inhibitors-in-hodgkin-lymphoma-a-meta-and-network-meta-analysis/2026-08-21T18:20:24+00:00https://lymphoma-stg.clarovantdigital.com/library/a-deep-learning-based-prognostic-model-for-diffuse-large-b-cell-lymphoma-incorporating-pet-ct-imaging-features/2026-08-21T18:20:24+00:00https://lymphoma-stg.clarovantdigital.com/library/outcomes-of-primary-gastrointestinal-diffuse-large-b-cell-lymphoma-in-the-rituximab-era/2026-08-21T18:20:24+00:00https://lymphoma-stg.clarovantdigital.com/library/first-line-treatment-with-epcoritamab-in-combination-with-bendamustine-plus-rituximab-induces-sustained-remissions-beyond-3-years-in-patients-with-follicular-lymphoma/2026-08-31T15:33:33+00:00https://lymphoma-stg.clarovantdigital.com/library/glofitamab-in-heavily-pretreated-mantle-cell-lymphoma-patients-a-multicenter-real-world-case-series/2026-08-21T18:20:25+00:00https://lymphoma-stg.clarovantdigital.com/library/factors-associated-with-mortality-in-diffuse-large-b-cell-lymphoma-dlbcl-with-disseminated-intravascular-coagulation-dic-a-national-inpatient-sample-analysis/2026-08-21T18:20:25+00:00https://lymphoma-stg.clarovantdigital.com/library/chronic-lymphocytic-leukemia-molecular-pathologies-and-therapeutic-strategies/2026-08-21T18:20:25+00:00https://lymphoma-stg.clarovantdigital.com/library/infection-incidence-and-survival-in-patients-with-multiple-myeloma-and-chronic-lymphocytic-leukaemia-a-growing-concern-in-the-era-of-modern-therapies/2026-08-21T18:20:25+00:00https://lymphoma-stg.clarovantdigital.com/library/mortality-in-patients-with-hodgkin-lymphoma-and-heart-failure-a-swedish-population-based-study/2026-08-21T18:20:25+00:00https://lymphoma-stg.clarovantdigital.com/library/impact-of-rituximab-maintenance-on-survival-in-patients-with-mantle-cell-lymphoma-a-population-based-cohort-study/2026-08-21T18:20:25+00:00https://lymphoma-stg.clarovantdigital.com/library/therapeutic-outcomes-of-tp53-mutated-diffuse-large-b-cell-lymphoma-a-systematic-review-and-meta-analysis/2026-08-21T18:20:26+00:00https://lymphoma-stg.clarovantdigital.com/library/socioeconomic-inequalities-in-the-mortality-of-hodgkin-and-non-hodgkin-lymphoma-a-two-decade-trend-analysis/2026-08-21T18:20:26+00:00https://lymphoma-stg.clarovantdigital.com/library/beyond-chemoimmunotherapy-emerging-cellular-and-targeted-therapies-in-transformed-follicular-lymphoma-a-scoping-review/2026-08-21T18:20:26+00:00https://lymphoma-stg.clarovantdigital.com/library/outcomes-of-loncastuximab-tesirine-in-heavily-pretreated-patients-with-diffuse-large-b-cell-lymphoma-including-the-post-car-t-cell-therapy-setting-a-meta-analysis/2026-08-21T18:20:26+00:00https://lymphoma-stg.clarovantdigital.com/library/real-world-outcomes-of-tafasitamab-lenalidomide-in-patients-with-transplant-ineligible-r-r-dlbcl-from-the-pro-mind-study/2026-08-21T18:20:26+00:00https://lymphoma-stg.clarovantdigital.com/library/resistance-pathways-and-next-generation-treatments-in-chronic-lymphocytic-leukemia/2026-08-21T18:20:26+00:00https://lymphoma-stg.clarovantdigital.com/library/contralateral-cutaneous-t-cell-lymphoma-as-a-mimicker-of-multi-decade-atopic-dermatitis/2026-08-21T18:20:27+00:00https://lymphoma-stg.clarovantdigital.com/library/early-identification-of-high-risk-myelosuppression-subtypes-in-dlbcl-patients-undergoing-r-chop-chemotherapy/2026-08-21T18:20:27+00:00https://lymphoma-stg.clarovantdigital.com/library/access-to-diagnosis-using-liquid-biopsy-adlib-identifying-lymphoma-in-a-tuberculosis-endemic-setting/2026-08-21T18:20:27+00:00https://lymphoma-stg.clarovantdigital.com/library/minimal-disease-detection-by-immunoglobulin-high-throughput-sequencing-in-pediatric-burkitt-lymphoma/2026-08-21T18:20:27+00:00https://lymphoma-stg.clarovantdigital.com/library/patient-reported-time-toxicity-with-bispecific-antibody-therapies-in-relapsed-refractory-follicular-lymphoma-and-diffuse-large-b-cell-lymphoma/2026-08-21T18:20:27+00:00https://lymphoma-stg.clarovantdigital.com/library/zr2-minichop-for-elderly-patients-with-newly-diagnosed-diffuse-large-b-cell-lymphoma/2026-08-21T18:20:27+00:00https://lymphoma-stg.clarovantdigital.com/library/eha-guidelines-on-management-of-chronic-lymphocytic-leukemia-and-richter-transformation/2026-08-21T18:20:27+00:00https://lymphoma-stg.clarovantdigital.com/library/phase-3-perspective-study-ibrutinib-with-rituximab-for-initial-treatment-of-patients-with-follicular-lymphoma/2026-08-21T18:20:28+00:00https://lymphoma-stg.clarovantdigital.com/library/hiv-associated-lymphomas-updates-from-pathogenesis-to-treatment-strategies/2026-08-21T18:20:28+00:00https://lymphoma-stg.clarovantdigital.com/library/surrogate-endpoints-in-cost-effectiveness-analysis-for-use-in-health-technology-assessment-a-qualitative-analysis/2026-08-21T18:20:28+00:00https://lymphoma-stg.clarovantdigital.com/library/frequency-of-exercise-and-cancer-related-fatigue-among-patients-with-lymphoma/2026-08-21T18:20:28+00:00https://lymphoma-stg.clarovantdigital.com/library/antigen-specific-b-cell-responses-in-treatment-naive-and-chlorambucil-treated-patients-with-chronic-lymphocytic-leukemia/2026-08-21T18:20:28+00:00https://lymphoma-stg.clarovantdigital.com/library/clinical-outcomes-and-prognostic-factors-in-hematologic-malignancy-patients-with-probable-cmv-pneumonia/2026-08-21T18:20:28+00:00https://lymphoma-stg.clarovantdigital.com/library/glofitamab-in-combination-with-immunochemotherapy-in-patients-with-relapsed-refractory-b-cell-non-hodgkin-lymphoma-phase-1b-dose-escalation-study/2026-08-21T18:20:28+00:00https://lymphoma-stg.clarovantdigital.com/library/patient-reported-outcomes-in-bruin-cll-321-a-randomized-phase-3-trial-comparing-pirtobrutinib-to-investigators-choice-of-idelalisib-plus-rituximab-or-bendamustine-plus-rituximab-in-patients-with-rela/2026-08-21T18:20:29+00:00https://lymphoma-stg.clarovantdigital.com/library/mortality-outcomes-among-long-term-hodgkin-lymphoma-survivors/2026-08-21T18:20:29+00:00https://lymphoma-stg.clarovantdigital.com/library/high-risk-single-refractory-and-double-refractory-chronic-lymphocytic-leukemia-feasibility-and-impact-of-allohct/2026-08-21T18:20:29+00:00https://lymphoma-stg.clarovantdigital.com/library/design-characteristics-and-survival-outcomes-of-local-trials-supporting-the-approval-of-targeted-anticancer-drugs-in-china/2026-08-21T18:20:29+00:00https://lymphoma-stg.clarovantdigital.com/library/impact-of-il-6-and-ferritin-dynamics-on-clinical-outcomes-after-anti-cd19-car-t-cell-therapy-in-diffuse-large-b-cell-lymphoma-patients/2026-08-21T18:20:29+00:00https://lymphoma-stg.clarovantdigital.com/library/real-world-evidence-in-asian-health-technology-assessment-evolving-roles-practices-and-future-directions-2015-2024/2026-08-21T18:20:30+00:00https://lymphoma-stg.clarovantdigital.com/library/advancing-stakeholder-analysis-power-and-participation-in-health-technology-assessment-policy-development-in-the-united-arab-emirates/2026-08-21T18:20:30+00:00https://lymphoma-stg.clarovantdigital.com/library/metachronous-ebv-positive-classical-hodgkin-lymphoma-following-ebv-positive-diffuse-large-b-cell-lymphoma-a-case-report-and-literature-review/2026-09-02T15:54:38+00:00https://lymphoma-stg.clarovantdigital.com/library/btk-inhibitors-for-the-treatment-of-mantle-cell-lymphoma-current-status-and-perspectives/2026-08-21T18:20:30+00:00https://lymphoma-stg.clarovantdigital.com/library/second-primary-malignant-neoplasms-after-t-cell-engaging-bispecific-antibody-therapy/2026-08-21T18:20:30+00:00https://lymphoma-stg.clarovantdigital.com/library/integrated-clinical-molecular-risk-stratification-in-diffuse-large-b-cell-lymphoma-machine-learning-survival-analysis/2026-08-21T18:20:30+00:00https://lymphoma-stg.clarovantdigital.com/library/allogeneic-stem-cell-transplantation-after-myeloablative-conditioning-with-fludarabine-thiotepa-and-cyclophosphamide-in-relapsed-or-refractory-aggressive-b-cell-and-t-cell-lymphomas-results-of-the/2026-08-27T21:28:41+00:00https://lymphoma-stg.clarovantdigital.com/library/projected-disease-burden-and-treatment-eligibility-of-patients-with-diffuse-large-b-cell-and-mantle-cell-lymphoma-in-the-united-states-over-the-next-decade/2026-08-27T21:44:25+00:00https://lymphoma-stg.clarovantdigital.com/library/impact-of-risk-factors-on-long-term-survival-and-post-transplant-failure-management-in-200-aggressive-non-hodgkin-lymphoma-patients-who-underwent-high-dose-chemotherapy-and-autologous-stem-cell-transp/2026-08-27T21:44:25+00:00https://lymphoma-stg.clarovantdigital.com/library/accelerated-step-up-dosing-of-glofitamab-in-rapidly-progressive-r-r-dlbcl-a-real-world-cohort-analysis/2026-08-27T21:44:25+00:00https://lymphoma-stg.clarovantdigital.com/library/tp53-mutant-chip-defines-a-pro-inflammatory-phenotype-and-predicts-adverse-outcomes-after-car-t-cell-therapy/2026-08-27T21:44:25+00:00https://lymphoma-stg.clarovantdigital.com/library/primary-cardioprotection-in-frontline-anthracycline-therapy-for-adult-hematologic-cancers/2026-08-27T21:44:26+00:00https://lymphoma-stg.clarovantdigital.com/library/first-line-treatment-of-chronic-lymphocytic-leukemia-in-italy-real-world-evidence-on-utilization-outcomes-and-healthcare-costs/2026-08-27T21:44:26+00:00https://lymphoma-stg.clarovantdigital.com/library/real-world-resource-utilization-toxicity-management-and-efficacy-outcomes-of-cd20-x-cd3-bispecific-antibodies-in-b-cell-lymphoma-a-study-from-the-geltamo-network/2026-08-27T21:44:26+00:00https://lymphoma-stg.clarovantdigital.com/library/primary-colonic-diffuse-large-b-cell-lymphoma-a-diagnostic-challenge/2026-08-27T21:44:26+00:00https://lymphoma-stg.clarovantdigital.com/library/mosunetuzumab-plus-polatuzumab-vedotin-for-relapsed-refractory-mcl-after-btk-inhibitor-therapy-a-phase-2-study/2026-08-27T21:44:26+00:00https://lymphoma-stg.clarovantdigital.com/library/primary-ocular-adnexal-non-hodgkin-lymphoma-in-a-peruvian-cohort-an-18-year-experience/2026-08-27T21:44:26+00:00https://lymphoma-stg.clarovantdigital.com/library/acalabrutinib-in-waldenstrom-macroglobulinemia-yields-durable-responses-with-5-years-of-follow-up/2026-08-27T21:44:27+00:00https://lymphoma-stg.clarovantdigital.com/library/diffuse-large-bcell-lymphoma-followed-by-myelodysplastic-syndrome-with-tp53-mutation-a-case-report-and-literature-review/2026-08-27T21:45:22+00:00https://lymphoma-stg.clarovantdigital.com/library/patient-and-care-partner-burden-in-cutaneous-t-cell-lymphoma-using-disease-specific-measures-of-symptoms-and-health-related-quality-of-life/2026-08-27T21:44:27+00:00https://lymphoma-stg.clarovantdigital.com/library/case-report-diagnostic-pitfall-and-biomarker-guided-therapy-in-cd20-negative-epstein-barr-virus-positive-diffuse-large-b-cell-lymphoma/2026-09-02T15:54:05+00:00https://lymphoma-stg.clarovantdigital.com/library/survival-improvement-of-dlbcl-patients-treated-with-third-line-and-beyond-in-the-recent-era-in-the-czech-republic/2026-09-04T18:55:28+00:00https://lymphoma-stg.clarovantdigital.com/library/redefining-fitness-in-chronic-lymphocytic-leukemia-a-treatment-specific-framework-for-the-targeted-therapy-era/2026-09-04T19:41:52+00:00https://lymphoma-stg.clarovantdigital.com/library/clinicopathological-profile-treatment-response-and-survival-outcomes-of-non-hodgkin-lymphoma-patients-in-southern-iraq-a-retrospective-cross-sectional-study/2026-09-04T19:48:20+00:00https://lymphoma-stg.clarovantdigital.com/library/pirtobrutinib-in-the-bruton-tyrosine-kinase-landscape-in-chronic-lymphocytic-leukemia-incremental-advance-or-new-standard/2026-09-04T19:53:00+00:00https://lymphoma-stg.clarovantdigital.com/library/european-hematology-association-eha-guideline-for-the-diagnosis-and-treatment-of-mantle-cell-lymphoma-from-the-perspective-of-the-polish-lymphoma-research-group-plrg-experts-in-2026/2026-09-04T19:58:16+00:00https://lymphoma-stg.clarovantdigital.com/library/allogeneic-stem-cell-transplantation-remains-an-effective-therapeutic-option-for-patients-with-relapsed-refractory-hodgkin-lymphoma-polish-single-center-retrospective-analysis/2026-09-04T20:02:21+00:00https://lymphoma-stg.clarovantdigital.com/library/dissecting-diffuse-large-b-cell-lymphoma-heterogeneity-new-insights-from-a-state-specific-molecular-characterisation/2026-09-04T20:24:34+00:00https://lymphoma-stg.clarovantdigital.com/library/primary-diffuse-large-b-cell-lymphoma-of-the-urinary-bladder-a-case-report-and-narrative-review-of-treatment-modalities-and-clinical-outcomes/2026-09-04T20:24:34+00:00https://lymphoma-stg.clarovantdigital.com/library/survival-in-mantle-cell-lymphoma-after-frontline-treatment-with-r-bendamustine-r-chop-and-the-nordic-mcl2-regimen-a-real-world-study-on-patients-diagnosed-in-sweden-2007-2017/2026-09-04T20:24:35+00:00https://lymphoma-stg.clarovantdigital.com/library/diagnostic-uncertainty-in-rapidly-progressive-brainstem-lesions-a-radiological-diagnosis-of-probable-cns-relapse-of-diffuse-large-b-cell-lymphoma/2026-09-04T20:24:35+00:00https://lymphoma-stg.clarovantdigital.com/library/favezelimab-plus-pembrolizumab-for-anti-pd-1-refractory-classic-hodgkin-lymphoma-an-open-label-phase-1-2-study-2/2026-09-04T20:24:35+00:00https://lymphoma-stg.clarovantdigital.com/library/circulating-tumor-dna-and-immune-response-markers-for-improved-treatment-outcome-prediction-in-diffuse-large-b-cell-lymphoma-a-scoping-review/2026-09-04T20:24:35+00:00https://lymphoma-stg.clarovantdigital.com/library/case-report-rapid-improvement-of-chronic-lymphocytic-leukemia-infiltration-of-the-scalp-by-bcl2-inhibitor/2026-09-04T20:24:35+00:00https://lymphoma-stg.clarovantdigital.com/library/ibrutinib-for-early-stage-cll-genetic-risk-factors-and-treatment-outcome-in-the-gcllsg-cll12-trial/2026-09-04T20:24:35+00:00https://lymphoma-stg.clarovantdigital.com/library/zanubrutinib-versus-fludarabine-cyclophosphamide-and-rituximab-in-fit-treatment-naive-patients-with-chronic-lymphocytic-leukemia-a-matching-adjusted-indirect-comparison/2026-09-04T20:24:36+00:00https://lymphoma-stg.clarovantdigital.com/library/prolymphocytic-progression-in-chronic-lymphocytic-leukemia-without-richter-transformation-an-eighteen-year-clinical-diagnostic-correlation/2026-09-04T20:24:36+00:00https://lymphoma-stg.clarovantdigital.com/library/epcoritamab-with-rituximab-and-lenalidomide-as-first-line-treatment-for-follicular-lymphoma-epcore-nhl-2-an-open-label-multicentre-phase-1-2-b-trial/2026-09-04T20:24:36+00:00https://lymphoma-stg.clarovantdigital.com/library/novel-targeted-therapies-for-central-nervous-system-involvement-in-chronic-lymphocytic-leukemia-a-systematic-review/2026-09-04T20:24:36+00:00https://lymphoma-stg.clarovantdigital.com/library/geriatric-assessment-based-therapy-for-older-patients-with-diffuse-large-b-cell-lymphoma-results-of-a-two-decade-clinical-experience/2026-09-04T20:24:36+00:00https://lymphoma-stg.clarovantdigital.com/library/mycosis-fungoides-with-yo-immunophenotype/2026-09-04T20:24:36+00:00https://lymphoma-stg.clarovantdigital.com/library/impact-of-fludarabine-dosage-on-outcomes-in-large-b-cell-lymphoma-patients-treated-with-car-t-cell-therapy-a-retrospective-study-of-the-ctiwp-of-the-ebmt/2026-09-04T20:24:37+00:00https://lymphoma-stg.clarovantdigital.com/library/sakk-35-14-randomized-trial-of-rituximab-with-or-without-ibrutinib-for-patients-with-untreated-follicular-lymphoma/2026-09-04T20:24:37+00:00https://lymphoma-stg.clarovantdigital.com/library/ctdna-for-mrd-assessment-is-prognostic-and-predictive-in-newly-diagnosed-and-relapsed-refractory-lymphoma/2026-09-04T20:24:37+00:00https://lymphoma-stg.clarovantdigital.com/library/chronic-intussusception-revealing-primary-diffuse-large-b-cell-lymphoma-of-the-small-intestine-a-case-report/2026-09-04T20:24:37+00:00https://lymphoma-stg.clarovantdigital.com/library/sequencing-asymmetry-the-case-for-caution-before-first-line-pirtobrutinib-in-chronic-lymphocytic-leukemia/2026-09-04T20:24:37+00:00https://lymphoma-stg.clarovantdigital.com/library/real-world-outcomes-and-toxicities-of-car-t-in-relapsed-refractory-follicular-lymphoma-a-multicenter-cohort-study/2026-09-04T20:24:37+00:00https://lymphoma-stg.clarovantdigital.com/library/refined-continuous-risk-index-for-accurately-predicting-outcomes-of-patients-with-chronic-lymphocytic-leukemia-after-limited-duration-therapy/2026-09-04T20:24:38+00:00https://lymphoma-stg.clarovantdigital.com/library/the-impact-of-chemotherapy-on-gonadal-function-in-female-patients-with-hodgkin-and-non-hodgkin-lymphoma-a-comprehensive-analysis-of-hormonal-kinetics-and-implications-for-fertility-and-contraceptive/2026-09-04T20:24:38+00:00https://lymphoma-stg.clarovantdigital.com/library/orelabrutinib-fludarabine-cyclophosphamide-and-obinutuzumab-ofcg-for-first-line-treatment-of-chronic-lymphocytic-leukemia-a-multicenter-phase-ii-trial-cwcll-001-trial/2026-09-04T20:24:38+00:00https://lymphoma-stg.clarovantdigital.com/library/unusually-long-remission-in-two-patients-with-follicular-lymphoma-receiving-immunomodulating-therapeutic-cancer-vaccines/2026-09-04T20:24:38+00:00https://lymphoma-stg.clarovantdigital.com/library/molecular-pathogenesis-and-therapeutic-response-of-diffuse-large-b-cell-lymphoma-genetic-subtypes/2026-09-04T20:24:38+00:00https://lymphoma-stg.clarovantdigital.com/library/interim-efficacy-and-preliminary-survival-outcomes-of-polatuzumab-vedotin-in-combination-for-diffuse-large-b-cell-lymphoma-a-retrospective-real-world-study/2026-09-04T20:24:38+00:00https://lymphoma-stg.clarovantdigital.com/library/comparative-efficacy-of-btk-inhibitors-in-treatment-naive-and-relapsed-refractory-mantle-cell-lymphoma-a-systematic-review-and-meta-analysis/2026-09-04T20:24:39+00:00https://lymphoma-stg.clarovantdigital.com/library/feasibility-and-outcomes-of-decentralized-point-of-care-cd19-car-t-cell-for-relapsed-large-b-cell-lymphoma-in-resource-limited-settings-2/2026-09-04T20:24:39+00:00https://lymphoma-stg.clarovantdigital.com/library/renoir-phase-iii-rituximab-lenalidomide-vs-rituximab-as-maintenance-treatment-in-relapsed-refractory-follicular-lymphoma/2026-09-11T20:08:32+00:00https://lymphoma-stg.clarovantdigital.com/library/age-anthracycline-and-mortality-in-28000-classic-hodgkin-lymphoma-patients-cohort-study-of-a-complete-population/2026-09-11T20:15:30+00:00https://lymphoma-stg.clarovantdigital.com/library/outcomes-of-chop-versus-choep-epoch-in-aggressive-adult-t-cell-leukemia-lymphoma-an-international-cohort-analysis/2026-09-11T20:18:30+00:00https://lymphoma-stg.clarovantdigital.com/library/reassessing-the-continuous-vs-fixed-duration-debate-in-frontline-chronic-lymphocytic-leukemia/2026-09-11T20:25:09+00:00https://lymphoma-stg.clarovantdigital.com/library/life-years-saved-by-advances-in-blood-cancer-therapy-a-retrospective-analysis/2026-09-11T20:29:54+00:00https://lymphoma-stg.clarovantdigital.com/library/treatment-outcomes-of-advanced-stage-classical-hodgkin-lymphoma-in-the-setting-of-vinblastine-and-dacarbazine-shortages-a-case-series/2026-09-11T20:46:07+00:00https://lymphoma-stg.clarovantdigital.com/library/bruton-tyrosine-kinase-inhibitor-based-therapy-versus-rituximab-containing-regimens-for-chronic-lymphocytic-leukemia-a-systematic-review-and-meta-analysis-of-randomized-controlled-trials/2026-09-11T20:46:07+00:00https://lymphoma-stg.clarovantdigital.com/library/performance-of-prame-immunohistochemistry-in-distinguishing-classic-hodgkin-lymphoma-from-anaplastic-large-cell-lymphoma-and-t-cell-lymphoma/2026-09-11T20:46:08+00:00https://lymphoma-stg.clarovantdigital.com/library/central-nervous-system-recurrence-of-diffuse-large-b-cell-lymphoma-risk-stratification-and-prophylaxis/2026-09-11T20:46:08+00:00https://lymphoma-stg.clarovantdigital.com/library/safe-integration-of-radiation-therapy-with-bispecific-antibodies-in-relapsed-refractory-b-cell-lymphomas/2026-09-11T20:46:08+00:00https://lymphoma-stg.clarovantdigital.com/library/an-unanchored-matching-adjusted-indirect-comparison-of-the-efficacy-of-zanubrutinib-versus-ibrutinib-for-the-treatment-of-relapsed-refractory-mantle-cell-lymphoma/2026-09-11T20:46:08+00:00https://lymphoma-stg.clarovantdigital.com/library/role-of-radiotherapy-in-refractory-relapsed-classical-hodgkin-lymphoma-in-the-era-of-targeted-therapies-and-immunotherapy/2026-09-11T20:46:08+00:00https://lymphoma-stg.clarovantdigital.com/library/brexucabtagene-autoleucel-for-relapsed-refractory-mantle-cell-lymphoma-in-asia-redefining-the-role-of-allogeneic-haematopoietic-stem-cell-transplantation/2026-09-11T20:46:09+00:00https://lymphoma-stg.clarovantdigital.com/library/factors-associated-with-palliative-intent-treatment-receipt-in-cutaneous-t-cell-lymphoma/2026-09-11T20:46:09+00:00https://lymphoma-stg.clarovantdigital.com/library/addition-of-rituximab-to-first-line-treatment-of-burkitt-lymphoma-in-children-and-young-adults-in-tanzania-a-cost-utility-analysis/2026-09-11T20:46:09+00:00https://lymphoma-stg.clarovantdigital.com/library/a-distinct-car-t-cell-phenotype-mediates-therapeutic-response-at-limited-doses/2026-09-11T20:46:09+00:00https://lymphoma-stg.clarovantdigital.com/library/integrating-flow-cytometry-in-the-diagnostic-work-of-hiv-associated-hodgkin-lymphomas/2026-09-11T20:46:09+00:00https://lymphoma-stg.clarovantdigital.com/library/variability-of-nutritional-status-during-hematopoietic-stem-cell-transplantation-and-its-association-with-clinical-outcomes-an-ambispective-observational-study-from-india/2026-09-11T20:46:09+00:00https://lymphoma-stg.clarovantdigital.com/library/single-route-cns-prophylaxis-for-aggressive-non-hodgkin-lymphomas-real-world-outcomes-from-21-us-academic-institutions/2026-09-11T20:46:10+00:00https://lymphoma-stg.clarovantdigital.com/library/a-prospective-multi-center-phase-iv-clinical-study-to-assess-the-safety-and-clinical-outcome-of-acalabrutinib-in-indian-adult-patients-with-chronic-lymphocytic-leukemia-small-lymphocytic-lymphoma-or/2026-09-11T20:46:10+00:00